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Breast cancer is the top leading cause of cancer and mortality in women 
worldwide, and it is the top cancer affecting Singapore women. Management 
and treatment of breast cancer are challenging due to its heterogeneous nature 
of the disease. Hence, identifying reliable prognostic factors has always been 
the ultimate goal to the researchers and physicians. 
Glycosaminoglycans and proteoglycans are discovered to be involved in 
human cancer progression and malignancy. In current study, an enzyme, N-
acetylgalactosaminyltransferase-1, CSGalNAcT-1, which initiates the 
biosynthesis of chondroitin sulfate/dermatan sulfate was investigated. This 
gene was found up-regulated in normal breast cell line, MCF-12A, while 
down-regulated in tested breast cancer cell lines, i.e. MCF7, ZR75-1 and 
MDA-MB-231. In order to understand the functional role of CSGalNAcT-1 in 
breast cancer, this gene was silenced in MCF-12A and over-expressed in 
MCF7 and MDA-MB-231. The results showed that CSGalNAcT-1 was 
involved in regulating cell migration, invasion, viability, apoptosis and 
adhesion. CSGalNAcT-1 silenced MCF-12A acquired tumorigenic phenotypes 
through increased migration and invasion in transwell and Matrigel™ chamber 
experiments. At the same time, the silenced MCF-12A had significant changes 
in the cell viability and apoptosis. Cell adhesion to collagen I and fibronectin 
remained unchanged upon CSGalNAcT-1 knockdown. The aggressiveness of 
breast cancer cell lines, MCF7 and MDA-MB-231, was hampered by 
CSGalNAcT-1 over-expression in the cells. Migration and invasion of the cells 
were remarkably reduced. Cell viability of the cancer cell lines were impeded 
and cell adhesion to fibronectin and collagen I were affected in CSGalNAcT-1 






Besides, downstream target gene was chosen from microarray result of 
CSGalNAcT-1 silenced MCF-12A. Silencing CSGalNAcT-1 resulted in 
chemokine CXCL14 up-regulation. It was hypothesized that CXCL14 
mediated the phenotypic changes downstream of CSGalNAcT-1 knockdown in 
MCF-12A. Double knockdown of CSGalNAcT-1 and CXCL14 restored the 
normal phenotypes of MCF-12A, including reduced metastasis and increased 
adhesion to collagen I and fibronectin. Other than CXCL14, silencing 
CSGalNAcT-1 in MCF-12A caused the expressional changes in few proto-
oncogenes and tumor suppressor genes. Therefore, CSGalNAcT-1 is 
hypothesized to interplay with these genes in mediating the signaling pathway 
of breast cancer progression.  
Immunohistochemistry was performed to investigate the expression and 
localization of CSGalNAcT-1 in microarray clinical samples of invasive 
ductal carcinoma tissue. It was found that CSGalNAcT-1 was expressed in 
epithelial cells, stromal cells and diffuse stroma of invasive ductal carcinoma 
tissue. High expression of CSGalNAcT-1 in stromal cells was negatively 
associated with increasing histological grade and mitotic index. However, low 
expression of CSGalNAcT-1 in diffuse stroma along with specific 
clinicopathological parameters, such as positive estrogen and progesterone 
receptor, negative lymph node involvement, and lower scoring of tubule 
formation, was correlated with better survival and longer recurrence free 
period.  
Taken together, the findings of this study had revealed the functional 






breast cell lines and the potential role of CSGalNAcT-1 as a prognostic factor 
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1.1. Breast development and anatomy 
The adult mature breasts extend from the second to the sixth ribs and from the 
sternum to the midaxillary line. Anteriorly, the breast is bounded by the skin; 
while posteriorly it lies on the pectoralis major, serratus anterior and the 
superior rectus sheath. Loose connective tissue in the retromammary space 
enables flexible mobility of the breast on the chest wall (P.O'Malley and 
E.Pinder, 2006). Each breast possesses a central, erectile nipple with a circular 
ovoid areola of darker skin. Figure 1.1 shows the gross anatomy of a female 
breast. Histologically, the parenchymal tree from the central ducts branches 
out to the lobules which are lined by cuboidal or low columnar epithelial cells. 
These epithelial cells form the interior lining of the ducts and are surrounded 
by continuous layer of myoepithelial cells. The lobules are composed of a 
compact and rounded clump of individual ductules or acini. Ductules or acini 
are embedded in a specialized myxoid connective tissue, where lymphoid and 
plasma cells are often present (P.O'Malley and E.Pinder, 2006). 
 
Female breast is a dynamic organ which changes as a female undergoes 
different stages of life from fetus growth in mother womb, puberty, pregnancy, 
lactation to menopause (Russo, 2004). The beginning of the breast 
development takes place in a 5-week old embryo. Mammary gland 
development in fetus can be divided into the following stages: Ridge, milk hill, 
mammary disc, G lobule type, cone, budding, indentation, branching, 
canalization and end-vesicle stage. End-vesicle stage appears during week 34 
of gestation. This stage is characterized by the production of colostrums.  





However, the breast lacks well-developed lobules, which only become 
apparent at the end of pregnancy of the fetus, so end-vesicle stage is not a fully 
differentiated stage. In the newborn, breast is presented in a very primitive 
structure; it is only composed of ducts ending with short ductules (Russo, 
2004).  
 
Puberty in the female starts in between 10 and 12 years old. At this period, 
glandular tissue and the surrounding stroma of the breasts start to proliferate. 
The outgrowth of small bundles of primary and secondary ducts increase the 
glandular mass (Russo, 2004). The ducts continue to grow and divide into 
terminal end buds (TEBs). Each TEB diverges into two smaller structures of 
alveolar buds (AB) which may further sprout into ductules. A terminal duct 
together with four to eleven ductules make up the Lobule type 1 (Lob 1) or 
virginal lobule (Russo, 2004). The hallmark of breast differentiation is lobule 
formation, which sets in one to two years after the first menstrual period. The 
breast tissue of non-pregnant women contains 3 types of lobules, the afore-
described Lob 1 and the more developed type 2 (Lob 2) and type 3 (Lob 3) 
lobules. Transition of Lob 1 to Lob 2 takes place when the gradual sprouting 
of ductules reaches an average number of 47 per lobules, and transition to Lob 
3 happens when at least 80 ductules are found around the terminal duct. In 
nulliparous women, Lob 1 presents predominantly, Lob 2 presents at minimal 
number and Lob 3 is barely identifiable. However in parous women, there is a 
significant increased in Lob 3 until a woman reaches the age of 40 (Russo, 
2004). 





During pregnancy, the breast reaches its maximum development. In the early 
stage, ductal lengthening and profuse branching occur rapidly for the 
progression of Lob 2 to Lob 3. Fully differentiated Lob 4 is formed from the 
progression of ductules to secretory acini; this indicates the beginning of 
secretory activity. From mid-pregnancy onwards, milk is secreted into the 
mammary alveoli and can be expelled from the nipple. No major 
morphological changes are observed during lactation. Breast regresses after 
lactation and contain more glandular tissue than breasts of women who have 
not experienced pregnancy and lactation (Russo, 2004). After menopause, Lob 


















1.2. Epidemiology of breast cancer 
According to the report generated from GLOBOCAN 2012 (2012), an 
estimate of 14.1 million people were diagnosed with cancer and 8.2 million 
died from the disease. Breast cancer is the most common cancer affecting 
female worldwide, 25.2% of the total cancer incidence and 14.7% of the 
cancer deaths in female came from breast cancer. In Singapore, based on data 
from the Singapore Cancer Registry, breast cancer was the top cancer among 
the female Singapore residents from 2009 to 2013 (Lee et al., 2014). Besides, 
breast cancer is the most common cancer affecting females in all three ethnic 
groups, i.e. Chinese, Malay and Indian. Correspondingly, breast cancer caused 
the most cancer deaths in Singapore females from 2009 to 2013.  
 
1.3. Risk factors of breast cancer 
Since breast cancer is the most common occurring cancer in females 
worldwide, it is important for each female to be aware of the risk factors of 
breast cancer. The risk factors of breast cancer can be grouped into non-
modifiable and modifiable factors. Most of the well-known breast cancer risk 
factors are not modifiable, such as age, genetic predisposition, family history, 
early menarche and late menopause. However, other risk factors such as use of 











1.3.1. Age  
Most common non-hormone-dependent adult cancers, for example colorectal 
cancer, increases in incidence with advancing age. While in the case of breast 
cancer, although the risk of breast cancer rises as a female gets older, the rate 
of the risk rises significantly after the age of 50. This could be due to the 
deterioration of the protective machinery critical in preventing the genesis of 
breast cancer as a female grows older (Roses, 2005).  
 
1.3.2. Family history of breast cancer 
Familial clustering of breast cancer is a recognized risk factor in the genesis of 
breast malignancy. A woman is susceptible to the disease if she has a positive 
family history of breast cancer; especially when one or a few first-degree 
relatives are affected. Highly penetrate mutant forms of breast cancer genes, 
BRACA1 and BRACA2 are inheritable and are responsible for an estimate of 
20% of the familial risk for breast cancer (Ponder, 2003). Other genetic 
abnormalities which contribute lesser cases of familial breast cancer are p53, 
checkpoint kinase 2 (Chk2) and ataxia telangiectasia mutated homolog (ATM) 
(Ponder, 2003). However, low penetrating genes could act together and give 
rise to familial aggregation of cases. Intense research of these genes and other 











1.3.3. Hormonal factors 
The influence of sex steroids estrogen and progesterone on the genesis of 
breast cancer is largely due to their effects on cell proliferation. Factors that 
induce cell proliferation can result in introduction of mutations in DNA hence 
malignant transformation of the cells. The effects of endogenous and 
exogenous sex hormones on cell proliferation are relevant only in the context 
of dose and duration but not of ever-never use consideration (Pike et al., 1983).  
 
The growth of normal breast epithelium is under the endocrine control of two 
important ovarian hormones estrogen and progesterone. Age at menarche and 
menopause determine the time of exposure to estrogen and progesterone of a 
female in her lifetime. Late menarche, i.e. after 12 years old, decreases breast 
cancer risk substantially with an approximate 15% decrease with each year 
that menarche is delayed (Pike et al., 1983). Hence, the sooner a female 
develops regular menstrual cycle, the greater the subsequent risk for breast 
cancer (Henderson et al., 1985). In addition, delayed menopause after age 55 
may increase the risk of breast cancer. Ovariectomy before the age of 40 could 
reduce breast cancer risk by a drastic 45% compared to women who 
experience normal menopause (Brinton et al., 1988).  
 
Common oral contraceptives (OCs) contain synthetic estrogen ethinylestradiol 
combined with one of the many available synthetic progestins. Available study 
showed that level of sex steroids in OCs appeared to promote the same extent 
of breast cell proliferation as a normal ovulatory cycle (Pike et al., 1993). 
Although administration of OC predisposes the user to increased risk of breast 





cancer, the risk will subside if OCs intake is terminated for more than ten 
years (1996). Hormone replacement therapy (HRT) is prescribed to post-
menopausal women to control menopause symptoms. Long term 
administration of HRT is associated with higher risk of getting breast cancers; 
however, the risk will be reduced after a 5-year termination of usage (Boyle, 
2005). 
 
1.3.4. Parity and age at first-term pregnancy 
Women with a first-full-term pregnancy (FFTP) under the age of 20 years 
have about 50% reduced breast cancer risk compared with nulliparous women 
(Collaborative Group on Hormonal Factors in Breast, 2002). Besides, 
subsequent additional babies exert further protection with an approximate 7% 
per child birth (Collaborative Group on Hormonal Factors in Breast, 2002). 
However, the protection from FFTP decreases for women who have an FFTP 
after the age of 32, and adversely imposes a greater breast cancer risk than 
nulliparous women (Kelsey and Bernstein, 1996). 
 
1.3.5. Physical activity and diet 
Several risk factors of breast cancer are modifiable. These include diet, 
alcohol consumption and physical activity. Physical activity is proven to 
decrease risk of breast cancer. It is well proven that exercise before menarche 
and in premenopausal women decreases risk (Bernstein et al., 1994), and there 
are evidences showing that exercise is protective in the postmenopausal period 
too (Patel et al., 2003). The effect of dietary fat on risk of breast cancer is still 
debatable; there is no significant correlation between intake of fat and an 





increase risk of breast carcinogenesis (Mazhar and Waxman, 2006). In 
contrast, alcohol intake imposes a positive association with increased breast 
cancer risk (Hamajima et al., 2002, Terry et al., 2006, Zhang et al., 2007). It is 
proposed that alcohol increases oestrogen level (Singletary and Gapstur, 2001).  
 
In summary, breast cancer is a complex disease that arises from the interplay 
of many factors. The nature of breast cancer imposes a challenge to treatment 
and prevention of this disease. 
 
1.4. Changes in cell properties of breast cancer cells 
1.4.1. Cell cycle 
Cell cycle is tightly regulated to control the correct duplication of genomic 
DNA. The four phases of cell cycle are G1, S, G2 and M phase (Li et al., 2015). 
S phase is the DNA replication phase; M phase is where the DNA is packaged 
and ready to be separated to daughter cells. G1 and G2 phases separate S phase 
and M phase to ensure the DNA replication is correct and DNA is packaged 
appropriately prior to division (Li et al., 2015). Cell cycle progression is 
positively regulated by cyclin-dependent kinases (CDKs). The activity of 
CDKs was activated upon association with specific activator called cyclin (Li 
et al., 2015). Cell cycle progression was activated by distinctive CDK-cyclin 
at different phases of cell cycle. The inhibition of CDKs could be established 
by phosphorylation of threonine 14/tyrosine 15 by two enzymes, Wee1 and 
Myt1 (Baldin and Ducommum, 1995) and this inhibition could be reversed by 
phosphatases CDC25A, CDC25B and CDC25C (Nilsson and Hoffmann, 
2000). In addition to inhibition by phosphorylation, CDKs are negatively 





regulated by two families of small-polypeptide inhibitory proteins called CDK 
inhibitors, or CKIs (Sherr and Robert, 1999). The Ink4 (inhibitors of CDK4) 









inhibit only CDK4 and CDK6 of G1 phase CDKs. The second family, Cip/Kip 






, bind to a broad 
range of CDKs but preferentially inhibit CDK2 complexes (Sherr and Robert, 
1999).  
 
Mutations or deregulated expressions of CDKs, cyclins, or CKIs are a frequent 
occurrence in cancer. Cyclin D1, which promotes the progression of G1 phase, 
is over-expressed in breast and esophageal cancers (Steeg and Zhou, 1998). 
Gene amplification of CDK4 and CDK2 is a hallmark of large B-cell 
lymphomas, lung tumors, and cervical carcinomas (Li et al., 2015). The 
expression of Cip/Kip inhibitors is deregulated in human cancers. Reduced 
p27
Kip1
 levels and inactivation of p16
Ink4a
 occurs frequently in breast, ovarian, 
lung, and bladder carcinomas (Serrano et al., 1996). 
 
1.4.2. Apoptosis  
Apoptosis is programmed cell death characterized by condensed chromatin, 
cell membrane blebbing, and cell shrinkage. The apoptotic cells are 
phagocytosed by macrophages and other cell types through recognition of 
phosphatidylserine exposed by the apoptotic cells (White et al., 2015). There 
are two major pathways of apoptosis, the mitochondrial (intrinsic) pathway 
and the death receptor (extrinsic) pathway. The mitochondrial pathway is 
initiated with the formation of mitochondrial outer membrane 





permeabilization (MOMP), followed by release of cytochrome c, SMAC, and 
Omi. Cytochrome c activates APAF-1 to oligomerize, and the latter binds and 
activates initiator caspase, caspase-9 which finally activates executioner 
caspase, caspase-3 (Wolf and Green, 1999). The regulation of mitochondrial 
pathway of apoptosis is by pro- and anti-apoptotic members of the Bcl-2 
family (Brunelle and Letai, 2009, Letai, 2008, Tait and Green, 2010). BAX 
and BAK are pro-apoptotic “effectors” proteins which homo-oligomerize to 
form the MOMP (Wei et al., 2001). Pro-apoptotic “activator” BH3-only 
proteins, which include BIM, BID, and PUMA, can directly interact with 
BAX and BAK to activate the pro-apoptotic activity (Willis et al., 2007). Anti-
apoptotic Bcl-2 family proteins include Bcl-2, Bcl-XL, Bcl-w, Mcl-1, and Bcl-
1. These proteins bind and sequester BAX or BAK protein before they can 
oligomerize to initiate apoptosis (Certo et al., 2006, Cheng et al., 2001, Letai 
et al., 2002a). Another subfamily, the pro-apoptotic “sensitizer” BH3-only 
proteins, which include BAD, BIK, and NOXA competitively inhibit the 
binding of anti-apoptotic proteins to activators, BAX, or BAK (Letai et al., 
2002a). The death receptor (extrinsic) pathway involves a subset of cell 
surface receptors belonging to the tumor necrosis factor (TNF) receptor 
(TNFR) superfamily (White et al., 2015). The death receptors include TNFR1, 
TRAIL receptors, and CD95. When the receptor is engaged by its ligand, the 
initiator caspase-8 is recruited and activated by the adapter protein, FADD or 
TRADD, depending on which death receptor is involved (White et al., 2015).  
 
Suppression of apoptosis is one of the hallmarks of cancer progression (Kerr et 
al., 1994). Tumor cells can evade apoptosis by the expression of anti-apoptotic 





protein, Bcl-2; or by down-regulation or mutation of pro-apoptotic protein, 
BAX (Miyashita et al., 1994). In order to escape immune destruction, 
expression of Fas receptor has been shown to be down-regulated in tumor cells. 
Other mechanisms include expression of malfunctioned Fas receptor and 
secretion of high levels of a soluble form of the Fas receptor which will 
sequester the Fas ligand from the receptor on the tumor cells (Cheng et al., 
1994, Elnemr et al., 2001). 
 
1.4.3. Migration, invasion, and adhesion 
Cell migration occurs as the result of coordinated polymerization and 
depolymerisation of the actin cytoskeleton to create an extended pseudopod at 
the leading edge of the cells, followed by contraction and disassembly of cell-
matrix adhesive contacts from the rear (Wolf and Friedl, 2006). Lamellipodial 
protrusions at the leading edge are nucleated by Arp2/3 complex, cortactin, 
and the GTPase Rac. Actin contractility from the rear is however regulated by 
myosin light-chain kinase and small GTPase, Rho and its effector Rho-kinase 
(ROCK) (Wolf and Friedl, 2006). Tumor cells can secrete autocrine factor to 
stimulate motility, such as lysophospholipase D and lysophosphatidic acid 
(LPA) (Acharyya et al., 2015). Binding of hepatocyte growth factor/scatter 
factor (HGF/SF) to its receptor, c-met, could induce chemokinetic activity of 
epithelial cells and result in an invasive phenotype (Acharyya et al., 2015). 
Chemotaxis gradient formed by the growth factors, chemokines of the CCR 
and CXC family in ECM could also induce a directional motility to the tumor 
cells (Acharyya et al., 2015).  
 





Tumor cell invasion is the distinguishing feature of malignancy in which the 
cells acquire the capacity to disrupt the basement membrane and penetrate the 
underlying stroma (Acharyya et al., 2015). Tumor invasion involves the loss 
of cell-cell cadherin adhesion, alterations in cell-matrix adhesion by integrins, 
proteolysis of the extracellular matrix by proteinases, and organization 
alterations in the actin cytoskeleton (Acharyya et al., 2015). 
 
Epithelial cell-cell interactions are mediated primarily by epithelial-specific 
cadherin, E-cadherin, which functions as a tumor and metastatic suppressor 
(Cavallaro and Christofori, 2004). Transcriptional repression of E-cadherin 
and proteolytic degradation of the Neural cell adhesion molecule (NCAM), 
deleted in colorectal carcinoma (DCC), carcinoembryonic antigen CAM1 
(CEACAM1), and Mel-CAM (melanoma-CAM), were demonstrated in 
several tumor types (Cavallaro and Christofori, 2004). The extracellular 
matrix (ECM) is composed of triple-helical collagens, glycoproteins such as 
laminins and fibronectin, and proteoglycans. ECM provides a scaffold for the 
organization of cells and serves as a repository for secreted regulatory proteins 
and growth factors (Boudreau and Bissel, 1998). Hence, interaction of cells 
with ECM molecules affects the survival, growth, differentiation, and 
migration of the cells (Boudreau and Bissel, 1998). Cells adhere to ECM via 
transmembrane glycoproteins integrins (Hynes, 2002). In tumor development, 
cancer cells switch to the expression of integrins that promote survival, 
migration, and proliferation but down-regulate the integrins that mediate 
adhesion (Guo and Giancotti, 2004). In general integrins α2β1 and α3β1 are 





suppressors of tumor progression, whereas αvβ3, αβ6, and α6β4 induce cellular 
proliferation and migration (Acharyya et al., 2015). 
 
1.5. Types of breast cancer 
Breast cancer can be divided into three groups: the in situ breast carcinoma 
(ductal or lobular), invasive breast carcinoma (ductal or lobular) and less 
common and unique types of breast malignancies such as phyllodes tumor, 
Paget disease and inflammatory breast carcinomas (Roses, 2005). As 
immunohistochemical staining of invasive ductal carcinoma is included in the 
current study, the pathology of this malignancy will be discussed.  
 
Invasive ductal carcinoma is the most common kind of breast cancer. It is 
composed of large cancer cells that are liberated from the boundaries of 
ductolobular system and have infiltrated the fibrous and fatty stroma of the 
breast, usually in a haphazard manner. The body reacts to this perturbation by 
producing dense fibrosis, the so-called desmoplastic response, frequently 
accompanied by variable degrees of chronic inflammation (Roses, 2005). 
Histological grading of invasive ductal carcinoma is important in determining 
the prognosis of the patients. The grading schemes largely in use today are 
based on the findings of Bloom and Richardson and include the assessment of 
three parameters: amount of tubule formation, degree of nuclear 
pleomorphism and mitotic rate (Bloom and Richardson, 1957). One difficulty 
that is encountered with the system is that, mitotic rate of smaller lesions is 
more difficult to be assessed. So in such instances, histological grading of 





invasive ductal carcinoma is based on tubule formation and degree of nuclear 
pleomorphism.   
 
1.6. Staging and classification of breast cancer 
Breast cancer, similar to other malignancies, is staged using a uniform system 
to ensure accuracy and consistency in classifying groups of patients with 
similar outcomes and delineating treatment approaches based on the severity 
of disease. In 1958, International Union against Cancer (UICC) first 
introduced a staging system based on histologic grounds, namely TNM 
classification system, representing primary tumor (T), regional nodes (N), and 
distant metastasis (M) (Roses, 2005). In the late 1980s, American Joint 
Committee on Cancer (AJCC) and UICC came out with a single TNM staging 
system. Over time, the TNM staging system has been revised several times to 
increase accuracy so as to prevent both under-treatment and over-treatment of  
the disease (Roses, 2005, Edge et al., 2011).  
 
Basically, the TNM staging can be grouped into (Edge et al., 2011): 
Stage 0: Early breast cancer cells are still contained within the duct or lobule.  
Stage I: Can be sub divided into two groups: 
Stage IA: Tumor size of 2 cm or less with no local lymph node metastasis and 
no distant metastasis of tumor cells. 
Stage IB: Primary tumor not detectable or tumor size of 2 cm or less with 
micrometastases in lymph node only and no distant metastasis of tumor cells. 
Stage II: Can be sub divided into two groups: 





Stage IIA: Primary tumor not detectable or tumor size up to 5 cm with either 
no local lymph node metastasis or metastasis in movable ipsilateral axillary 
lymph nodes; and no distant metastasis of tumor cells.  
Stage IIB: Tumor size of more than 2 cm or size of more than 5 cm with 
either no local lymph node metastasis or metastasis in ipsilateral axillary 
lymph nodes; and no distant metastasis of tumor cells.  
Stage III: Can be sub divided into three groups: 
Stage IIIA: Primary tumor not detectable or tumor size larger than 5 cm with 
metastasis in moveable, fixed or matted ipsilateral axillary lymph nodes; and 
no distant metastasis of tumor cells. 
Stage IIIB: Tumor of any size surfacing to chest wall or skin with either no 
local lymph node metastasis or with metastasis in moveable, fixed or matted 
ipsilateral axillary lymph nodes; and no distant metastasis of tumor cells. 
Stage IIIC: Tumor of any size and pattern with metastasis in ipsilateral 
infraclavicular lymph node(s) with or without lymph node involvement; and 
no distant metastasis of tumor cells. 
Stage IV: Tumor of any size and pattern with any lymph node metastasis 
pattern; and distant metastasis of tumor cells. 
 
1.7. Symptoms and signs of breast cancers  
Symptoms and signs of breast cancer include lump in the breast, altered in 
breast morphology and size, breast pain, nipple retraction, and bleeding or 
discharge from nipple. However, there are cases where no symptoms are 
observed, especially in the early stage of breast cancer. This is the stage 
proven to have most effective treatment responses following early detection. 





Therefore, women are highly encouraged to follow the recommended 
guidelines for routine breast examination and screening (Roses, 2005).  
 
1.8. Breast cancer detection 
Mortality of breast cancer could be largely reduced if disease is detected early, 
as treatment is more effective in early stage of breast cancer. In recent decades, 
public health campaigns are organized to raise awareness of early detection for 
breast cancer and encourage females who have reached certain age to undergo 
periodic examination. Screening test provides acceptable specificity to 
minimize false-positive examinations. The test imposes low risk to patients 
and with acceptable cost. Some commonly used screening methods include 
breast self-examination, mammography tests, ultrasound and magnetic 
resonance imaging. 
 
1.8.1. Breast self-examination and clinical breast examination 
Breast self-examination aids women to be more vigilant and increases 
awareness of normal breast composition so that changes can be detected and 
consultation to physicians can be made immediately. Self-examination can be 
performed monthly. The patients look for lumps, thickening, discharge or any 
changes in the breast. For menstruating women, the best time to self-examine 
is a week after the start of the period. Pregnant and lactating women, as well 
as post-menopausal women are advised to continue perform self-examination 
monthly (Roses, 2005).  
 





The only difference between clinical breast examination and breast self-
examination is that, examiner helps to inspect for abnormalities of breast and 
detect existence of lumps and any changes in shape and texture of breasts. For 
women age 40 and above, clinical breast examination is recommended to be 
taken once a year in complement with mammography examination. 
 
1.8.2. Mammography 
Mammography uses low-dose x-ray to visualize the internal structure of the 
breast. In US and in Singapore, mammography screening is advised for most 
women beginning at the age of 40 years (Smith et al., 2003). Younger women 
can benefit from mammography screening only if they are in extremely high-
risk group of developing breast cancer at an early age (Smith et al., 2003). It is 
recommended by many major medical organizations that women from the age 
of 40 to 49 years old be screened annually (Smith et al., 2003, Feig, 1994). 
Smaller tumor can be detected by mammography thus the ability of screening 
mammography to substantially reduce breast cancer mortality is well 
established and not debatable (Smith et al., 2003, Seidman et al., 1987). A 
study by Duffy and associates described that among women aged 40 to 69 
years, breast cancer mortality was reduced 44% for screened women and 39% 
for women offered screening compared with the prescreening era (Duffy et al., 
2002). However, not all breast cancer can be detected by a mammogram. 
Besides, like any other diagnostic tests, mammography could also give false-
positive test results that lead patients to unnecessary follow-up examinations 
(Duffy et al., 2010). 
 






Ultrasound is a highly sensitive technique to evaluate dense breasts and 
differentiate between cystic and solid masses (Stavros et al., 1995). Tumor 
masses as small as 5 mm can be localized by ultrasound and physicians may 
perform subsequent ultrasound-guided aspiration biopsy or core biopsy for 
further diagnosis. 
 
1.8.4. Magnetic resonance imaging 
Unlike mammography, magnetic resonance imaging (MRI) uses magnetic 
fields instead of x-rays to give the image of cross-sectional body. Patients are 
injected with a contrast material (usually gadolinium DTPA) before MRI is 
taken (Duffy et al., 2010). MRI is a useful tool for detecting primary breast 
carcinoma. MRI could detect microscopic multifocal or multicentric disease in 
patients. These markers indicate higher risk of local recurrence and 
identification of these markers could assist physicians in deciding suitable 
surgical managements to patients. MRI evaluation might help to identify 
patients who will not benefit from breast conservative therapy, although does 
not change the overall mastectomy rate. MRI is a technique with high 
sensitivity but low specificity, so validation by core or excision biopsy of 
MRI-identified suspicious lesions is necessary before any treatment decision is 
made (Bedrosian et al., 2003). For women in breast cancer high-risk group, 
they are recommended to have MRI screening along with a yearly 
mammogram beginning at age 30. MRI complements mammography 
screening but is not its replacement. 
 





1.9. Treatment of breast cancer 
Treatment decisions are given by physician and under patient‟s consent with 
careful consideration. A few considerations of the optimal treatment are the 
stage and biological characteristic of the cancer, the preferences and 
conditions of patients, and the pros and cons associated with each treatment 
protocol. 
 
1.9.1. Surgery  
Surgery removal of breast cancer is a primary form of treatment to the disease. 
The types of surgical procedure include lumpectomy, total mastectomy and 
modified radical mastectomy (Alteri et al., 2011). In a lumpectomy, only 
cancerous tissue and circumcised tissues are removed while entire breast is 
removed in total mastectomy. Lumpectomy is usually followed by duration of 
5 to 7 weeks of radiation therapy. Women who chose mastectomy may 
consider having breast reconstruction after surgery. Patients may also undergo 
modified radical mastectomy, which involves removal of the entire breast and 
lymph nodes under the arm. The presence of cancer cells in the lymph nodes 
can help the physicians to decide subsequent treatment regime (2011). 
  
1.9.2. Radiation therapy 
Radiation therapy is recommended to patients after a lumpectomy, before 
surgery to reduce the size of tumors, or after mastectomy to eliminate remnant 
cancer cells after surgery (Vogel et al., 2010). There are two types of radiation 
therapy and each type is given depending on the type, stage, and location of 
the tumor being treated. External radiation is beamed onto the area affected by 





cancer from a machine. External beam radiation is usually administered to 
patients over a period of 5 to 7 weeks. Internal radiation therapy is an invasive 
method, which uses a needle, wire, or seed that is sealed with radioactive 
substance to place into or near the cancer site. Accuracy of radiation therapies 
has increased dramatically over years to effectively diminish the side effects 
and also reduce treatment time (2011). 
 
1.9.3. Systemic therapy 
Systemic therapy is the use of anti-cancer drugs on patients via oral 
administration or vein injection. Systemic therapy includes biologic therapy, 
chemotherapy, and hormone therapy (Freedman et al., 2003). Neoadjuvant 
therapy is systemic therapy given to patients before surgery. It aims to shrink 
the tumor size to ease surgical removal and this may allow exemption to total 
mastectomy in some patients. Neoadjuvant therapy is proven to give better 
prognosis in terms of survival and recurrence of the disease (Freedman et al., 
2003). Conversely, systemic therapy given after surgery is called adjuvant 
therapy. It is used to eliminate any undetected tumor cells that may have 
metastasized to distant organs of the body. Systemic therapy is also applied in 
treating late stage of breast cancer where metastasis has occurred and surgery 
removal of cancer is not possible anymore (Waters et al., 2010). 
 
1.9.3.1. Biologic therapy 
One of the profound key biomarkers of breast cancer is HER2/neu. 
Approximately 15-30% of breast cancers over-express the growth promoting 
protein HER2/neu. Tumor growth is accelerated and tumors are more likely to 





recur in these cases (Domchek et al., 2010). Monoclonal antibody Herceptin 
(trastuzumab) specifically targets the HER2 protein and has proven to reduce 
the risk of relapsing and death of early-stage breast cancer by 52% and 33%, 
respectively (Domchek et al., 2010). Patients who have become resistant to 
trastuzumab could benefit from Lapatinib, which was found to be effective in 
delaying disease progression in women with HER2-positive, late stage breast 
cancer (Tuttle et al., 2009). 
 
1.9.3.2. Chemotherapy 
Multiple factors could affect the efficacy of chemotherapy, including tumor 
size, lymph nodes involvement, and the biological characteristics of the cancer 
cells (Tuttle et al., 2009). Research has shown that combination of drugs in 
chemotherapy brings additive benefits than just using one drug alone for 
breast cancer treatment (Tuttle et al., 2007). Some of the most commonly used 
drugs are methotrexate, 5-fluorouracil, doxorubicin and many others. The 
usual course of adjuvant in chemotherapy is three to six months.  
 
1.9.3.3. Hormone therapy 
Estrogen promotes the growth of tumor cells. Women tested with estrogen 
receptors positivity can be given tamoxifen to block the effects of estrogen on 
the cancer cells (Recht, 2009). Tamoxifen is administered to both 
premenopausal and postmenopausal patients who are hormone receptors 
positive for a recommendation of five years therapy. Tamoxifen therapy has 
been shown to reduce annual recurrence rate and death rate by 41% and 33%, 
respectively (Recht, 2009). Aromatase inhibitors, for example anastrozole, are 





a class of drugs preferably prescribed to postmenopausal women because these 
drugs inhibit an enzyme responsible for producing minimal amounts of 
estrogen in postmenopausal women.  
 
1.10. Glycosaminoglycans 
Glycosaminoglycans (GAGs) are linear polymers consisting of alternating 
units of N-acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc) 
and an uronic acid such as glucuronate or iduronate. GAGs are commonly 
linked to a protein core via a serine residue to form proteoglycans (PGs) which 
are ubiquitously distributed at the extracellular and cellular (cell membrane 
and intracellular) levels. The GAG family consists of hyaluronic acid, keratan 
sulfate (KS), heparan sulfate (HS) and chondroitin sulfate/ dermatan sulfate 
(CS/DS) (Yip et al., 2006). The structure of each member is illustrated in 
Figure 1.2. 







Figure 1.2 The structures of various glycosaminoglycans. 
Glycosaminoglycans are covalently linked to a protein core via a serine 
residue to form proteoglycans; except for hyaluronan, which is freely 
distributed in the extracellular matrix.  
 





Unlike other GAGs, hyaluronan (HA) does not attach to a protein core to form 
proteoglycan, the repeating dissacharide units are non-sulfated. HA was 
discovered at a significant amount in tissue regions which were characterized 
by high cell division and cell mobility (Toole, 2001). HA was found to act as a 
signaling mediator via binding with CD44, Toll-like receptors 2 and 4, 
lymphatic vessel endothelial hyaluronan receptor (LYVE-1) and hyaluronan-
mediated motility receptor (RHAMM). Among these molecules, CD44 and 
RHAMM were recently recognized as major receptors implicated in cancer 
progression (Patel et al., 2007, Turley et al., 2002, Jackson, 2009, Kouvidi et 
al., 2011).  
 
Keratan sulfate (KS) is distinctively different from other GAGs because the 
dissacharide units are composed of galactose sugar instead of an uronic acid. 
KS was found in abundance in cornea to maintain a critical hydration level for 
corneal transparency (Funderburgh, 2000). KS was also suggested to have 
potential role in the implantation process whereby cell-associated KS reached 
a peak abundance when embryo implantation occurred (Graham et al., 1994).  
 
Heparan sulfate (HS) consists of repeating disaccharide units of GlcNAc and 
hexuronic acid residues [glucuronic acid (GlcA) and iduronic acid (IdoA)] 
with twelve known sulfation profiles at the hydroxyl groups and the amino 
groups of glucosamine (Karamanos et al., 1997, Militsopoulou et al., 2002, 
Malavaki et al., 2011). Sulfated HS chains regulated the interactions of HS 
with growth factors, cytokines and proteins, therefore affecting the biological 
roles of these molecules in normal and pathological conditions (Malavaki et al., 





2011). HS chains of heparan sulfate proteoglycans (HSPGs) helped to 
organize the extracellular matrix through binding with other matrix molecules. 
Studies showed that presence of HS chains promoted cell adhesion; however 
their absence caused invasion and migration of malignant cells (Timpl and 
Brown, 1996, Sanderson, 2001). HS could also act as a „reservoir‟ in 
mediating the bioavailability of selective growth factors and peptides, which 
are important in regulating tumor progression and angiogenesis (Vlodavsky et 
al., 1987). 
 
As shown in Figure 1.3, chondroitin sulfate (CS) is composed of repeating 
disaccharides of N-acetylgalactosamine and glucuronic acids while dermatan 
sulfate (DS) is composed of repeating disaccharides of N-acetylgalactosamine 
and iduronic acid. CS has various sulfation patterns which enable specific 
interactions with various molecules, including growth factors, cytokines, 
chemokines, adhesion molecules and lipoproteins (Asimakopoulou et al., 
2008). Proteoglycans (PGs) containing CS/DS chains are located at the 
cellular membrane and at intra- and extra-cellular space. Expression of 
chondroitin sulfate proteoglycans (CSPGs) was correlated with both normal 
and pathological conditions. Hence, CSPGs are key regulator in numerous 
important cellular processes, including proliferation, apoptosis, migration, 
adhesion and invasion, as well as extracellular matrix (ECM) assembly 
(Asimakopoulou et al., 2008). Besides, chondroitin sulfate is a well-known 
supplement to treat degenerative joint disease because of its important role in 
the maintenance of healthy joint tissues (Kelly, 1998). On the other hand, 





dermatan sulfate (DS) was primarily recognized to be involved in wound 




Figure 1.3 The disaccharide units of chondroitin sulfate and dermatan sulfate. 
(A) The structure of disaccharide units of chondrotin sulfate consists of 
glucuronic acid (GlcA) covalently conjugated with N-acetlygalactosamine 
(GalNAc). (B) While in the case of dermatan sulfate, iduronic acid (IdoA) 
instead of GlcA is covalently conjugated with GalNAc. Dashed lines denote 




1.10.1. Biosynthesis of chondroitin sulfate/ dermatan sulfate and the respective 
proteoglycans 
The biosynthesis of chondroitin sulfate/ dermatan sulfate 
(galactosaminoglycans) is a highly complex process that occurs mainly in the 
lumen of the golgi. A high number of biosynthetic enzymes are co-
coordinately involved in the generation of these chains. The complex 
biosynthesis process of chondroitin sulfate/ dermatan sulfate is illustrated in 
Figure 1.4. First of all, the linker tetrasaccharide is synthesized sequentially by 
the addition of xylose, two galactoses, and glucuronic acid catalyzed by 





xylosyltransferase I (XylT-I), galactosyltransferase I (GalT-I), 
galactosyltransferase II (GalT-II) and glucuronyltransferase I (GlcAT-I), 
respectively (Nicola, 2006). Linker tetrasaccharide is conjugated to core 
protein via a serine residue to form proteoglycan. It is conserved and common 
for heparin, heparan sulfate, chondroitin sulfate and dermatan sulfate.  
 
Post-translational modifications of the linkage region regulate the type of 
glycan chain to be synthesized. Sulfation at position O-4 and/or O-6 of the 
galactose residues is only found in linkage region of CS/DS, but does not 
occur in heparin/HS (de Waard et al., 1992, Sugahara and Kitagawa, 2000, 
Sugahara et al., 1988), even when these two GAGs are attached to the same 
protein core (Ueno et al., 2001). However, 2-phosphorylation in xylose residue 
was found in all types of GAG chains (Fransson et al., 1985, Moses et al., 
1997). Phosphorylation of xylose is most prominent after the addition of two 
galactose residues (Moses et al., 1999) but is rapidly dephosphorylated after 
glucuronic acid is added (Moses et al., 1997). The role of C2-phosphorylation 
in xylose remains unclear, although it is postulated that it might provide a 
signal for secretory transport of PGs or for further modifications of the 
growing GAGs (Moses et al., 1999). 
 
After completion of the linker tetrasaccharide synthesis, the addition of 
galactosamine by chondroitin sulfate N-acetylgalactosaminyltransferase I 
(CSGalNAcT-1) determines the GAG chain to CS/DS but not HS (Prydz and 
Dalen, 2000). Elongation of chondroitin sulfate is mediated by the alternate 
transfer of GalNAc and GlcA by galactosaminyltransferases and 





glucuronyltransferases, chondroitin sulfate N-acetylgalactosaminyltransferase 
II (CSGalNAcT-II) (Sato et al., 2003, Uyama et al., 2003), chondroitin 
synthase 1 (CHSY1) (Kitagawa et al., 2001), chondroitin sulfate synthase 3 
(CHSY3) (Yada et al., 2003), chondroitin polymerizing factor (CHPF) 
(Kitagawa et al., 2003) and chondroitin sulfate glucuronyltransferase 
(CSGlcAT) (Gotoh et al., 2002b, Izumikawa et al., 2008). In dermatan sulfate, 
epimerization of glucuronic acid to iduronic acid is catalyzed by the dermatan 
sulfate epimerase (DSE) (Maccarana et al., 2006). 
 
The sulfation of GAGs also occurs in the Golgi compartment and is catalyzed 
by sulfotransferases. Sulfate group from the universal donor 3'-phosphoadenyl 
5'-phosphosulphate (PAPS) is transferred to hydroxyl group of a specific 
position of the sugar residue. Sulfation at 6-O position is catalyzed by 
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 (CHST7/C6ST1) 
(Fukuta et al., 1998), carbohydrate (chondroitin 6) sulfotransferase 3 
(CHST3/C6ST2) (Kitagawa et al., 2001), and chondroitin 6-O-sulfate 
sulfotransferase (GalNAc4S-6ST) (Ohtake et al., 2001). Three 
sulfotransferases i.e. carbohydrate (chondroitin 4) sulfotransferase 13 
(CHST13/C4ST1) (Yamauchi et al., 2000, Hiraoka et al., 2000), carbohydrate 
(chondroitin 4) sulfotransferase 11 (CHST11/C4ST2) (Hiraoka et al., 2000), 
and carbohydrate (chondroitin 4) sulfotransferase 12 (CHST12/C4ST3) (Kang 
et al., 2002) are involved in 4-O sulfation of GalNAc units. Finally, sulfation 
at position 2 of the GlcA involves Uronyl-2-sulfotransferase (UST) 
(Kobayashi et al., 1999). In dermatan sulfate, the GAG chain is sulfated by 
Carbohydate (N-acetylgalactosamine 4-O) sulfotransferase 14 





(CHST14/D4ST1) (Evers et al., 2001). Thus, based on the different sulfation 
patterns, CS chains are classified as CS-A [Glc-GalNAc-4-sulfate], CS-C 
[Glc-GalNAc-6-sulfate], CS-D [GlcA (2-O-sulfate)-GalNAc (6-O-sulfate) or 
CS-E [GlcA-GalNAc-(4, 6)-O-disulfate]. Dermatan sulfate is formerly 
designated as CS-B. Sulfation of DS may involve IdoA (2-O-sulfate) and/or 
GalNAc (4-O-sulfate and/or 6-O-sulfate) (Afratis et al., 2012). 
 
A.  













Figure 1.4 The biosynthesis of galactosaminoglycans (GalAGs). (A) The 
synthesis of the linkage region. CSGalNAcT-1 commits the nascent chain to 
GalAG formation. Linker tetrasaccharide is conjugated to core protein via 
serine residue to form proteoglycans. (B) Chain polymerization is mediated by 
a variety of enzymes. (C) Chain modification such as sulfation and 




1.10.1.1. N-acetlygalactosaminyltransferase (CSGalNAcT-1) enzyme family: 
CSGalNAcT-1 and CSGalNAcT-2 
The cDNA of CSGalNAcT was cloned and described by two groups of 
researchers from Japan (Gotoh et al., 2002a, Uyama et al., 2002). 
CSGalNAcT-1 and -2 enzymes are ubiquitously expressed in various tissues 
and cell types and especially highly expressed in thyroid and placenta (Gotoh 
et al., 2002a). The amino acid sequences of CSGalNAcT-1 and CSGalNAcT-2 
are highly homologous (Sato et al., 2003). Assay of CSGalNAcT activity 
revealed that CSGalNAcT-1 is involved in initiation of chondroitin sulfate 
synthesis and in elongation of the chondroitin sulfate chain. In contrast, 
CSGalNAcT-2 showed stronger elongation activity by enhancing the transfer 
of N-acetylgalactosamine to glucuronic acid of chondroitin poly- and 
oligosaccharides, and to chondroitin sulfate poly- and oligosaccharides 
harbouring β1-4 linkage (Sato et al., 2003).  CSGalNAcT-1 was proven to 





favor elongation of chondroitin instead of chondroitin sulfate poly- and 
oligosaccharide (Gotoh et al., 2002a).   
 
Chondroitin sulfate is commercially available in pharmacy as a health 
supplement for patients suffering from cartilage degenerative diseases, 
osteoarthritis and spinal disorders with back pain (Sakai et al., 2007). 
Aggrecan is the major proteoglycan found in the extracellular matrix of 
cartilage and consists of approximately 100 chains of chondroitin sulfate 
attached to the protein core (Doege et al., 1994, Plaas et al., 1997). Study 
showed that expression of CSGalNAcT-1 was the highest among other 
glycosyltransferases in developing cartilage of mouse embryo by in-situ 
hybridization and real time qPCR techniques (Sakai et al., 2007). Aggrecan 
generated from CSGalNAcT-1 over-expressing chondrocytic cell line revealed 
a greater number of chondroitin sulfate chains attached to aggrecan core 
proteins (Sakai et al., 2007). Hence, this enzyme is shown to be important in 
chondroitin sulfate synthesis in cartilage. A non-redundant role of 
CSGalNAcT-1 in chondroitin sulfate synthesis was also demonstrated in a 
vivo study analyzing CSGalNAcT-1-null mice. These mice expressed 50% 
reduction of chondroitin sulfate synthesis during embryonic stage, and 
demonstrated defects in skeletal and cartilage development (Watanabe et al., 
2010).  
 
Chondroitin sulfate proteoglycans (CSPGs) was shown to be important in the 
healing process of injured spinal cord and in the recovery of the motor 
function during the acute phase after injury (English, 2005). A study revealed 





the possible association between missense mutations of CSGalNAcT-1 with 
neuropathies. Poor productivity of CSPGs due to defective CSGalNAcT-1 
enzymatic activity impaired the effectiveness of the healing of injured 
peripheral nervous system (Saigoh et al., 2011). 
 
The role of CSGalNAcT-1 in breast cancer and other cancer types have not 
been investigated thus far. However, since CSGalNAcT-1 enzyme determines 
the biosynthesis of chondroitin/ dermatan sulfate GAG chains; and these 
molecules are intensively investigated in cancers, it is highly possible that 
CSGalNAcT-1 is implicated, if not, indirectly, in breast cancer. 
 
1.10.2. Major species of CSPGs/DSPGs 
Aggrecan is the major proteoglycan found in cartilage and also presents in a 
number of other connective tissues such as tendon, ligament, joint capsule, and 
neural tissue (Nicola, 2006). Aggrecan helps to maintain the hydration of the 
cartilage by attracting and binding to water and in doing so gives the tissue its 
ability to resist compression (Maroudas et al., 1969). 
 
Versican is the most common PG present in the ECM of most connective 
tissues as well as smooth muscle, the nervous system and the kidney (Nicola, 
2006). Versican is the largest PG in the family due to the large core protein of 
the size of 400 kDa; and four splice variants of versican has been identified in 
mammalian tissues and are termed V0, V1, V2, and V3 (Dours-Zimmermann 
and Zimmermann, 1994). Similar to aggrecan, versican is important for the 
maintenance of the hydration of ECM (LeBaron et al., 1992). Versican is 





likely to be involved in the organization of the ECM through its interaction 
with a number of extracellular macromolecules and cell surface receptors 
(Aspberg et al., 1999). Study showed that the V0 and V1 splice variants 
inhibited the adherence of cells to Type I collagen, fibronectin, and laminin, 
probably due to the CS chains associated with these PGs (Yamagata et al., 
1993) . Abundance of versican expressed by rapidly growing cells could imply 
the involvement of versican in regulating cell proliferation and migration 
(Zimmermann et al., 1994). Versican is also essential in development because 
knockout mice did not survive in utero (Mjaatvedt et al., 1998). 
 
Neurocan and brevican are two CSPGs expressed specifically by the nervous 
system. Neurocan is synthesized by neural cells. It mediates the adhesion and 
outgrowth of neural cells as it specifically interacts with neural cell adhesion 
molecules (Ng-CAM and NCAM) and tenascin-C. It has been shown that the 
presence of CS chains was critical for these interactions (Margolis and 
Margolis, 1997). Brevican is expressed by astrocytes in the central nervous 
system. Brevican deficient mice showed some changes in the brain 
development and acquired a poor memory (Brakebusch et al., 2002). 
 
Decorin and biglycan are members of the small leucine-rich family of PGs. 
Decorin is predominantly presents in dense connective tissues such as tendon 
and ligaments (Vogel and Heinegard, 1985). Decorin has been found to 
interact with Type I and II collagens and influence collagen fibrillogenesis 
resulting in thinner collagen fibrils (Vogel et al., 1984). Decorin was involved 
in the regulation of cell proliferation by interacting directly with cells or with 





growth factors (Nicola, 2006). The core protein of decorin could bind to 
transforming growth factor-β (TGF- β) and control the level of availability of 
this growth factor in cell signaling; thus affecting a number of cellular 
function including cell division, differentiation, adhesion, and organization of 
ECM (Yamaguchi et al., 1990). Biglycan is found in a number of tissues that 
include capillary endothelium, skeletal muscle, cartilage, bone, and tendon 
(Fisher et al., 1989). In biglycan-knockout mice, the rate of bone growth was 
affected and the animals showed signs of early osteoporosis, which indicated 
that biglycan was essential in cell division and regeneration of bone marrow 
stromal cells (Xu et al., 1998).  
 
NG2 is one of the important CS transmembrane PGs and is known as high-
molecular weight melanoma-associated antigen or cell surface CSPG. NG2 
was identified due to its expression in most human melanoma cell lines as 
tumor-associated antigen (Paulus et al., 1996). NG2 is expressed in numerous 
embryonic and non-differentiated cell types (Nishiyama et al., 1991, Ozerdem 
et al., 2001) and is widely distributed in central and peripheral nervous system 
(Petrini et al., 2003). NG2 was primarily studied in melanoma progression, but 
the expression of this PG was also discovered in different nervous system 
tumors (Chekenya et al., 1999), basal cell, breast cancer (Kageshita et al., 
1985, Walter-Yohrling et al., 2003, Smith et al., 1996), and leukemia of 









1.10.3. The roles of chondroitin sulfate/ dermatan sulfate and the respective 
proteoglycans in cancer 
Chondroitin sulfate/ dermatan sulfate is widely expressed intercellularly (in 
extracellular matrix), at the cell membrane and intracellularly. Incorporation 
of synthesizing and post-modification enzymes gives rise to the huge 
repertoire of diverse structures found in chondroitin sulfate/ dermatan sulfate. 
Besides, post-modification of the protein backbones and numbers and varieties 
of GAG chains attached to the protein cores also contribute to the complexity 
of the glycoproteins. The functions of proteoglycans derived primarily from 
the types of GAG chains attached and the modification patterns, such as 
sulfation pattern on the GAG chains (Asimakopoulou et al., 2008, Yip et al., 
2006).   
 
Changes in expression of CSPGs/DSPGs are correlated with pathological 
conditions. Versican and decorin were over-expressed in the stroma of 
malignant tumors, including osteosarcoma, testicular tumors, breast, 
pancreatic and colon cancer (Theocharis et al., 2006, Labropoulou et al., 2006, 
Skandalis et al., 2011). Over-expression of versican in melanoma cells was 
shown to correlate with poor prognosis and cancer relapse in breast and 
prostate cancers (Ricciardelli et al., 2002, Ricciardelli et al., 1998). Expression 
of CS chains predominantly consist of 6-O-sulfated and non-sulfated 
disaccharide was enhanced in pancreatic, rectal and gastric carcinomas 
(Theocharis et al., 2006, Skandalis et al., 2006, Theocharis et al., 2003). 
Enzymes that involve in the biosynthesis of CS determine the CS chain profile 
in a malignant environment. For example, chondroitin-polymerizing factor, 





glucuronyltransferase and chondroitin synthase III were expressed at much 
higher levels in colorectal cancer tissue compared with adjacent normal tissue, 
the expression of these enzymes increased as the cancer stage advanced 
(Kalathas et al., 2011). 
 
As mentioned earlier, the sulfation pattern of CS determines the function of 
the GAG chains; thus, sulfation pattern is a critical factor in cancer 
progression (Theocharis et al., 2006). CS-E and CS-A chains acted as a 
„growth-factors reservoir‟ for FGF2 by regulating the storage and release of 
the growth factors; binding to FGF2 led to activation of the mitogen-activated 
protein kinase (MAPK) pathway and eventually malignant transformation 
(Nikitovic et al., 2008, Deepa et al., 2002). CS-E was found highly expressed 
in ECM of ovarian adenocarcinoma, mediating VEGF binding and promoting 
tumor progression (ten Dam et al., 2007). The importance of sulfation pattern 
in CS/DS chains could also be seen in their specific selection of binding to cell 
membrane receptors such as L- and P-selectins and CD44, leading to 
malignant transformation of tumor cells (Asimakopoulou et al., 2008, 
Kawashima et al., 2000, Monzavi-Karbassi et al., 2007). In melanoma cells, 
CS-A chains of melanoma chondroitin sulfate proteoglycans (MCSP) 
specifically enhanced formation of a complex with membrane type-3 MMP 
(MT3-MMP) and pro-MMP2, leading to activation of MMP3, which is the 
primary extracellular matrix degrading enzyme in the metastatic cascade (Iida 
et al., 2007). 
 





1.10.3.1. Chondroitin sulfate/ dermatan sulfate and the respective 
proteoglycans in breast cancer 
The roles of chondroitin sulfate/ dermatan sulfate were reported to implicate in 
breast cancer tumorigenesis. In a paper published earlier (Alini and Losa, 
1991), comparison of biochemical composition of proteoglycans in invasive 
mammary carcinoma and benign lesions of the breast was made. In neoplastic 
tissue, there was an increased level of chondroitin sulfate but dermatan sulfate 
level was lower compared with tissue from benign lesions. Similar alteration 
in proteoglycans composition was detected by another group of researchers 
when comparing proteoglycans composition in breast cancer tissue with 
normal tissue. Extracted proteoglycans from breast cancer tissue could 
stimulate endothelial cells proliferation by 1.3- to 1.5-fold, and the 
proliferative action was the consequent of the increased chondroitin sulfate 
content (Vijayagopal et al., 1998). Decorin was shown to possess anti-
proliferative property. Decorin is a ligand for EGF receptor. In breast cancer, 
the ectopic expression of decorin inhibited EGF signaling through interaction 
with EGF receptor (Iozzo, 1998, Wegrowski and Maquart, 2004), leading to 
the down-regulation of ErbB2 and MAP kinases (Santra et al., 2000) and 
upregulation of p21
Cip1
/WAF1 CDK inhibitor (De Luca et al., 1996), causing 
an inhibition of cell proliferation and specific induction in transformed cells 
(Tralhao et al., 2003). In invasive breast carcinoma, reduced expression of 
lumican, another member of SLRP family, was demonstrated to correlate with 
cancer progression (Troup et al., 2003). In patients with node-negative 
invasive breast cancer, reduced expression of decorin and lumican were 
associated with poor prognosis. Low decorin was shown to predict recurrence 





and poor survival from multivariate cox regression analysis model (Troup et 
al., 2003). One explanation for this observation was that as both decorin and 
lumican were important in maintaining normal collagen organization, the 
reduced expressions of these proteoglycans dampened the strength of 
extracellular matrix as physical barrier to tumor spread (Peyrol et al., 1997). 
Besides, stroma with lower expression of decorin was unable to sequester 
TGF-β effectively, thus led to poor disease outcome in later stages of 
epithelial tumors (Akhurst and Balmain, 1999, Reiss and Barcellos-Hoff, 1997, 
Arteaga et al., 1996).  
 
Versican is a high molecular mass stroma PG decorated with CS chains. In 
breast cancer, versican expression was found positively correlated with 
recurrence and more advanced disease (Wilson et al., 1983). Versican was 
demonstrated as a potential prognostic marker in predicting recurrence in 
node-negative primary breast cancer (Ricciardelli et al., 2002). Cox analyses 
from the study showed that patients with low peritumoral versican level had 
lower relapse rate than those with high versican levels.  
 
Chondroitin sulfate chains containing sulfation pattern of [GlcA-GalNAc (4, 
6-O-disulfate)] and [IdoA-GalNAc (4, 6-O-disulfide)] binds P-selectin with 
high affinity (Kawashima et al., 2002). It was demonstrated in a study that 
CSPGs on the surface of a metastatic breast cancer cell line, 4T1, were major 
P-selectin ligands and this interaction promoted pro-metastatic heterotypic 
adhesion of tumor cells to platelets and endothelial cells (Monzavi-Karbassi et 
al., 2007). The same group of researchers further extended the experiment to 





indicate that the expression of CHST11 gene controlled the construction of 
CS-A chains. In aggressive breast cancer cells, CHST11 gene expression was 
associated with metastatic phenotypes and synthesis of P-selectin ligands 
(Cooney et al., 2011).  In addition, expression of CHST11 and CSPG4 were 
assessed by qRT-PCR in primary invasive breast cancer clinical specimens. 
Both of these genes were over-expressed in tumor-containing tissues 
compared with normal tissues. The significance of interaction between CS 
chains and P-selectin was further evident when CS chains in highly metastatic 
mammary cell line were removed by enzymatic methods. The formation of 





















1.11. Objectives of project 
To the best of my knowledge, this is the first study conducted to investigate 
the functional role of CSGalNAcT-1 in breast cancer. CSGalNAcT-1 was 
hypothesized to mediate the phenotypic changes of the breast cell lines. 
 
The objectives of this study are as follows: 
1. To determine the expression of CSGalNAcT-1 in different breast cell lines 
and investigate the functions of this gene in affecting cellular behaviors by 
silencing CSGalNAcT-1 in normal breast cell line, MCF-12A; and over-
expressing CSGalNAcT-1 in breast cancer cell lines, MCF7 and MDA-
MB-231.  
2. To investigate if CXCL14 is a downstream target of CSGalNAcT-1. 
3. To determine the localization and expression of CSGalNAcT-1 in clinical 
samples of breast invasive ductal carcinoma by immunohistochemistry and 
to study the association of CSGalNAcT-1 with clinicopathological 
parameters and its value in predicting clinical outcome.    
 
















2. MATERIALS AND METHODS 
2.1. In vitro cell culture 
2.1.1. Cell lines 
A few breast cell lines were used in this project. A non-tumorigenic human 
breast cell line, MCF-12A (ATCC:  CRL-10782) and breast cancer cell lines, 
MCF-7 (ATCC: HTB-22), MDA-MB-231 (ATCC: HTB-26), and ZR75-1 
(ATCC: CRL 1500) were obtained from American Type Culture Collection 
(ATCC, Manassas, VA, USA). MCF-12A was propagated in DMEM/F12 
(Invitrogen, Carlsbad, CA, USA) supplemented with 20 ng/ml human 
epidermal growth factor (EGF) (Sigma-Aldrich, Missouri, USA), 100 ng/ml 
cholera toxin (Sigma-Aldrich, Missouri, USA), 0.01 mg/ml bovine insulin 
(Sigma-Aldrich, Missouri, USA), 500 ng/ml hydrocortisone (Sigma-Aldrich, 
Missouri, USA) and 5% fetal bovine serum (FBS) (Hyclone, Logan, Utah). 
MCF-7, a poorly invasive human breast adenocarcinoma cell line was cultured 
in DMEM supplemented with 10% FBS. ZR75-1 is a less invasive breast 
cancer cell line and MDA-MB-231 is a highly invasive human breast 
adenocarcinoma cell line. These two cell lines were cultivated in RPMI 1640 
supplemented with 10% FBS. All cell lines were incubated in a humidified 
incubator at 37°C in a 5% CO2, 95% air atmosphere.  
 
2.1.2. Thawing of human breast cell lines 
The frozen vial of human breast cell lines was thawed immediately in 37°C 
water bath upon removal from liquid nitrogen storage tank. Cryopreserved 
cells were neutralized with 4 ml of culture medium and centrifuged at 125 x g 
for 5 minutes to remove the cytotoxic, cryoprotectant dimethyl sulphoxide 





(DMSO) (Sigma-Aldrich, Missouri, USA). Cell pellet was resuspended in 5 
ml of culture medium and transferred into a 25 cm
2 
culture flask and incubated 
at 37°C, 5% CO2 incubator.  
 
2.1.3. Subculture of human breast cell lines 
Cells were ready to be subcultured when cell confluency of 80% was reached. 
Culture medium was decanted from the culture flasks and washed with 1X 
PBS to remove any cell debris. MCF7, ZR75-1 and MDA-MB-231 were 
detached from the surface of the flask with 1X pre-warmed trypsin- 
ethylenediaminetetraacetic acid (trypsin-EDTA) (Invitrogen, Carlsbad, CA, 
USA) for 5 minutes at 37°C inside incubator. However, the highly adherent 
MCF-12A cells need to be trypsinized using 5X pre-warmed trypsin-EDTA 
for 10 minutes at 37°C inside incubator. The detached cells were then 
resuspended with complete medium at 3X the volume of added trypsin to 
inactivate the trypsin activity. The cell suspension was centrifuged at 125 x g 
for 5 minutes and resuspended with fresh complete medium before dividing 
into culture flasks at ratio of 1:3.  
 
2.1.4. Cryopreservation of human breast cell lines 
The cryopreservation medium used for the various breast cell lines comprised 
of culture medium supplemented with 20% FBS and 5% DMSO. The cells 
were transferred to cryovials and placed in freezing container Mr. Frosty 
(Nalgene, Rochester, NY) for overnight at -80°C before long-term storage in 
liquid nitrogen. 





2.2. RNA extraction, cDNA synthesis, quantitative real time polymerase chain 
reaction (qRT-PCR) of human breast cell lines 
Total RNA was extracted from breast cell lines grown in culture flasks and 6-
well plates using RNeasy Mini kit (Qiagen, Hilden, Germany), as according to 
manufacturer protocol. RNA yield was quantified using Nanodrop ND-100 
spectrophotometer (Thermo Fisher Scientific, Wilmington, USA). The purity 
of extracted RNA was determined using the absorbance ratio of A260/A280, 
which should range from 1.8 to 2.1. cDNA synthesis from total RNA was 
performed using the Superscript III First-strand cDNA synthesis kit 
(Invitrogen, Carlsbad, USA), following the manufacturer protocol. The cDNA 
was used for quantitative real-time PCR using the QuantiTect SYBR Green 
PCR kit (Qiagen, Hilden, Germany) on the Roche LightCycler 2 machine 
(Roche Diagnostics Corporation, Roche Applied Science). Primers used for 
qRT-PCR are listed in Table 2.1 (1
st
 Base, Singapore). Program settings used 
for qRT-PCR is as described: An initial activation step at 95 °C for 15 minutes, 
followed by 45 cycles of a 3 three-step process of denaturation at 94 °C for 15 
seconds, annealing at 60 °C for 25 seconds, and extension at 72°C for 12 













Table 2.1 Sequences of qRT-PCR primers used 
Gene symbol Forward primer Reverse primer Product 
size 
β-actin tggcaccacaccttctacaat gatagcacagcctggatagca 166 
CSGalNAcT-1 gagatgtgcattgagcagga gaagttggcagctttggaag 114 
CSGalNAcT-2 tccccttggagagaaactga cggaagagggtcacatgtct 141 
CXCL14  accaagagcgtgtccaggta ttgcacaagtctcccaactg 175 
GAPDH gaaggtgaaggtcggagtcaacg tgccatgggtggaatcatattgg 157 
T7, BGH  taatacgactcactataggg cttatgagtatttcttccagggta 177 
 
2.3. Gene silencing in MCF-12A 
2.3.1. Single siRNA silencing 
ON-TARGETplus SMARTpool CSGalNAct-1 siRNA, negative control ON-
TARGETplus siCONTROL Non-targeting pool siRNA and positive control 
ON-TARGETplus siCONTROL GAPDH SMARTpool siRNA as the positive 
control were used (Dharmacon Inc, Colorado, United States of America). The 
sequences of CSGalNAcT-1 siRNA are listed in Table 2.2. Before transfection, 
MCF-12A cells were trypsinized and resuspended in Opti-MEM I Reduced 
Serum Medium (Invitrogen, Carlsbad, CA, USA). For each well in a 6-well 
plate, 30 nM of siRNA was diluted in 96.25 µl of Opti-MEM I and a mixture 
of 8 µl siPORT Amine transfection reagent (Ambion, Inc/Applied Biosystems, 
Texas, USA) with 92 µl of Opti-MEM I were incubated for 25 minutes at 
room temperature. The two diluents that made up a total volume of 200 µl 
were mixed gently and incubate for 15 minutes at room temperature to allow 
transfection complexes to form. After that, 2 x 10
5
 MCF-12A cells in 2.3 ml of 
Opti-MEM I were seeded into each well and 200 µl of siRNA complex was 
added into the cell suspension. The 6-well plate was swirled gently to mix the 
complexes and cells evenly. Finally, incubate the 6-well plate at 37°C in 5% 
CO2 incubator for 8 hours.  





Following incubation, transfection complexes were totally replaced with 2.5 
ml complete DMEM/F12 in every well. After 24 hours post transfection, every 
well was replaced with fresh 2.5 ml complete medium again. Silenced cells 
were harvested at either 48 hours or 72 hours post transfection for further 
experiments. The silencing efficiencies of transfected MCF-12A cells were 
determined using qRT-PCR. 
 
Table 2.2 ON-TARGETplus SMARTpool CSGalNAcT-1 siRNA sequence  


















Same transfection protocol was applied in silencing MCF-12A with Ambion 
Silencer® Select CXCL14 siRNA (Ambion, Inc / Applied Biosystems, Texas, 
USA). A final concentration of 10 nM siRNA and 8 µl siPORT Amine 
transfection reagent (Ambion, Inc / Applied Biosystems, Texas, USA) were 
added to each well. Table 2.3 listed the sequences of CXCL14 siRNA used. 
Ambion Silencer® Select siRNA Negative Control was used as negative 










Table 2.3 Ambion Silencer Select
®













2.3.2. Double siRNA silencing 
The same transfection method as above was adopted in double siRNA 
silencing. Four experimental groups were included: double silenced group 30 
nM CSGalNAcT-1 siRNA + 10 nM CXCL14 siRNA; double negative group 
30 nM ON-TARGETplus siCONTROL Non-targeting pool siRNA + 10 nM 
Ambion Silencer® Select siRNA Negative Control siRNA; CSGalNAcT-1 
single silenced group 30 nM CSGalNAcT-1 siRNA + 10 nM Ambion 
Silencer® Select siRNA Negative Control siRNA and CXCL14 single silenced 
group 10 nM CXCL14 siRNA + 30 nM N-TARGETplus siCONTROL Non-
targeting pool siRNA.  
 
2.4. Microarray analysis 
CSGalNAcT-1 silenced MCF-12A cells were harvested 48 hours post 
transfection as described in section 2.3.1. Total RNA was extracted using 
RNeasy Mini kit (Qiagen, Hilden, Germany) and RNA purity and 
concentration was obtained as described in section 2.2. Sample RNA was 
confirmed to have good quality before sending to Origen Labs (Origen 
Laboratories, Singapore) for hybridization to Affymetrix Human U133 Plus 
version 2.0 array. Raw microarray data was processed using GeneSpring 
software (Agilent Technologies, United States). MultiExperiment Viewer 





(TM4 Microarray Software Suite) was used to perform further data 
visualization. Gene ontology grouping was performed using The Database for 
Annotation, Visualization and Integrated Discovery (DAVID) version 6.7 
(NIH, Maryland, United States). 
 
2.5. Stable over-expression of CSGalNAcT-1 in MCF-7 and MDA-MB-231 
The plasmid was kindly provided by Prof Hideto Watanabe from Institute for 
Molecular Science of Medicine, Aichi Medical University, Nagakute, Aichi 
(Sakai et al., 2007) and pcDNA 3.1 empty vector was kindly provided by 
Associate Professor Ann Lee Siew Gek from National Cancer Centre, 
Singapore. Full CSGalNAcT-1 mRNA sequence was cloned into pcDNA 3.1 
vector (Invitrogen, Carlsbad, USA). The plasmid contains both Ampicillin and 
Neomycin (G418) resistant gene for selection purpose. The details of 
CSGalNAcT-1 cloning were described in Sakai et al., 2007. 
 
2.5.1. Plasmid transformation 
Competent Escherichia coli (E.coli) (Sigma-Aldrich, Missouri, USA) were 
used for plasmid transformation. 20 ng of plasmid was added to the competent 
cells. The cells were placed on ice for 20 minutes followed by heating up to 
42°C for 90 seconds and then placed back on ice for 2 minutes. After heat 
shock, 1 ml of LB broth was added to the cells and the culture was placed on 
shaker at 300 rpm for 1 hour. After that, the cells were streaked onto agar 
plates containing 100 μg/ml of Ampicillin (Sigma-Aldrich, Missouri, USA). 
The agar plates were placed in oven at 37°C overnight. 
 





2.5.2. Colony polymerase chain reaction (PCR) 
Several colonies were picked up partially for colony PCR. This is to ensure the 
gene of interest remains in the plasmids during the transformation. 
CSGalNAcT-1 primers were used in the PCR; while T7 forward primer and 
BGH reverse primer were used to bind to empty vector in the PCR. The PCR 
setup is as follows: initial denaturation at 94 °C for 3 minutes, followed by 44 
cycles of 94 °C  30 seconds, 55 °C  30 seconds and 72 °C  1 minute, and final 
extension step of 72 °C  10 minutes. Taq PCR Core Kit from Qiagen, Hilden, 
Germany was used in the PCR. Subsequently, the PCR products were run on a 
2% DNA gel electrophoresis to verify the correct product size. The DNA gel 
electrophoresis was run at 90 V for one hour.  
 
2.5.3. Colony expansion and plasmid extraction 
After colony PCR, the remaining part of the colonies were picked up and 
inoculated into LB broth containing 100 ug/ml Ampicillin and left on shaker 
to shake overnight again at 37°C at speed of 300 rpm. The next day the 
cultures were used for plasmid extraction using Qiagen Mini-prep kit (Qiagen, 
Hilden, Germany), following the manufacturer protocol. Plasmid yield was 
quantified using Nanodrop ND-100 spectrophotometer (Thermo Fisher 
Scientific, Wilmington, USA). The purity of extracted plasmid was 
determined using the absorbance ratio of A260/A280, which should range from 









2.5.4. CSGalNAcT-1 plasmid stable transfection in MCF-7 and MDA-MB-231 
MCF-7 (8 x 10
4
 cells) and MDA-MB-231 (5 x 10
4
 cells) were seeded in 24-
well plate to reach a confluency of 80-90% the next day. 0.2 μg of 
CSGalNAcT-1 plasmid and 0.5 μg of the plasmid were transfected into MCF7 
and MDA-MB-231 respectively using Lipofectamine 2000 reagent (Invitrogen, 
Carlsbad, USA), according to the manufacturer protocol. 24 hours later, each 
well was replaced with complete medium. To achieve optimal condition for 
antibiotic selection, transfected cells were reseeded at 2 x 10
4 
cells per well for 
Neomycin (Invitrogen, Carlsbad, USA) selection. MCF-7 cells were added 
with 700 μg/ml of Neomycin while MDA-MB-231 cells were added with 450 
μg/ml of Neomycin. Two weeks later, colonies were picked up for expansion. 
The over-expression level of CSGalNAcT-1 in MCF-7 and MDA-MB-231 
were determined by qRT-PCR.  
 
2.6. Cell migration assay 
Cell migration assay was performed in Transwell Inserts (Corning 
Incorporated, New York) of polycarbonated membrane with 8.0 µm pore size. 
To improve cell attachment, the transwell inserts were hydrated with medium 
overnight at 4°C. The transwell inserts were placed in incubator at 37°C for an 
hour before use. After 48 hours of siRNA transfection, MCF-12A cells were 
trypsinized and reseeded at a density of 5 x 10
4
 into the chamber. CSGalNAcT-
1 over-expressed MCF-7 and MDA-MB-231 were seeded at a seeding density 
of 5 x 10
4
 cells per well. The chambers were incubated for 24 hours in the 
humidified incubator at 37°C, 5% CO2.  
 





Following incubation, cell suspension was removed from the Transwell Inserts 
and washed with 1X PBS. Migrated cells were fixed by methanol for 15 
minutes. Subsequently, the inserts were rinsed with 1X PBS again and left to 
air dry. The inserts were then stained aqueous crystal violet (0.5% w/v) for 30 
minutes. Excessive stain was removed by clean tap water. Non-migrated cells 
on the upper surface of the membrane insert were removed with a cotton swab. 
Migrated cells on the underneath surface of the inserts were visualized at 10X 
objective under stereo microscope (Nikon SMZ 1500) coupled to a digital 
camera (Nikon DXM1200F). Images of five random fields per insert were 
captured for quantification.   
 
2.7. Cell invasion assay 
In vitro cell invasion was assayed using BD BioCoat™ Cell Environments, 
Matrigel™ Invasion Chambers inserts (BD, Franklin Lakes, NJ, USA) on a 
24-well format. The invasion chambers were dehydrated by medium overnight 
at 4°C. The invasion chambers were placed in incubator at 37°C for 1 hour 
before use. After 48 hours of siRNA transfection, MCF-12A cells were 
trypsinized and reseeded at a density of 5 x 10
4
 into the chamber. CSGalNAcT-
1 over-expressed MCF-7 and MDA-MB-231 were seeded at a density of 1 x 
10
5
 cells per well. The wells were filled with medium supplemented with 
different concentration of FBS. The chambers were incubated for 24 hours in 
the humidified incubator at 37°C, 5% CO2. The subsequent fixation and 
quantification procedure was the same as described in section 2.6.  
 
 





2.8. Cell viability assay 
Cell viability was analyzed using a colorimetric technique CellTiter 96 
Aqueous Non-radioactive cell proliferation assay (Promega, Madison, USA) 
72 hours post transfection. The reagent contains a novel tetrazolium 
compound, [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl-2H-tetrazolium, inner salt; MTS). MTS is bioreduced into 
formazan by living cell mitochondrial dehydrogenase. The quantity of 
formazan is directly proportional to the amount of living cells in culture. The 
samples were incubated for 4 hours before measuring absorbance at 490 nm in 
a TECAN plate reader (GENios, Austria).  
 
2.9. Cell apoptosis assay 
Cell apoptosis was assayed using a fluorescent technique Apo-ONE® 
Homogenous Caspase-3/7 Assay (Promega, Madison, USA). 48 hours post 
siRNA transfection, MCF-12A cells were reseeded into 96-well black opaque 
plate at a seeding density of 1 x 10
4
 cells per well and the cells were incubated 
overnight. Caspase profluorescent substrate and Apo-ONE® Caspas-3/7 
buffer were thawed and mixed in 1:100 ratios before use. 100 µl of Apo-
ONE® Caspase-3/7 reagent was added to each well. The plate was placed at 
room temperature for one hour. Subsequently, fluorescence was measured at 










2.10. Cell adhesion assay 
96-well plate was pre-coated with collagen Type I (BD, Franklin Lakes, NJ, 
USA) or fibronectin (BD, Franklin Lakes, NJ, USA) overnight at 4°C. the 
plate was blocked with 1% bovine serum albumin (Sigma-Aldrich, St. Louis, 
MO, USA) for one hour the next day. Transfected cells were reseeded at 1 x 
10
4
 cells per well (for Collagen Type I coated plate) or 3 x 10
4
 cells per well 
(for Fibronectin coated plate). Each treatment group consists of washed and 
unwashed group. The washed group has to be washed with 1X PBS thrice 
before 1 hour incubation and no washing is done to the unwashed group. MTS 
assay was performed to compare the amount of adhered cells. Absorbance was 
taken at 490 nm 4 hours after MTS was added.  
 
2.11. Western blotting 
2.11.1. Protein extraction 
Cells were harvested 48 hours post siRNA transfection. Protein was extracted 
using M-PER Mammalian Protein Extraction Reagent (Pierce, Illinois, USA) 
with Halt Protease Inhibitor cocktail and EDTA (Pierce, Illinois, USA) added 
at 10 µl/ml to produce a 1X final concentration. The protein extraction buffer 
was added to the wells and waited for 5 minutes on ice. Adherent cells were 
scrapped with cell scrapper (TPP, Switzerland) and centrifuged at 13000 rpm 
for 10 minutes at 4°C. The supernatant which contained protein was aspirated 









2.11.2. Protein quantification 
The protein concentration was quantified using a colorimetric method, 





 in the alkaline medium. The concentration of protein is 
directly proportional to the amount of reduction which is presented in a purple 
coloration. 25 µl of protein sample was added into a 96-well plate along with 
BCA working reagent containing 50 parts of BCA solution and 1 part of 4% of 
cupric sulphate solution. Samples were incubated at 37°C for 30 minutes 
before absorbance reading at 562 nm. The final absorbance values were 
recorded after subtracting away blank absorbance readings. A standard curve 
was plotted using the final absorbance values of serial diluted bovine serum 
albumin standards. Protein concentration of each sample was derived from the 
standard curve. 
 
2.11.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
10% resolving gel was casted. The resolving gel contained deionised water, 30% 
acrylamide mix, Tris (1.5 M, pH 8.8), 10% sodium dodecyl sulfate, 10% 
ammonium persulfate, and tetramethylelthylenediamine (TEMED). Gel liquid 
was allowed to polymerize in 30 minutes. After that 5% stacking gel was 
prepared and added on top of polymerized resolving gel. Stacking gel 
contained deionised water, 30% acrylamide mix, Tris (1.0 M, pH 6.8), 10% 
SDS, 10% ammonium persulfate and TEMED.  
 





30 µg of protein was diluted in 5X SDS loading buffer containing Tris-Cl (250 
mM, pH 6.8, 30% glycerol, 5% dithiothretol (DTT) and 0.02% bromophenol 
blue. The diluted samples were heated at 95°C for 5 minutes and cooled at 
room temperature. Samples and Precision Plus Protein dual color marker 
(Biorad, CA, USA) were loaded into wells and electrophoresis was performed 
at 80V with 1X SDS Tris-glycine buffer for 2.5 hours. 
 
2.11.4. Semi-dry electroblotting 
Polyvinyl difluoride (PVDF) membrane (Biorad, CA, USA) was activated by 
sequential rinsing of PVDF in methanol for 15 seconds, followed by deionised 
water and lastly 1X transfer buffer (Biorad, CA, USA). The gel was removed 
and equilibrated in 1X transfer buffer upon completion of electrophoresis run. 
In addition, two thick filter pads were pre-wetted in 1X transfer buffer as well. 
A gel-sandwich was assembled by placing a filter pad at the bottom, following 
the PVDF membrane, gel and lastly, another filter pad. Protein transfer was 
performed via Trans-Blot Semi-Dry Transfer Cell (Biorad, CA, USA) at 15V 
for 1 hour.  
 
2.11.5. Western blot 
Once the transfer was completed, the PVDF membrane was rinsed twice with 
1X TBS in 0.1% Tween-20 (1X TBST) for 5 minutes and blocked with 5% 
non-fat milk (Biorad, CA, USA) in 1X TBST for 1 hour. Subsequently, the 
membrane was probed with primary antibody in 5% non-fat milk with 1X 
TBST at 4°C overnight. The membrane was washed thrice with 1X TBST for 
10 minutes in each wash, followed by incubation with secondary antibody for 





1 hour at room temperature. The dilutions of primary and secondary antibodies 
used are listed in Table 2.4. After secondary antibody, membrane was washed 
thrice again with 1X TBST and bound antibodies were detected by enhanced 
chemilluminescence (ECL) using Femto Substrate System (Pierce, Illinois, 
USA). Equal volumes of stable peroxide solution and luminal solution were 
mixed and added carefully on to the membrane. X-ray films were exposed to 
the membrane in the dark and developed using an automatic film processor. 
The same protocol was used in CSGalNAcT-1 western blot except that the 
washing buffer and buffer for blocking was 1X PBS in 0.05% Tween-20 (1X 
PBST) and the primary and secondary antibody was diluted in 1X PBST with 


































































2.11.6. Densitometric analysis 
The protein band intensities were scanned and evaluated by densitometry (GS-
800 Calibrated Imaging Densitometer, BioRad, CA, USA). The intensities of 
the bands were processed and measured using Quantity-One Image Analysis 
Software version 4.6.9 (Biorad, CA, USA). Protein band intensity for each 
sample was normalised against band intensity of loading control, β-actin. 





2.12. Immunofluorescence  
2.12.1. F-actin immunofluorescence 
Cells were seeded on coverslips in a 6-well plate. CSGalNAcT-1 over-
expressed MCF-7 and MDA-MB-231 were seeded directly while silenced 
MCF-12A was assayed 48 hours post-transfection. Coverslips were rinsed 
thrice with 1X PBS. Fixation was performed using 4% paraformaldehyde for 
15 minutes. Subsequently, coverslips were washed thrice with 1X PBS-Triton 
X. Blocking was performed using 1% bovine serum albumin (BSA) for an 
hour followed by incubation with Alexa Fluor 488 Phalloidin for F-actin 
(Invitrogen, Carlsbad, CA, USA) at 1:40 dilution in 1% BSA for 20 minutes. 
After that, coverslips were washed thrice with 1X PBS for 5 minutes in each 
wash and mounted with VECTASHIELD mounting medium with DAPI 
(Vector Laboratories, CA, United States). Fluorescence was viewed and 
captured using Leica DM6000 M microscope (Leica Microsystems, Wetzlar, 
Germany). Fluorescence intensity was measured using ImageJ software 
version 1.42q (National Institutes of Health). 





2.12.2. CXCL14 immunofluorescence 
CSGalNAcT-1 over-expressed MCF-7 and MDA-MB-231 were seeded 
directly on 6-well plate while silenced MCF-12A was assayed 48 hours post-
transfection. Coverslips were rinsed thrice with 1X PBS. Fixation was 
performed using 4% paraformaldehyde for 15 minutes. Subsequently, 
coverslips were washed thrice with 1X PBS-Triton X. Blocking was 
performed using 1% bovine serum albumin (BSA) for an hour. Incubation of 
CXCL14 antibody (ab46010, Abcam, CA, USA) was done at a dilution of 
1:100 overnight at 4 °C. The next day, coverslips were washed thrice with 1X 
PBS-Tx for 5 minutes in each wash. Secondary antibody Alexa Fluor 488 goat 
anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA) diluted at 1:400 was 
incubated for another one hour at room temperature in the dark and followed 
by three washes of 1X PBS-Tx for 5 minutes in each wash. Finally, coverslips 
were mounted with VECTASHIELD mounting medium with DAPI (Vector 
Laboratories, CA, United States). Fluorescence was viewed and captured 
using Leica DM6000 M microscope (Leica Microsystems, Wetzlar, Germany). 
Fluorescence intensity was measured using ImageJ software version 1.42q 
(National Institutes of Health). 
 
2.12.3. CSGalNAcT-1 immunofluorescence in over-expressed MCF-7 and 
MDA-MB-231 cells 
CSGalNAcT-1 over-expressed MCF-7 and MDA-MB-231 were seeded 
directly on 6-well plate. Coverslips were rinsed thrice with 1X PBS. Fixation 
was performed using 4% paraformaldehyde for 15 minutes. Subsequently, 
coverslips were washed thrice with 1X PBS-Triton X. Blocking was 





performed using 1% bovine serum albumin (BSA) for an hour. Incubation of 
CSGalNAcT-1 antibody (ab67128, Abcam, CA, USA) was done at a dilution 
of 1:36 for 2 hours at room temperature. After that, coverslips were washed 
thrice with 1X PBS-Tx for 5 minutes in each wash. Secondary antibody Alexa 
Fluor 568 goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) diluted at 
1:200 was incubated for another one hour at room temperature in the dark and 
followed by three washes of 1X PBS-Tx for 5 minutes in each wash. Finally, 
coverslips were mounted with VECTASHIELD mounting medium with DAPI 
(Vector Laboratories, CA, United States). Fluorescence was viewed and 
captured using Leica DM6000 M microscope (Leica Microsystems, Wetzlar, 
Germany). Fluorescence intensity was measured using ImageJ software 
version 1.42q (National Institutes of Health). 
 
2.13. Tissue microarray samples and clinicopathological data 
Tissue microarray blocks of paraffin-embedded invasive ductal cancer 
specimens were constructed by the Department of Pathology, Singapore 
General Hospital. Briefly, specific regions representative of the breast tumours 
are selected and punched out from the donors‟ blocks. Cores of invasive ductal 
carcinomas (IDCs) (2 mm diameter) were inserted sequentially into different 
recipient blocks. Control tissues (e.g. colon, liver and testis) of 1 mm diameter 
were included in the series of tissue microarray on invasive ductal carcinomas. 
4 μm sections were cut from these recipient blocks and mounted on pre-coated 
poly-lysine slides. A total of 297 cases of breast invasive ductal carcinomas 
dated from year 1998 to 2004 were included in the tissue microarrays. 
Clinicopathological information of patients diagnosed with breast invasive 





ductal carcinomas included patient age, race, tumor size, staging, histological 
grade, lymph node status, DCIS grade, steroid hormone receptors, HER2 
status, Bloom-Richardson scoring, tumor tubule formation, pleomorphism and 
mitotic index are obtained.  
 
2.14.  Immunohistochemistry 
2.14.1. CSGalNAcT-1 immunohistochemistry  
Formalin-fixed, paraffin-embedded tissue microarray sections of 4 μm 
thickness were deparaffinized in 2 changes of histoclear, followed by 
rehydration in a graded series of ethanol. The sections were washed with 1X 
Tris buffered saline (TBS) for 5 minutes before endogenous peroxidase 
activity was quenched with 3% hydrogen peroxide (H2O2) for 30 minutes. 
Antigen retrieval was performed by microwaving the sections in 0.1 M citric 
acid buffer and 0.1 M sodium citrate buffer at 100 °C for 20 minutes. The 
slides were washed in 1X TBS-Triton X (TBS-Tx) thrice and 5 minutes each 
prior to 1 hour incubation of blocking serum at room temperature. Next, the 
sections were incubated overnight with the mouse CSGalNAcT-1 polyclonal 
primary antibody (Abnova, Taipei, Taiwan) at a dilution of 1:100 at 4 °C. 
Negative controls were assessed by replacing primary antibody with 1X TBS-
Tx. After rinsing with 1X TBS-Tx, biotinylated secondary antibody was added 
for 1 hour at room temperature. Visualisation was achieved by the avidin-
biotin-complex technique (ABC kit, Vector Laboratories) using 
diaminobenzidine (DAB) as the substrate, followed by counterstaining with 
hematoxylin. The sections were dehydrated in graded series of ethanol and 
histoclear before mounted in permount.  





2.14.2. Semi-quantitative analysis of CSGalNAcT-1 immunostaining in breast 
invasive ductal carcinomas (IDCs) 
Every tissue microarray case was examined using ImageScope software 
version 10.2.1.2314 for Windows (Aperio Technologies, Inc, CA, USA). 
Assessment of CSGalNAcT-1 staining was scored independently by one 
individual, followed by verification by a pathologist from Singapore General 
Hospital. Any discordant in immunoscoring will be re-evaluated until 
consensus was reached. Prior knowledge of the clinical data was not known 
during the immunoscoring of the TMA sections to avoid any bias in scoring. 
The scoring criteria of CSGalNAcT-1 in the stroma and epithelial components 
of invasive ductal carcinomas were divided into different categories as follows: 
staining intensities of 0 = no staining; 1+ = weak staining; 2+ = moderate 
staining; 3+ = intense staining and the percentage immune-positivity. 
Weighted average intensity (WAI) is the semi-quantitative measurement of the 
amount of a molecule being expressed.  Total percentage score (TPS) is the 
total percentage of cells stained. A final immunoreactivity score (IRS) is the 
multiplication of WAI and TPS. 
 
2.14.3.  Statistical Analysis 
The results of CSGalNAcT-1 immunostaining in invasive ductal carcinomas 
were analysed using SPSS 17.0 for Windows (SPSS Inc, Chicago, IL, USA). 
The association of CSGalNAcT-1 immunostaining with other 
clinicopathological parameters was evaluated using Fisher‟s exact test, while 
correlation with ordinal parameters was evaluated using Kendall‟s tau-b and c 
test. Statistical significance was defined as a P-value of <0.05. Besides, 





multivariate analysis was performed to investigate the confounding effect in 
these parameters with CSGalNAcT-1 immunoscoring. 
 
Timeline analyses were then carried out to assess the recurrence and survival 
of the malignant IDC cases. The timeline measurements used were: (1) 
Overall Survival (OS) = Date of Death – Date of Diagnosis; (2) Disease Free 
Survival (DFS) = Date of Recurrence – Date of Diagnosis; (3) Survival After 
Recurrence (SAR) = Date of Death – Date of Recurrence. Analyses were done 
using the Log Rank (Mantel-Cox) test and Kaplan-Meier graphs were 
constructed. Statistical significance was also defined as a P-value of <0.05.   
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3. FUNCTIONAL ANALYSIS OF CSGALNACT-1 IN BREAST CELL 
LINES 
The objective of this section of study is to determine the functional role of 
CSGalNAcT-1 in breast cell lines. The expression of CSGalNAcT-1 in 
different breast cell lines was investigated. Subsequently, the functional 
impact of this gene was determined by knocking it down in normal breast cell 
line, MCF-12A; and over-expressing it in breast cancer cell lines, MCF7 and 
MDA-MB-231. The functional properties of CSGalNAcT-1 were assessed by 
examining the changes in migration, invasion, survival and adhesion of the 
cells. Microarray analysis was done to identify downstream targets of the 
CSGalNAcT-1 signaling pathway. CXCL14 was subsequently selected for 
double knockdown experiments to determine if CXCL14 works downstream of 
CSGalNAcT-1 in mediating the phenotypic changes of MCF-12A cells. 
 
3.1. CSGalNAcT-1  expression in different breast cell lines 
The expression of CSGalNAcT-1 was measured by qRT-PCR in breast cancer 
cell lines (MCF7, ZR75-1 and MDA-MB-231) in relative to MCF-12A, the 
normal breast cell line. The result is shown in Figure 3.1. Expression level of 
CSGalNAcT-1 in breast cancer cell lines is significantly lower in normal breast 
cell line, MCF-12A. 
 

































Tukey's Multiple Comparison Test:
MCF-12A vs MCF7 P< 0.001
MCF-12A vs ZR75-1 P< 0.001
MCF-12A vs MDA-MB-231 p< 0.001










Figure 3.1 Expression level of CSGalNAcT-1 in breast cancer cell lines 
(MCF7, ZR75-1 and MDA-MB-231) and MCF-12A, the normal breast cell 
line. Data shows that expression of CSGalNAcT-1 is lower in breast cancer 
cell lines as compared with MCF-12A normal breast cell line. Error bar 




3.2. Knockdown of CSGalNAcT-1 in MCF-12A cells 
CSGalNAcT-1 gene was silenced in MCF-12A with Dharmacon ON-
TARGETplus SMARTpool CSGalNAcT-1 siRNA. After optimization, 
CSGalNAcT-1 was successfully knockdown by 76.42% as shown in Figure 3.2. 
 





















Figure 3.2 Silencing efficiency of CSGalNAcT-1 gene in MCF-12A normal 
breast cell line. CSGalNAcT-1 was successfully knockdown by 76.42%. Error 
bar represents standard error. 





3.2.1. Knockdown of CSGalNAcT-1 expression in MCF-12A is specific 
To confirm that Dharmacon ON-TARGETplus SMARTpool CSGalNAcT-1 
siRNA specifically knockdown CSGalNAcT-1 only but not its isoform 
CSGalNAcT-2, qRT-PCR was performed to analyze the expression level of 
CSGalNAcT-2 in CSGalNAcT-1 silenced MCF-12A cells. As shown in Figure 
3.3, there is no significant change in mRNA expression of CSGalNAcT-2 after 




















Figure 3.3 Transfection of CSGalNAcT-1 in MCF-12A cells did not cause a 
change in the expression of its isoform CSGalNAcT-2, indicating the 




3.2.2. Assessment of CSGalNAcT-1 protein expression in MCF-12A cells 
after silencing 
The CSGalNAcT-1 protein level was examined 48 hours post silencing and 
the expression level was assessed by western blotting. As shown in Figure 
3.4A, band intensity of protein extracted from CSGalNAcT-1 silenced MCF-
12A (61 kDa) was markedly reduced compared to negative control group. 
Figure 3.4B indicates the expression of the housekeeping gene, β-actin (41 
kDa), as the reference gene. In Figure 3.4C, quantification of the band 





intensity was performed and the result showed that expression of 
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Figure 3.4 Western blot analysis of CSGalNacT-1 protein level 48 hours post 
transfection in MCF-12A cells. (A) Band intensity of CSGalNAcT-1 in 
silenced cells was reduced as compared with si-Neg. (B) β-actin protein acts 
as a normalizer and the expression was unaffected in the silencing process. (C) 
Densitometric analysis of protein bands revealed that CSGalNAcT-1 protein 
level is significantly reduced by 42% in silenced cells as compared with the si-
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3.2.3. Analysis of cell motility in CSGalNAcT-1 silenced MCF-12A cells 
3.2.3.1. Transwell migration assay 
Cell migration assay was performed in transwell inserts to study the migratory 
behavior of MCF-12A cells after CSGalNAcT-1 silencing. A chemoattractant 
gradient was created by supplementing medium with 15% FBS in the bottom 
chamber while no FBS is added to the cell suspension seeded into the top 
insert. Figure 3.5 shows that a remarkable increase in the migration of MCF-
12A cells was observed when CSGalNAcT-1 is suppressed. 
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Figure 3.5 Silencing of CSGalNAcT-1 in MCF-12A promoted cell migration. 
(A) and (B) showed migrated cells in chambers. (C) Cells treated with 
CSGalNAcT-1 siRNA exhibited almost a double fold of increase in migration 
















3.2.3.2. F-actin immunofluorescence 
F-actin is an indicator of cell motility. Generally, fluorescence intensity of F-actin in CSGalNacT-1 silenced MCF-12A was greater than the 
negative control, as shown in Figure 3.6A and 3.6B. This result agrees with that of transwell migration assay in section 3.2.3.1, indicating that 




F-actin staining DAPI staining Merged 
si-Neg si-Neg si-Neg 






si-CSGalNAcT-1 si-CSGalNAcT-1 si-CSGalNAcT-1 
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Figure 3.6 Changes in F-actin polymerization after CSGalNAcT-1 knockdown 
in MCF-12A. (A, B) Immunofluorescence images stained with F-actin (left), 
DAPI in nucleus (DAPI blue, middle) and merged figures (right) of si-Neg 
and CSGalNAcT-1 silenced group. Mean fluorescence intensity is measured by 
the ImageJ software. (C) Statistically, F-actin intensity increased significantly 




3.2.4. Assessment of the cell invasiveness of CSGalNAcT-1 silenced MCF-
12A using Matrigel assay 
In vitro cell invasion was assayed in BD Biocoat invasion chambers of PET 
membrane with 8.0 µm pore size. Lower wells were added with medium 
supplemented with 15% FBS to serve as chemoattractant. A profound increase 
in CSGalNAcT-1 suppressed cells invading across the Matrigel coated 
membrane was observed in Figure 3.7A and 3.7B. The invasive capability was 
increased by 87.8% in CSGalNAcT-1-silenced group as shown in Figure 3.7C. 
 











































Figure 3.7 Down-regulation of CSGalNAcT-1 induced MCF-12A cells 
invasion across matrigel membrane. (A) and (B) showed the invaded cells in 
chambers. (C) The invasive capability of CSGalNAcT-1 silenced cells was 


















3.2.5. CSGalNAcT-1 silencing promotes cell viability in MCF-12A 
To test whether silencing of CSGalNAcT-1 brings any effect on the MCF-12A 
cell viability, the cell viability was measured by CellTiter 96 Aqueous Non-
radioactive cell proliferation assay 72 hours later after transfection. In Figure 
3.8, the analysis showed slight but significant increase in viability after 
CSGalNAcT-1 was silenced.  
 
Figure 3.8 Cell viabilities were measured based on absorbance of formazan 
produced by MCF-12A cells 48 hours after transfection. CSGalNAcT-1 
silenced group has significant 17% increase of proliferation as compared to 




3.2.6. Assessment of cell apoptosis in CSGalNAcT-1 silenced MCF-12A 
3.2.6.1. Caspase-3/7 apoptosis assay 
Caspase-3/7 apoptosis assay measured the activities of caspase-3 and -7, 
which are the members of the cystein aspartic acid-specific protease (caspase) 
family that play key effector roles in apoptosis in mammalian cells. The result 
in Figure 3.9 shows that there were significantly more apoptotic cells 
following the silencing of CSGalNAcT-1 in MCF-12A as compared to 
























































Figure 3.9 Apo-ONE Homogenous Caspase-3/7 assay was performed for the 
assessment of apoptosis in CSGalNAcT-1 silenced MCF-12A. There was a 
significant increase in apoptosis after CSGalNAcT-1 was silenced in MCF-




3.2.6.2. Phosphorylated BAD (pBAD) protein expression 
BAD interacts with anti-apoptotic Bcl-2 and Bcl- XL and sequesters this two 
protein away from the Bax-like proteins thus promotes apoptosis. However, 
phospohorylated BAD (pBAD) indirectly promote cell survival, due to the 
consequence of its inability to bind Bcl-2 or Bcl-XL. CSGalNAcT-1 silenced 
MCF-12A cells had increased apoptosis; this is reflected in reduced protein 
expression of pBAD (25kDa) in CSGalNAcT-1 silenced MCF-12A (Figure 
3.10B and 3.10E). Although total BAD protein (25kDa) expression had no 
significant differences between knockdown and negative control group (Figure 
3.10A and 3.10D), relative pBAD protein level is still significantly reduced in 























































































Total Bad: 25kDa 
Phosphorylated  Bad (pBAD): 25kDa 
β-actin: 41kDa 
  si-Neg-1          s -Neg-2           si-Neg-3    
 
si-CSGalNAcT-1-1   si-CSGalNAcT-1-2  si-CSGalNAcT-1-3 
 
    si-Neg-1               si-Neg-2             si-Neg-3      
 
si-CSGalNAcT-1-1   si-CSGalNAcT-1-2  si-CSGalNAcT-1-3 
 
  si-Neg-1              si-Neg-2             si-Neg-3      
 
si-CSGalNAcT-1-1   si-CSGalNAcT-1-2  si-CSGalNAcT-1-3 
 








































Figure 3.10 Western blot analysis of total BAD and phosphorylated BAD 
(pBAD) in CSGalNAcT-1 silenced MCF-12A. (A, D) No significant change in 
total BAD (25 kDa) protein expression level was found in between si-Neg and 
silenced group. (B, E) pBAD (25 kDa) protein level was significantly reduced 
by 37% in CSGalNAcT-1 silenced MCF-12A, indicating reduced survival in 
silenced cells. (F) Relative total BAD to pBAD protein level also showed a 
significant reduction pattern. (C) β-actin protein level (41 kDa) acts as 
normalizer and the expression level was unaffected in the silencing process. 




3.2.7. Cell adhesion analysis in CSGalNAcT-1 silenced MCF-12A 
In addition to cell migration and invasion, adhesion is one of the most 
important factors in tumorigenesis. This assay was done to investigate the 
effect of CSGalNAcT-1 silencing on the adhesion of MCF-12A cells to 
extracellular matrix (ECM). Two major components of ECM, which are 
collagen I and fibronectin were used to mimic ECM environment in the assay. 
The negative control and silenced group did not adhere differently to collagen 
I (Figure 3.11A) and fibronectin (Figure 3.11B).  


























































Figure 3.11 Analysis of adhesiveness of CSGalNAcT-1 silenced MCF-12A to 
collagen I and fibronectin. Absorbance of each group (negative control and 
CSGalNAcT-1 silenced group) was normalized based on the ratio of washed 
wells to unwashed wells. (A and B) No significant changes in adhesion to 
collagen I and fibronectin were observed upon CSGalNAcT-1 silencing in 
MCF-12A cells. Error bar represents standard error. 
 
 
3.3. Microarray analysis of CSGalNAcT-1 silenced MCF-12A 
To understand the mechanisms of CSGalNAcT-1 in mediating cellular 
behavior, a microarray analysis using Affymetrix Human U133 Plus version 
2.0 array was performed. MCF-12A cells were transfected with non-targeting 
siRNA and CSGalNAcT-1 siRNA as described in section 3.2. Total RNA was 
extracted and sent to Origen Labs to determine the good quality of the RNA 
samples. The RNA samples had OD 260/280 ratios of 1.779 to 2.201 and 
concentration range from 66.89 ng/μl to 149.41 ng/μl, as shown in Table 3.1. 





Quality of the RNA was assessed based on the electrophoretic trace (Figure 
3.12) of the RNA sample and the RNA integrity number (Table 3.1). As 
determined by the Agilent Bioanalyzer, all the samples had RNA integrity 
values of 10, indicating good quality of RNA samples. 
 
For each sample, 100 ng total RNA was used for the 3‟ IVT Express assay 
according to Origen Labs SOP. RNA was reverse transcribed to cDNA and 
subsequently used as a template to create a biotinylated labeled amplified 
RNA (aRNA). aRNA was then fragmented and hybridized to Affymetrix 
Human U133 Plus version 2.0 array. CEL files were generated from GeneChip 
Operating Software (GCOS) and imported into Expression Console (EC) 1.1 
software for quality control of arrays. GeneSpring software was used for raw 
data analysis.  
 














0.0149 0.0076 0.0000 1.779 66.89 10 
CSGalNAcT-1 
silenced #2 
0.0323 0.0154 0.0000 2.094 129.88 10 
CSGalNAcT-1 
silenced #3 
0.0286 0.0153 0.0000 1.872 114.26 10 
Negative #1 0.0286 0.0153 0.0000 1.852 115.72 10 
Negative #2 0.0282 0.0135 0.0000 1.968 119.14 10 














Figure 3.12 Electrophoregrams of RNA samples determined by Agilent 
Bioanalyzer. RNA samples with good quality are typified by intact 18S and 
28S ribosomal subunit peaks, flat baseline throughout electrophoregrams and 
no well-defined peaks between 18S and 28S peaks.  
 
 
3.3.1. Microarray table of genes and heat map 
Results from GeneSpring software analysis indicate a total of 30 genes that 
were significantly up and down regulated between the negative control and 
silenced group. The change of each gene was at least 1.5 fold. These genes are 
represented along with fold change and p-value in Table 3.2. Heat map was 
plotted in Figure 3.13 to display list of genes that were significantly up- and 
down-regulated between the negative control and CSGalNAcT-1 silenced 
group. Heat map adopted color-coding method, i.e. green and red color, to 
represent direction of expression and the color gradient represents increasing 
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Table 3.2 List of genes that were significantly up- and down-regulated at least 
by 1.5 fold following the silencing of CSGalNAcT-1 in normal breast cell line 
MCF-12A.   
 
Number Gene symbol Probe set ID p-value Fold 
change 
Regulation 
1 ATL3 224893_at 9.32E-04 1.7441963 Down 
2 C6orf120 221786_at 6.52E-05 2.0711255 Down 
221787_at 0.001319238 1.5095084 Down 
3 CMAS 218111_s_at 0.005513553 1.5049442 Down 
4 CPOX 204172_at 6.71E-04 1.7968925 Down 
5 CSGalNAcT-1 219049_at 7.20E-08 10.77752 Down 
6 EXOC2 226270_at 0.004970458 1.6187352 Down 
7 LYPLA2 202292_x_at 8.52E-04 1.8298787 Down 
215566_x_at 4.31E-04 2.0218742 Down 
8 LYPLA2P1 216606_x_at 2.29E-05 1.819549 Down 
9 MAPRE1 200713_s_at 2.57E-05 2.2625957 Down 
10 NCAM1 212843_at 0.004154318 1.5822985 Down 
11 PLEKHA8 227247_at 2.56E-05 2.0324197 Down 
12 RAB28 227003_at 0.002662569 1.5219765 Down 
13 RCBTB1 218352_at 8.06E-05 2.1755447 Down 
14 TRAPPC2 219351_at 3.98E-05 1.873583 Down 
15 APOL6 1557236_at 0.011513989 1.6276952 Up 
16 CALB1 205625_s_at 0.039278515 1.5815449 Up 
205626_s_at 0.011313328 1.5016893 Up 
17 CDKN1C 213182_x_at 4.55E-04 1.6526825 Up 
213348_at 3.17E-04 1.5226234 Up 
216894_x_at 0.001148584 1.6225524 Up 
219534_x_at 1.89E-04 1.6592742 Up 
18 CXCL14 218002_s_at 2.94E-04 1.904126 Up 
222484_s_at 1.95E-04 1.8966751 Up 
19 GAS1 204457_s_at 0.005914766 1.519408 Up 
20 HIVEP3 235122_at 0.04710484 1.6094921 Up 
21 HOPX 211597_s_at 0.031734325 1.5025384 Up 
22 HSPB3 206375_s_at 0.016321188 1.5295488 Up 
23 KIAA0774 214961_at 0.027066868 1.9408674 Up 
24 KIF26A 232069_at 4.86E-04 1.666597 Up 
25 NIPBL 242352_at 0.018583402 1.5061634 Up 
26 ONECUT2 233446_at 0.032158457 1.552688 Up 
27 RRAD 204803_s_at 0.005861233 1.538713 Up 
28 SULT1E1 219934_s_at 1.32E-05 1.5776308 Up 
222940_at 0.001612507 1.5213795 Up 
29 TNFSF10 202687_s_at 0.003737635 1.5123925 Up 
202688_at 0.015174521 1.5859073 Up 













Figure 3.13 Heat map displaying list of 29 genes (excluding CSGalNAcT-1) 
that were significantly up- and down-regulated between the negative control 
and CSGalNAcT-1 silenced groupd. Down-regulated genes are presented in 
green color whereas up-regulated genes are presented in red color.  
 
 
3.3.2. Functional gene ontology classification 
The list of 29 genes (excluding CSGalNAcT-1) in Table 3.2 was classified 
based on their functional ontologies by using a sophisticated software 
Database for Annotation, Visualization and Integrated Discovery (DAVID). 
The functional gene ontology of up-regulated and down-regulated genes is 
displayed in Figure 3.14 and the list of genes from each gene ontology group 
is listed in Table 3.3. 
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Table 3.3 List of genes that are functionally grouped into each ontology group 
Gene ontology groupings  Genes 
Up-regulated Down-regulated 













ER to Golgi vesicle-mediated transport  ATL3 
TRAPPC2 
 




































3.3.3. Selection of CXCL14 as a candidate gene for CSGalNAcT-1 
downstream signaling investigation 
Among the 16 genes which were up-regulated in Table 3.2, CXCL14 was 
selected for the investigation of CSGalNAcT-1 downstream signaling pathway. 
The selection criterion was based on the literatures that indicated the role of 
CXCL14 in promoting tumorigenesis in various types of cancer. 
 
3.3.3.1. CXCL14 expression was up-regulated by CSGalNAcT-1 silencing 
in MCF-12A  
Figure 3.15 shows that CXCL14 expression level was significantly increased 
by 2-fold in CSGalNAcT-1 silenced MCF-12A as compared with negative 
control from the microarray results. 























































Figure 3.15 Both CXCL14 probe sets were significantly up-regulated in 
CSGalNAcT-1 silenced MCF-12A compared to the negative control MCF-12A 
cells from the microarray results. Error bar represents standard error. 
 





Validation of CSGalNAcT-1 expression was carried out by qRT-PCR as well, 
as shown in Figure 3.16A. In Figure 3.16 B-D, up-regulation of CXCL14 
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Figure 3.16 Transcript level and protein level of CXCL14 was up-regulated in 
CSGalNAcT-1 silenced MCF12A. (A) qRT-PCR validation of CXCL14 in 
CSGalNAcT-1 silenced MCF-12A showed an up-regulation of the gene in the 
silenced group. (B, C) CXCL14 was stained green (left), nucleus was stained 
blue with DAPI (middle) in immunofluorescence and the merged figure is on 
the right. Mean fluorescence intensity was measured by the ImageJ software. 
CXCL14 protein level in the presentation of immunofluorescence (D) and 






















3.3.3.2. Silencing of CXCL14 in MCF-12A 
CXCL14 was silenced in MCF-12A using 10 nM of Ambion Silencer® Select 
siRNA. Two siRNAs (sequence ID s18332 and s18333) were employed for 
the validation of silencing efficiency. CXCL14 was knockdown by 98% with 
both siRNAs. The siRNA with sequence ID s18333 was selected to be 
silenced with CSGalNAcT-1 in double knockdown experiment in MCF-12A. 
Silencing efficiencies of both CXCL14 siRNAs are shown in Figure 3.17. The 
CXCL14 siRNA with sequence ID s18333 was used for subsequent double 
silencing experiment. Knockdown of CXCL14 in return did not affect the 
expression of CSGalNAcT-1 in MCF-12A. qRT-PCR result of CSGAlNAcT-1 
expression in CXCL14 (sequence ID s18333) silenced MCF-12A is shown in 
Figure 3.18.   
 






















Figure 3.17 Successful knockdown of both CXCL14 siRNA sequences in 
MCF-12A. Both siRNAs gave 98% and 98.9% silencing efficiency in MCF-











Figure 3.18 CSGalNAcT-1 expression was not affected in CXCL14 silenced 
MCF-12A. Result showed that silencing of CXCL14 does not affect 




3.3.3.3. Double knockdown of CSGalNAcT-1 and CXCL14 in MCF-12A 
Based on results from Section 3.3.3.1, CXCL14 expression was up-regulated 
by CSGalNAcT-1 silencing in MCF-12A. The aim of double knockdown 
experiment is to prevent the up-regulation of CXCL14 when CSGalNAcT-1 
was silenced. Thus, it is expected that double silencing will result in down-
regulation of CSGalNAcT-1 and reduce the impact of CXCL14 up-regulation 
thereafter. Double silencing of CSGalNAcT-1 and CXCL14 was successful as 
shown in Figure 3.19A and 3.19B.  
 





















































































































Figure 3.19 Successful double knockdown of CSGalNAcT-1 and CXCL14 in 
MCF-12A. (A) CSGalNAcT-1 was successfully silenced in both single 
silenced (93% knockdown) and double silenced (92% knockdown) groups; 
silencing CXCL14 did not affect the expression of CSGalNAcT-1 in feedback 
loop. (B) Similarly, CXCL14 was successfully silenced in both the single 
silenced (93% knockdown) and double silenced (98% knockdown) samples; 
the expression of CXCL14 was up-regulated by 2.2 fold in CSGalNAcT-1 
single silenced sample. Error bar represents standard error. 





3.3.3.4. Impact of CSGalNAcT-1 and CXCL14 double silencing on MCF-
12A cell migration 
Cell motility of the siRNA transfected cells were assessed using transwell 
migration method as mentioned in section 3.2.3.1. As Figure 3.20 shows, 
MCF-12A cells silenced with CSGalNAcT-1 significantly increased migration 
by 34.4% as compared with negative siRNA transfected cells. In contrast, 
silencing CXCL14 brought down the migration of the cells by 23.3%. While 
when MCF-12A was double silenced with CSGalNAcT-1 and CXCL14, cell 
migration dropped below basal level (double negative). Thus, double silencing 
of these two transcripts abolishes the cell migration initially observed in 
CSGalNAcT-1 silenced MCF-12A; this result implies the impact of CXCL14 



































































Figure 3.20 Cell motility changes as a result of double knockdown of 
CSGalNAcT-1 and CXCL14 in MCF-12A. CSGalNAcT-1 silenced MCF-12A 
significantly increased migration by 34.4%. CXCL14 silenced MCF-12A had 
significant reduction in migration. Double silencing of both CSGalNAcT-1 and 
CXCL14 reduced the migration of MCF-12A which was initially increased by 
silencing CSGalNAcT-1. Error bar represents standard error. 
 





3.3.3.5. Impact of CSGalNAcT-1 and CXCL14 double silencing on MCF-
12A cell invasion 
Cell invasion was assessed by the ability of cells to invade through the 
basement membrane of Matrigel invasion chambers as mentioned in section 
3.2.4. As shown in Figure 3.21, knockdown of CSGalNAcT-1 increased MCF-
12A cell invasion by 21%; while there was a remarkable decrease in cell 
invasion of CXCL14 silenced MCF-12A by 40.4%. However, when MCF-12A 
was silenced simultaneously with CSGalNAcT-1 and CXCL14, the effect of 
increase in invasion by silencing CSGalNAcT-1 was neutralized by CXCL14 
knockdown, cell invasion dropped below baseline level. This finding once 



































































Figure 3.21 Changes in MCF-12A cell invasiveness in double knockdown of 
CSGalNAcT-1 and CXCL14. Knockdown of CSGalNAcT-1 significantly 
increased invasiveness of MCF-12A by 21% while CXCL14 silenced MCF-
12A had reduced invasiveness in the cells. CSGalNAcT-1 and CXCL14 double 





silenced MCF-12A had reduced cell invasion below the baseline level. Error 




3.3.3.6. Impact of CSGalNAcT-1 and CXCL14 double silencing on MCF-
12A cell viability 
Cell viability of siRNA transfected cells were measured 72 hours post 
transfection by the MTS assay method as described in section 3.2.5. In Figure 
3.22, CSGalNAcT-1 silenced MCF-12A had more cells that are viable but the 
difference was not significant. In CXCL14 silenced MCF-12A, the cell 
viability dropped but was not significant too. No significant difference in cell 




























































Figure 3.22 No significant changes in cell viability were seen in MCF-12A 
silenced with CSGalNAcT-1 and CXCL14. Error bar represents standard error. 
 
 





3.3.3.7. Impact of CSGalNAcT-1 and CXCL14 double silencing on MCF-
12A cell adhesion 
Cell adhesion to major extracellular matrix constituents, collagen I and 
fibronectin, was analyzed. As shown in Figure 3.23A, knockdown of both 
CSGalNAcT-1 and CXCL14 individually had no significant changes in 
adhesion to collagen I of the cells. However, when MCF-12A cells were 
double silenced with both genes, cells significantly became more adhesive to 
collagen I. 
 
Similarly, adhesion to fibronectin was not significant in CSGalNAcT-1 
silenced MCF-12A, as shown in Figure 3.23B. However, adhesion to 
fibronectin was significantly improved upon CXCL14 silencing in the cells. 
Moreover, double silenced of these two genes brought back the adhesiveness 
to baseline level. 
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Figure 3.23 Adhesion to collagen and fibronectin in CSGalNAcT-1 and 
CXCL14 double knockdown MCF-12A. (A) No significant changes in 
adhesion to collagen after CSGalNAcT-1 and CXCL14 was silenced 
individually in MCF-12A. However, double silenced MCF-12A had increased 
adhesiveness to collagen. (B) CSGalNAcT-1 silenced MCF-12A did not have 
significant change in fibronectin adhesion. Knockdown of CXCL14 increased 
adhesion to fibronectin significantly but was brought back to baseline level 
when the cells were double silenced with both CSGalNAcT-1 and CXCL14. 
















3.4. Over-expression and functional analysis of CSGalNAcT-1 in breast 
cancer cell line MCF7 and MDA-MB-231  
3.4.1. CSGalNAcT-1 over-expression in breast cancer cell line MCF7 and 
MDA-MB-231 
Figure 3.1 showed that expression level of CSGalNAcT-1 in breast cancer cell 
lines MCF-7 and MDA-MB-231 was lower as compared with normal breast 
cell line MCF-12A. Hence, it would be interesting to find out the implications 
of CSGalNAcT-1 to the behavioral changes of the cells after being over-
expressed in MCF7 and MDA-MB-231. CSGalNAcT-1 plasmid was 
transfected to the cells to establish stable cell lines after Neomycin antibiotic 
selection. Two CSGalNAcT-1 over-expression clones were generated in MCF7 
and were abbreviated OE1 and OE3. One empty vector clone was generated in 
MCF7, and was given the name EV2. One CSGalNAcT-1 over-expression 
clone was generated in MDA-MB-231, and was abbreviated OE2.  One empty 
vector clone was also generated in MDA-MB-231, and was abbreviated EV3. 
Over-expression level of the CSGalNAcT-1 in MCF7 and MDA-MB-231 was 
determined by qRT-PCR and immunofluorescence as shown in Figure 3.24 
(A-E) and Figure 3.25 (A-D). 
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MCF7 EV2 MCF7 EV2 
CSGalNAcT-1 staining DAPI staining Merged 
MCF7 OE1 MCF7 OE1 MCF7 OE1 
DAPI staining Merged CSGalNAcT-1 staining 
MCF7 EV2 






MCF7 OE3 MCF7 OE3 MCF7 OE3 
DAPI staining Merged CSGalNAcT-1 staining 










































Figure 3.24 Over-expression transcript and protein level of CSGalNAcT-1 in 
MCF7. (A) Two MCF7 CSGalNAcT-1 over-expression clones were generated. 
EV2 being empty vector clone 2; OE1 and OE3 are over-expression clones 1 
and 3 respectively. Both clones exhibited more than 20,000 fold increased in 
CSGalNAcT-1. (B-D) CSGalNAcT-1 was stained red (left), nucleus was 
stained blue by DAPI (middle) and merged figure is on the right. (E) 
CSGalNAcT-1 protein level showed significant up-regulation in the over-
expression clones. Mean fluorescence intensity was measured by ImageJ 
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Figure 3.25 Over-expression transcript and protein level of CSGalNAcT-1 in 
MDA-MB-231. (A) CSGalNAcT-1 was over-expressed at 926-fold in MDA-
MB-231. EV3 being empty vector clone 3 and OE2 is over-expression clone 2. 
(B, C) CSGalNAcT-1 protein was stained red (left), nucleus was stained blue 
by DAPI (middle) and merged figure is on the right. (D) Protein level of 
CSGalNAcT-1 showed significant up-regulation by 94.3% in the over-
expression clones. Mean fluorescence intensity was measured by ImageJ 




















3.4.2. Transcript and protein level of CXCL14 in CSGalNAcT-1 over-
expressed MCF7 and MDA-MB-231 
Expression level of CXCL14 was investigated in the over-expression clones. 
As illustrated in Figure 3.26 (A-E) and Figure 3.27 (A-C), transcript level of 
CXCL14 was examined by qRT-PCR while protein level of CXCL14 was 
investigated by immunofluorescence technique. Indeed, there were reciprocal 
down-regulation of CXCL14 transcript and protein level in CSGalNAcT-1 







































MCF7 EV2 MCF7 EV2 
CXCL14 staining DAPI staining Merged 
MCF7 OE1 MCF7 OE1 
CXCL14 staining DAPI staining Merged 









































MCF7 OE3 MCF7 OE3 MCF7 OE3 
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Figure 3.26 Transcript and protein level of CXCL14 were significantly down-regulated in CSGalNAcT-1 over-expressed MCF7. (A) CXCL14 
transcript level was significantly down-regulated in MCF7 over-expression clones. (B-D) CXCL14 was stained green (left), nucleus was stained 
blue by DAPI (middle) and merged figure is on the right. (E) Protein level of CXCL14 also showed significant down-regulation in the clones. 
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CXCL14 staining DAPI staining Merged 
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Figure 3.27 Protein level of CXCL14 was significantly down-regulated in 
CSGalNAcT-1 over-expressed MDA-MB-231. (A, B) CXCL14 was stained 
green (left), nucleus was stained blue by DAPI (middle) and merged figure is 
on the right. (C) Protein level of CXCL14 showed significant down-regulation 
in the MDA-MB-231 over-expression clones. Mean fluorescence intensity is 




3.4.3. Cell migration analysis in CSGalNAcT-1 over-expressed MCF7 and 
MDA-MB-231  
3.4.3.1. Transwell migration assay 
Cell migration assay using transwell method was performed on CSGalNAcT-1 
over-expressed MCF7 and MDA-MB-231 clones. A chemoattractant gradient 
was created by supplementing medium with 15% FBS in the bottom chamber 
while no FBS is added to the cell suspension seeded into the top insert. From 
Figure 3.28, both MCF7 and MDA-MB-231 breast cancer cell lines had 
reduced migratory capability when CSGalNAcT-1 was over-expressed in the 
cells. 












































































Figure 3.28 Transwell migration assay of CSGalNAcT-1 over-expressed 
MCF7 and MDA-MB-231. Migration of both MCF7 and MDA-MB-231 
breast cancer cell lines was reduced after CSGalNAcT-1 gene was over-
expressed as presented in (A) and (B). The changes were statistically 




3.4.3.2. F-actin immunofluorescence 
As shown in Figure 3.29 (A-D) and Figure 3.30 (A-C), cell motility of 
CSGalNAcT-1 over-expressed MCF7 and MDA-MB-231 was presented in F-
actin immunofluorescence staining as well. In general, CSGalNAcT-1 over-
expression reduced F-actin staining intensity in both MCF7 and MDA-MB-
231.  
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F-actin staining DAPI staining Merged 












































MCF7 OE3 MCF7 OE3 MCF7 OE3 
F-actin staining DAPI staining Merged 





Figure 3.29 Changes in F-actin polymerization after CSGalNAcT-1 over-expression in MCF7. (A-C) F-actin was stained green (left), nucleus 
was stained blue by DAPI (middle) and merged figure is on the right. (D) F-actin intensity was decreased in MCF7 after CSGalNAcT-1 over-
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Figure 3.30 Changes in F-actin polymerization after CSGalNAcT-1 over-
expression in MDA-MB-231. (A, B) F-actin was stained green (left), nucleus 
was stained blue by DAPI (middle) and merged figure is on the right. (C) F-
actin intensity was decreased in CSGalNAcT-1 over-expressed MDA-MB-231. 
Mean fluorescence intensity is measured by the ImageJ software. Error bar 
represents standard error. 
 
 
3.4.4. Assessment of cell invasiveness in CSGalNAcT-1 over-expressed 
MCF7 and MDA-MB-231 by Matrigel chamber 
In vitro cell invasion was assayed in BD Biocoat invasion chambers as 
described earlier in 3.2.4. Lower wells were added with medium supplemented 
with 15% FBS to serve as chemoattractant. Similar to cell migration, cell 
invasion was reduced in both MCF7 and MDA-MB-231 cell lines after 
CSGalNAcT-1 gene was over-expressed (Figure 3.31). 
 
 





























































































Figure 3.31 Invasion assay in CSGalNAcT-1 over-expressed MCF7 and MDA-
MB-231. CSGalNAcT-1 over-expression MCF7 and MDA-MB-231 clones 
exhibited reduced invasion as displayed in both (D) and (G). The reduction in 
invasion as compared with corresponding empty vector is significantly 
different. Figure A, B, C, E, and F showed the cells invaded through the 













3.4.5. Over-expressing CSGalNAcT-1 impedes cell viability in MCF7 and 
MDA-MB-231 
Cell viability of the CSGalNAcT-1 over-expression clones was determined by 
using CellTiter 96 Aqueous Non-radioactive cell proliferation assay. Figure 
3.32 shows that both MCF7 and MDA-MB-231 CSGalNAcT-1 over-
expression clones exhibited reduced viability as compared with the respective 





























































Figure 3.32 Viability assay in CSGalNAcT-1 over-expressed MCF7 and 
MDA-MB-231. MCF7 and MDA-MB-231 over-expression clones had 
significant reduction in viability as compared with empty vectors. Results are 
displayed in figures (A) and (B). Error bar represents standard error. 
 
 





3.4.6. Assessment of CSGalNAcT-1 over-expressed MCF7 and MDA-MB-
231 cell adhesion to collagen I 
Collagen adhesion assay was done to examine the adhesiveness of 
CSGalNAcT-1 over-expression clones to the collagen I which is one of the 
major and ubiquitous constituents in extracellular matrix. Over-expressing 
CSGalNAcT-1 in MCF7 and MDA-MB-231 caused the cells to be less 




























































Figure 3.33 Collagen I adhesion assay in CSGalNAcT-1 over-expressed MCF7 
and MDA-MB-231. The adhesiveness of MCF7 and MDA-MB-231 over-
expression clones to collagen I reduced significantly as seen in figures (A) and 
(B). Error bar represents standard error. 
 





3.4.7. Assessment of CSGalNAcT-1 over-expressed MCF7 and MDA-MB-
231 cell adhesion to fibronectin 
Besides collagen I adhesion assay, fibronectin adhesion assay was also carried 
out on CSGalNAcT-1 over-expressed MCF7 and MDA-MB-231. MCF7 
clones exhibited decreased adhesion to fibronectin (Figure 3.34A) while 
MDA-MB-231 clones had increased adhesion to fibronectin (Figure 3.34B) 
































































Figure 3.34 Fibronectin adhesion assay in CSGalNAcT-1 over-expressed 
MCF7 and MDA-MB-231. (A) MCF7 CSGalNAcT-1 over-expression clones 
had reduced adhesion to fibronectin. (B) However, MDA-MB-231 clones 
increased the adhesion to fibronectin after CSGalNAcT-1 was over-expressed. 
Error bar represents standard error.



























In this chapter, the expression and localization of CSGalNAcT-1 was detected 
by immunohistochemistry in breast invasive ductal carcinoma clinical samples. 
The aim is to determine if there is any association between the expression 
patterns of CSGalNAcT-1 in different compartments of breast invasive ductal 
carcinoma clinical samples and their clinicopathological parameters.  At the 
same time, survival analysis was done to determine the prognosis value of 
CSGalNAcT-1 in breast invasive ductal carcinoma patients.  
 
4.1. Clinical and demographic data of breast IDC patients 
A total of 297 breast IDC tissue microarrays (TMAs) from 1998 to 2004 were 
included in this study, consisting of 52 normal and 245 IDC cases. Among the 
245 IDC cases, 52 cases had enough normal tissue to be dissected and stained 
for comparison. Among the 245 IDC cases, 52 cores were dropped or folded 
during immunohistochemical procedure, so these cases were excluded from 
the analysis with the remaining of 193 cases.  Whilst 23 cases from the 52 
cases of normal cases were eliminated from analysis due to dropped off or 
folded during immunohistochemical procedure. The clinicopathological data 
of IDC patients were summarized in Table 4.1. All of these cases were female 












Table 4.1 Clinicopathological features and distribution of invasive carcinoma 
tissue sections. The numbers in the brackets represent the percentage of cases 




    
Number of patients 193 
    
Age (mean, in years) 56.76 
Age (median, in years) 56 
    
Tumor size (mean, in mm) 34.60 








Number of cases (%) 
    
Race Bloom-Richardson score 
Chinese  127 (65.8) ≤5 10 (5.2) 
Malay  11 (5.7) >5 101 (52.3) 
Indian  7 (3.6) Not available 82 (42.5) 
Others 8 (4.1)   
Not available 40 (20.7) Lymph node involvement 
  Negative 82 (42.5) 
Histological grade Positive 54 (28.0) 
Grade 1 and 2 89 (46.1) Not available 57 (29.5) 
Grade 3 96 (49.7)   
Not available 8 (4.1) Lymph node stage 
  1-9 LN metastasis 139 (72.0) 
Staging ≥10 LN metastasis 41 (21.2) 
Stage 1 and 2 100 (51.8) Not available 13 (6.7) 
Stage 3 11 (5.7)   
Not available 82 (42.5) ER status 
  Negative 98 (50.8) 
Nuclear pleomorphism Positive 83 (43.0) 
Grade 1 and 2 60 (31.1) Not available 12 (6.2) 
Grade 3 63 (32.6)   
Not available 70 (36.3) PR status 
  Negative 79 (40.9) 
Tumor tubule formation Positive 101 (52.3) 
Score 1 and 2 42 (21.8) Not available 13 (6.7) 
Score 3 81 (42.0)   
Not available 70 (36.3) HER2 status 
  Negative 126 (65.3) 
Mitotic index Positive 44 (22.8) 
Grade 1 and 2 65 (33.7) Not available 23 (11.9) 
Grade 3 58 (30.1)   
Not available 70 (36.3)   









4.2. Localization of CSGalNAcT-1 in breast IDC 
Expression of CSGalNAcT-1 was observed in epithelial cells, stromal cells 
and diffuse stroma components in breast IDC samples as these three 
compartments were stained brown immunohistochemically. Weak to strong 
staining can be detected in the cytoplasm of IDC epithelial cells with score of 
1+ to 3+. Expression of CSGalNAcT-1 in diffuse stroma was weak or 
moderate with score of 1+ and 2+ whereas stromal cells staining was 
predominantly weak with score of 1+ and with a few cases that have 2+ 
staining. Immunostaining of CSGalNAcT-1 in various components are shown 
in Figure 4.1. Diffuse stroma is also known as the extracellular matrix, which 
comprises of cell types such as fibroblast, epithelial cells, immune 
inflammatory cells, endothelial cells, pericytes, and adipocytes (Mao et al., 
2013, Hanahan and Weinberg, 2011). Cells in diffuse stroma are collectively 
called stromal cells. Under the guidance of Singapore General Hospital 
pathologist, only CSGalNAcT-1 staining in fibroblasts were scored in current 















     




















   















     
   
 
Figure 4.1 CSGalNAcT-1 staining was detected in breast epithelial cells, stromal cells and diffuse stroma. (A) Weak (1+), moderate (2+) and 
strong (3+) immunostaining of CSGalNAcT-1 in breast epithelial cells. Red arrows indicate the different staining intensity of the 
immunopositive epithelial cells. (B) Weak (1+) and moderate (2+) immunostaining of CSGalNAcT-1 in stromal cells. Red arrows indicate the 
different staining intensity of the immunopositive stromal cells. (C) Diffuse stroma was stained weakly (1+) and moderately (2+) with 
CSGalNAcT-1. Red arrows indicate the different staining intensity of the immunopositive diffuse stroma. (D) No background immunoreactivity 
detected in negative control which was done by omitting CSGalNAcT-1 primary antibody. 





D. Negative control 





4.3. Comparison of CSGalNAcT-1 staining in normal breast tissue and breast IDC 
A total of 21 available paired normal and IDC cases were compared for the CSGalNAcT-1 immunostaining in epithelial cells, stromal cells and 
diffuse stroma, respectively, using non-parametric Wilcoxon matched pairs test for statistical analysis. Generally, in stromal cells, CSGalNAcT-
1 immunostaning in normal cases was significantly weaker than in IDC cases (Figure 4.2B). However, in diffuse stroma, significant stronger 
expression of CSGalNAcT-1 was found in normal cases as compared to IDC cases (Figure 4.2C). All comparisons from each component were 
displayed in Figure 4.2.  
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Figure 4.2 Graphs and figures showing the immunoscores comparisons of CSGalNAcT-1 expression in normal and IDC cases in three stained 
components. (A) No significant difference in CSGalNAcT-1 immunostaining was detected in epithelial cells of normal and IDC cases. (B) The 
expression of CSGalNAcT-1 in stromal cells was stronger in malignant cases. Figures indicate the stromal cells in IDC cases have higher 
staining intensity than in normal cases. Red arrows indicate the CSGalNAcT-1 immunopositive stromal cells. (C) However, expression of 
CSGalNAcT-1 in diffuse stroma was stronger in normal cases. Figures indicate the diffuse stroma in normal cases have higher staining intensity 
than in IDC cases. Red arrows indicate the CSGalNAcT-1 immunopositive diffuse stroma. The results were expressed in mean±SE. 
 
 
4.4. Comparison of CSGalNAcT-1 staining in low grade and high grade breast IDC 
Among the 193 malignant IDC cases, 89 cases belongs to low grade IDC (histological grade 1 and 2) and 96 cases are high grade IDC 
(histological grade 3), whilst eight cases with no available data. Comparisons of CSGalNAcT-1 immunostaining in epithelial cells, stromal cells 
and diffuse stroma were made between low grade and high grade IDC (Figure 4.3). Only stromal cells WAI showed significant difference 
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B. Stromal cells 
CSGalNAcT-1 immunostaining
in stromal cells
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C. Diffuse stroma 
CSGalNAcT-1 immunostaining
in diffuse stroma



























































































Figure 4.3 Immunostaining of CSGalNAcT-1 in low grade and high grade IDC. Expression of CSGalNAcT-1 in epithelial cells (A), stromal 
cells (B) and diffuse stroma (C) is generally higher in low grade IDC than in high grade IDC. (B) Only the comparison in WAI of stromal cells is 
significant. Figures indicate that stromal cells in low grade IDC have stronger expression of CSGalNAcT-1 than in high grade IDC. Red arrows 












4.5. Associations of CSGalNAcT-1 immunoreactivity in breast IDC with 
clinicopathological parameters  
The banding of each immunoscoring measurement (i.e. IRS, TPS, WAI) in all 
three stained components and the number of each cases in each banded 
category were shown in Table 4.2. The cut-off points were used throughout 
the following analysis. This is an exploratory study to investigate the 
expression of CSGalNAcT-1 in IDC cases. As nothing is known about the use 
of CSGalNacT-1 to differentiate between IDC patients with good and bad 
prognosis, different cut-offs were examined to find a suitable value to 
differentiate between the two groups. In future, a different set of IDC samples 
can be used to validate this cut-off value. The associations of 
clinicopathological parameters with CSGalNAcT-1 immunostaining in all 
three components, i.e. epithelial cells, stromal cells and diffuse stroma, were 

















Table 4.2 Different types of CSGalNAcT-1 immunoscoring in epithelial cells, 
stromal cells and diffuse stroma and their cut-offs in each immunoscoring 
factor. 
 
Components Immunoscores Cut-offs Number of cases 
(%) 
Epithelial cells IRS ≤150 188 (97.4) 
>150 5 (2.6) 
TPS ≤90 156 (80.8) 
>90 37 (19.2) 
WAI ≤1.7 182 (94.3) 
>1.7 11 (5.7) 
 
Stromal cells IRS ≤50 172 (89.1) 
>50 21 (10.9) 
TPS ≤50 172 (89.1) 
>50 21 (10.9) 
WAI ≤0.9 51 (26.4) 
>0.9 142 (73.6) 
 
Diffuse stroma IRS ≤100 189 (97.9) 
>100 4 (2.1) 
TPS ≤20 97 (50.3) 
>20 96 (49.7) 
WAI ≤1.0 187 (96.9) 









4.5.1. Epithelial cells 
CSGalNAcT-1 was stained in epithelial cells of IDC. The following tables show the associations between IDC clinicopathological parameters 
and IRS (Table 4.3), TPS (Table 4.4), and WAI (Table 4.5) of CSGalNAcT-1 in epithelial cells. 
 
Table 4.3 Correlation of clinicopathological parameters of IDC with CSGalNAcT-1 immunoreactivity score (IRS) of epithelial cell. No 
significant correlation was found. 
 
Clinicopathological parameters Immunoreactivity score (IRS) P-value 
 ≤150 >150 Valid cases (%) Missing cases 
(%)  Number of cases 
(%) 
Number of cases 
(%) 
Age ≤50 73 (96.1%) 3 (3.9%) 192 (99%) 1 (1%) 0.386 
>50  114 (98.3%) 2 (1.7%) 
Race Chinese 123 (96.9%) 4 (3.1%) 153 (78.9%) 40 (21.1%) 0.840 
Malay 11 (100%) 0 
Indian 7 (100%) 0 
Others 8 (100%) 0 
Tumor size ≤30mm 101 (97.1%) 3 (2.9%) 189 (97.4%) 4 (2.6%) 1.000 
>30mm 83 (97.6%) 2 (2.4%) 
Histological grade Grade 1 and 2 87 (97.8%) 2 (2.2%) 185 (95.4%) 8 (4.6%) 0.939 
Grade 3 94 (97.9%) 2 (2.1%) 
Staging Stage 1 and 2 96 (96%) 4 (4%) 111 (57.2%) 82 (42.8%) 0.070 





Stage 3 11 (100%) 0 
DCIS nuclear grade None and low 65 (97%) 2 (3%) 174 (89.7%) 19 (10.3%) 0.650 
Intermediate and 
high 
105 (98.1%) 2 (1.9%) 
Lymph node 
involvement 
Negative 80 (97.6%) 2 (2.4%) 136 (70.1%) 57 (29.9%) 0.649 
Positive 52 (96.3%) 2 (3.7%) 
Lymph node stage 1-9 LN metastasis 135 (97.1%) 4 (2.9%) 180 (92.8%) 13 (7.2%) 0.875 
10 and above LN 
metastasis 
40 (97.6%) 1 (2.4%) 
ER Negative 96 (98%) 2 (2%) 181 (93.3%) 12 (6.7%) 1.000 
Positive 81 (97.6%) 2 (2.4%) 
PR Negative 78 (98.7%) 1(1.3%) 180 (92.8%) 13 (7.2%) 0.632 
Positive 98 (97%) 3 (3%) 
HER2 Negative 123 (97.6%) 3 (2.4%) 170 (87.6%) 23 (12.4%) 0.605 
Positive 42 (95.5%) 2 (4.5%) 
BloomRichardson ≤5 10 (100%) 0 111 (57.2%) 82 (42.8%) NA 
>5 101 (100%) 0 
Mitotic index Grade 1 and 2 65 (100%) 0 123 (63.4%) 70 (36.6%) NA 
Grade 3 58 (100%) 0 
Nuclear 
pleomorphism 
Grade 1 and 2 60 (100%) 0 123 (63.4%) 70 (36.6%) NA 
Grade 3 63 (100%) 0 
Tumor tubule 
formation 
Score 1 and 2 42 (100%) 0 123 (63.4%) 70 (36.6%) NA 
Score 3 81 (100%) 0 
 





Table 4.4 Correlation of clinicopathological parameters of IDC with CSGalNAcT-1 total percentage score (TPS) of epithelial cell. No significant 
correlation was found. 
 
Clinicopathological parameters Total percentage score (TPS) P-value 
 ≤90 >90 Valid cases (%) Missing cases 
(%)  Number of cases 
(%) 
Number of cases 
(%) 
Age ≤50 57 (75%) 19 (25%) 192 (99%) 1 (1%) 0.134 
>50  98 (84.5%) 18 (15.5%) 
Race Chinese 101 (79.5%) 26 (20.5%) 153 (78.9%) 40 (21.1%) 0.562 
Malay 9 (81.8%) 2 (18.2%) 
Indian 7 (100%) 0 
Others 7 (87.5%) 1 (12.5%) 
Tumor size ≤30mm 82 (78.8%) 22 (21.2%) 189 (97.4%) 4 (2.6%) 0.585 
>30mm 70 (82.4%) 15 (17.6%) 
Histological grade Grade 1 and 2 70 (78.7%) 19 (21.3%) 185 (95.4%) 8 (4.6%) 0.533 
Grade 3 79 (82.3%) 17 (17.7%) 
Staging Stage 1 and 2 76 (76%) 24 (24%) 111 (57.2%) 82 (42.8%) 0.817 
Stage 3 8 (72.7%) 3 (27.3%) 
DCIS nuclear grade None and low 53 (79.1%) 14 (20.9%) 174 (89.7%) 19 (10.3%) 0.724 
Intermediate and 
high 
87 (81.3%) 20 (18.7%) 
Lymph node 
involvement 
Negative 65 (79.3%) 17 (20.7%) 136 (70.1%) 57 (29.9%) 0.834 
Positive 10 (18.5%) 44 (81.5%) 
Lymph node stage 1-9 LN metastasis 112 (80.6%) 27 (19.4%) 180 (92.8%) 13 (7.2%) 0.729 
10 and above LN 32 (78%) 9 (22%) 






ER Negative 78 (79.6%) 20 (20.4%) 181 (93.3%) 12 (6.7%) 1.000 
Positive 67 (80.7%) 16 (19.3%) 
PR Negative 63 (79.7%) 16 (20.3%) 180 (92.8%) 13 (7.2%) 1.000 
Positive 81 (80.2%) 20 (19.8%) 
HER2 Negative 97 (77%) 29 (23%) 170 (87.6%) 23 (12.4%) 0.278 
Positive 38 (86.4%) 6 (13.6%) 
BloomRichardson ≤5 9 (90%) 1 (10%) 111 (57.2%) 82 (42.8%) 0.684 
>5 81 (80.2%) 20 (19.8%) 
Mitotic index Grade 1 and 2 53 (81.5%) 12 (18.5%) 123 (63.4%) 70 (36.6%) 0.663 
Grade 3 49 (84.5%) 9 (15.5%) 
Nuclear 
pleomorphism 
Grade 1 and 2 34 (56.7%) 26 (43.3%) 123 (63.4%) 70 (36.6%) 0.252 
Grade 3 42 (66.7%) 21 (33.3%) 
Tumor tubule 
formation 
Score 1 and 2 35 (83.3%) 7 (16.7%) 123 (63.4%) 70 (36.6%) 0.931 











Table 4.5 Correlation of clinicopathological parameters of IDC with CSGalNAcT-1 weighted average intensity (WAI) of epithelial cell. No 
significant correlation was found. 
 
Clinicopathological parameters Weighted average intensity (WAI) P-value 
 ≤1.70 >1.70 Valid cases (%) Missing cases 
(%)  Number of cases 
(%) 
Number of cases 
(%) 
Age ≤50 72 (94.7%) 4 (5.3%) 192 (99%) 1 (1%) 1.000 
>50  110 (94.8%) 6 (5.2%) 
Race Chinese 119 (93.7%) 8 (6.3%) 153 (78.9%) 40 (21.1%) 0.757 
Malay 10 (90.9%) 1 (9.1%) 
Indian 7 (100%) 0 
Others 7 (87.5%) 1 (12.5%) 
Tumor size ≤30mm 98 (94.2%) 6 (5.8%) 189 (97.4%) 4 (2.6%) 1.000 
>30mm 80 (94.1%) 5 (5.9%) 
Histological grade Grade 1 and 2 83 (93.3%) 6 (6.7%) 185 (95.4%) 8 (4.6%) 0.258 
Grade 3 93 (96.9%) 3 (3.1%) 
Staging Stage 1 and 2 92 (92%) 8 (8%) 111 (57.2%) 82 (42.8%) 0.904 
Stage 3 10 (90.9%) 1 (9.1%) 
DCIS nuclear grade None and low 64 (95.5%) 3 (4.5%) 174 (89.7%) 19 (10.3%) 0.553 
Intermediate and 
high 
100 (93.5%) 7 (6.5%) 
Lymph node 
involvement 
Negative 76 (92.7%) 6 (7.3%) 136 (70.1%) 57 (29.9%) 1.000 
Positive 51 (94.4%) 3 (5.6%) 
Lymph node stage 1-9 LN metastasis 130 (93.5%) 9 (6.5%) 180 (92.8%) 13 (7.2%) 0.687 
10 and above LN 39 (95.1%) 2 (4.9%) 






ER Negative 93 (94.9%) 5 (5.1%) 181 (93.3%) 12 (6.7%) 1.000 
Positive 79 (95.2%) 4 (4.8%) 
PR Negative 76 (96.2%) 3 (3.8%) 180 (92.8%) 13 (7.2%) 0.733 
Positive 95 (94.1%) 6 (5.9%) 
HER2 Negative 121 (96%) 5 (4%) 170 (87.6%) 23 (12.4%) 1.000 
Positive 42 (95.5%) 2 (4.5%) 
BloomRichardson ≤5 10 (100%) 0 111 (57.2%) 82 (42.8%) 1.000 
>5 96 (96%) 4 (4%) 
Mitotic index Grade 1 and 2 62 (95.4%) 3 (4.6%) 123 (63.4%) 70 (36.6%) 0.353 
Grade 3 57 (98.3%) 1 (1.7%) 
Nuclear 
pleomorphism 
Grade 1 and 2 58 (96.7%) 2 (3.3%) 123 (63.4%) 70 (36.6%) 0.960 
Grade 3 61 (96.8%) 2 (3.2%) 
Tumor tubule 
formation 
Score 1 and 2 39 (92.9%) 3 (7.1%) 123 (63.4%) 70 (36.6%) 0.157 












4.5.2. Stromal cells 
CSGalNAcT-1 was expressed in IDC stromal cells. The following tables show the correlation between clinicopathological parameters and and 
IRS (Table 4.6), TPS (Table 4.7, and WAI (Table 4.8) of CSGalNAcT-1 in stromal cells. There were significant correlation between 
CSGalNAcT-1 WAI in stromal cells with patients‟ age, histological grade and mitotic index (Table 4.9). 
 
Table 4.6 Correlation of clinicopathological parameters of malignant IDC with CSGalNAcT-1 immunoreactivity score (IRS) of stromal cells. No 
significant correlation was found. 
 
Clinicopathological parameters Immunoreactivity score (IRS) P-value 
 ≤50 >50 Valid cases (%) Missing cases 
(%)  Number of cases 
(%) 
Number of cases 
(%) 
Age ≤50 66 (86.8%) 10 (13.2%) 192 (99%) 1 (1%) 0.482 
>50  105 (90.5%) 11 (9.5%) 
Race Chinese 113 (89%) 14 (11%) 153 (78.9%) 40 (21.1%) 0.694 
Malay 9 (81.8%) 2 (18.2%) 
Indian 7 (100%) 0 
Others 7 (87.5%) 1 (12.5%) 
Tumor size ≤30mm 90 (86.5%) 14 (13.5%) 189 (97.4%) 4 (2.6%) 0.234 
>30mm 79 (92.9%) 6 (7.1%) 
Histological grade Grade 1 and 2 80 (89.9%) 9 (10.1%) 185 (95.4%) 8 (4.6%) 0.768 





Grade 3 85 (88.5%) 11 (11.5%) 
Staging Stage 1 and 2 85 (85%) 15 (15%) 111 (57.2%) 82 (42.8%) 0.534 
Stage 3 10 (90.9%) 1 (9.1%) 
DCIS nuclear grade None and low 60 (89.6%) 7 (10.4%) 174 (89.7%) 19 (10.3%) 0.814 
Intermediate and 
high 
97 (90.7%) 10 (9.3%) 
Lymph node 
involvement 
Negative 72 (87.8%) 10 (12.2%) 136 (70.1%) 57 (29.9%) 1.000 
Positive 48 (88.9%) 6 (11.1%) 
Lymph node stage 1-9 LN metastasis 127 (91.4%) 12 (8.6%) 180 (92.8%) 13 (7.2%) 0.187 
10 and above LN 
metastasis 
34 (82.9%) 7 (17.1%) 
ER Negative 87 (88.8%) 11 (11.2%) 181 (93.3%) 12 (6.7%) 0.811 
Positive 75 (90.4%) 8 (9.6%) 
PR Negative 72 (91.1%) 7 (8.9%) 180 (92.8%) 13 (7.2%) 0.628 
Positive 89 (88.1%) 12 (11.9%) 
HER2 Negative 111 (88.1%) 15 (11.9%) 170 (87.6%) 23 (12.4%) 0.784 
Positive 40 (90.9%) 4 (9.1%) 
BloomRichardson ≤5 10 (100%) 0 111 (57.2%) 82 (42.8%) 0.595 
>5 91 (90.1%) 10 (9.9%) 
Mitotic index Grade 1 and 2 60 (92.3%) 5 (7.7%) 123 (63.4%) 70 (36.6%) 0.851 
Grade 3 53 (91.4%) 5 (8.6%) 
Nuclear 
pleomorphism 
Grade 1 and 2 56 (93.3%) 4 (6.7%) 123 (63.4%) 70 (36.6%) 0.560 
Grade 3 57 (90.5%) 6 (9.5%) 
Tumor tubule 
formation 
Score 1 and 2 38 (90.5%) 4 (9.5%) 123 (63.4%) 70 (36.6%) 0.694 
Score 3 75 (92.6%) 6 (7.4%) 
 





Table 4.7 Correlation of clinicopathological parameters of malignant IDC with CSGalNAcT-1 total percentage score (TPS) of stromal cells. No 
significant correlation was found. 
 
Clinicopathological parameters Total percentage score (TPS) P-value 
 ≤50 >50 Valid cases (%) Missing cases 
(%)  Number of cases 
(%) 
Number of cases 
(%) 
Age ≤50 66 (86.8%) 10 (13.2%) 192 (99%) 1 (1%) 0.482 
>50  105 (90.5%) 11 (9.5%) 
Race Chinese 113 (89%) 14 (11%) 153 (78.9%) 40 (21.1%) 0.694 
Malay 9 (81.8%) 2 (18.2%) 
Indian 7 (100%) 0 
Others 7 (87.5%) 1 (12.5%) 
Tumor size ≤30mm 90 (86.5%) 14 (13.5%) 189 (97.4%) 4 (2.6%) 0.234 
>30mm 79 (92.9%) 6 (7.1%) 
Histological grade Grade 1 and 2 80 (89.9%) 9 (10.1%) 185 (95.4%) 8 (4.6%) 0.768 
Grade 3 85 (88.5%) 11 (11.5%) 
Staging Stage 1 and 2 85 (85%) 15 (15%) 111 (57.2%) 82 (42.8%) 0.534 
Stage 3 10 (90.9%) 1 (9.1%) 
DCIS nuclear grade None and low 60 (89.6%) 7 (10.4%) 174 (89.7%) 19 (10.3%) 0.814 
Intermediate and 
high 
97 (90.7%) 10 (9.3%) 
Lymph node 
involvement 
Negative 72 (87.8%) 10 (12.2%) 136 (70.1%) 57 (29.9%) 1.000 
Positive 48 (88.9%) 6 (11.1%) 
Lymph node stage 1-9 LN metastasis 127 (91.4%) 12 (8.6%) 180 (92.8%) 13 (7.2%) 0.187 
10 and above LN 34 (82.9%) 7 (17.1%) 






ER Negative 87 (88.8%) 11 (11.2%) 181 (93.3%) 12 (6.7%) 0.811 
Positive 75 (90.4%) 8 (9.6%) 
PR Negative 72 (91.1%) 7 (8.9%) 180 (92.8%) 13 (7.2%) 0.628 
Positive 89 (88.1%) 12 (11.9%) 
HER2 Negative 111 (88.1%) 15 (11.9%) 170 (87.6%) 23 (12.4%) 0.784 
Positive 40 (90.9%) 4 (9.1%) 
BloomRichardson ≤5 10 (100%) 0 111 (57.2%) 82 (42.8%) 0.595 
>5 91 (90.1%) 10 (9.9%) 
Mitotic index Grade 1 and 2 60 (92.3%) 5 (7.7%) 123 (63.4%) 70 (36.6%) 0.851 
Grade 3 53 (91.4%) 5 (8.6%) 
Nuclear 
pleomorphism 
Grade 1 and 2 56 (93.3%) 4 (6.7%) 123 (63.4%) 70 (36.6%) 0.560 
Grade 3 57 (90.5%) 6 (9.5%) 
Tumor tubule 
formation 
Score 1 and 2 38 (90.5%) 4 (9.5%) 123 (63.4%) 70 (36.6%) 0.694 











Table 4.8 Correlation of clinicopathological parameters of malignant IDC with CSGalNAcT-1 weighted average intensity (WAI) of stromal cells. 
P-value with asterisk represents statistically significant results.  
 
Clinicopathological parameters Weighted average intensity (WAI) P-value 
 ≤0.90 >0.90 Valid cases (%) Missing cases 
(%)  Number of cases 
(%) 
Number of cases 
(%) 
Age ≤50 29 (38.2%) 47 (61.8%) 192 (99%) 1 (1%) 0.004* 
>50  22 (19%) 94 (81%) 
Race Chinese, Malay 
and Indian 
37 (25.5%) 108 (74.5%) 153 (78.9%) 40 (21.1%) 0.007* 
Others 6 (75%) 2 (25%) 
Tumor size ≤30mm 25 (24%) 79 (76%) 189 (97.4%) 4 (2.6%) 0.328 
>30mm 26 (30.6%) 59 (69.4%) 
Histological grade Grade 1 and 2 17 (19.1%) 72 (80.9%) 185 (95.4%) 8 (4.6%) 0.025* 
Grade 3 32 (33.3%) 64 (66.7%) 
Staging Stage 1 and 2 12 (12%) 88 (88%) 111 (57.2%) 82 (42.8%) 0.287 
Stage 3 3 (27.3%) 8 (72.7%) 
DCIS nuclear grade None and low 15 (22.4%) 52 (77.6%) 174 (89.7%) 19 (10.3%) 0.328 
Intermediate and 
high 
31 (29%) 76 (71%) 
Lymph node 
involvement 
Negative 17 (20.7%) 65 (79.3%) 136 (70.1%) 57 (29.9%) 0.834 
Positive 12 (22.2%) 42 (77.8%) 
Lymph node stage 1-9 LN metastasis 38 (27.3%) 101 (72.7%) 180 (92.8%) 13 (7.2%) 0.146 
10 and above LN 
metastasis 
7 (17.1%) 34 (82.9%) 





ER Negative 23 (23.5%) 75 (76.5%) 181 (93.3%) 12 (6.7%) 0.245 
Positive 26 (31.3%) 57 (68.7%) 
PR Negative 21 (26.6%) 58 (73.4%) 180 (92.8%) 13 (7.2%) 1.000 
Positive 27 (26.7%) 74 (73.3%) 
HER2 Negative 32 (25.4%) 94 (74.6%) 170 (87.6%) 23 (12.4%) 0.177 
Positive 16 (36.4%) 28 (63.6%) 
BloomRichardson ≤5 3 (30%) 7 (70%) 111 (57.2%) 82 (42.8%) 0.691 
>5 22 (21.8%) 79 (78.2%) 
Mitotic index Grade 1 and 2 14 (21.5%) 51 (78.5%) 123 (63.4%) 70 (36.6%) 0.027* 
Grade 3 23 (39.7%) 35 (60.3%) 
Nuclear 
pleomorphism 
Grade 1 and 2 14 (23.3%) 46 (76.7%) 123 (63.4%) 70 (36.6%) 0.106 
Grade 3 23 (36.5%) 40 (63.5%) 
Tumor tubule 
formation 
Score 1 and 2 9 (21.4%) 33 (78.6%) 123 (63.4%) 70 (36.6%) 0.113 












Table 4.9 Summary of statistically significant correlation between CSGalNAcT-1 WAI in stromal cells and clinicopathological parameters. 
Immunoscores Parameters Remarks  
WAI 0.90 Race Higher expression was found in Chinese, Malay and Indian 
 
Age cut off at 50 WAI increases with age 
 
Histological grade Higher expression – lower histological grade 
 















4.5.3. Diffuse stroma 
CSGalNAcT-1 expression was located in IDC diffuse stroma. The following tables show the correlation between clinicopathological parameters 
and and IRS (Table 4.10), TPS (Table 4.11), and WAI (Table 4.12) of CSGalNAcT-1 in diffuse stroma. 
 
Table 4.10 Correlation of clinicopathological parameters of malignant IDC with CSGalNAcT-1 immunoreactivity score (IRS) of diffuse stroma. 
No significant correlation was found. 
 
Clinicopathological parameters Immunoreactivity score (IRS) P-value 
 ≤100 >100 Valid cases (%) Missing cases 
(%)  Number of cases 
(%) 
Number of cases 
(%) 
Age ≤50 74 (97.4%) 2 (2.6%) 192 (99%) 1 (1%) 0.649 
>50  114 (98.3%) 2 (1.7%) 
Race Chinese 125 (98.4%) 2 (1.6%) 153 (78.9%) 40 (21.1%) 0.347 
Malay 10 (90.9%) 1 (9.1%) 
Indian 7 (100%) 0 
Others 8 (100%) 0 
Tumor size ≤30mm 103 (99%) 1 (1%) 189 (97.4%) 4 (2.6%) 0.328 
>30mm 82 (96.5%) 3 (3.5%) 
Histological grade Grade 1 and 2 89 (100%) 0  185 (95.4%) 8 (4.6%) 0.153 
Grade 3 94 (97.9%) 2 (2.1%) 
Staging Stage 1 and 2 98 (98%) 2 (2%) 111 (57.2%) 82 (42.8%) 0.179 





Stage 3 11 (100%)  0 
DCIS nuclear grade None and low 66 (98.5%) 1 (1.5%) 174 (89.7%) 19 (10.3%) 0.750 
Intermediate and 
high 
106 (99.1%) 1 (0.9%) 
Lymph node 
involvement 
Negative 80 (97.6%) 2 (2.4%) 136 (70.1%) 57 (29.9%) 0.518 
Positive 54 (100%) 0 
Lymph node stage 1-9 LN metastasis 136 (97.8%) 3 (2.2%) 180 (92.8%) 13 (7.2%) 0.917 
10 and above LN 
metastasis 
40 (97.6%) 1 (2.4%) 
ER Negative 98 (100%) 0 181 (93.3%) 12 (6.7%) 0.209 
Positive 81 (97.6%) 2 (2.4%) 
PR Negative 79 (100%) 0 180 (92.8%) 13 (7.2%) 0.505 
Positive 99 (98%) 2 (2%) 
HER2 Negative 124 (98.4%) 2 (1.6%) 170 (87.6%) 23 (12.4%) 0.276 
Positive 42 (95.5%) 2 (4.5%) 
BloomRichardson ≤5 10 (100%) 0 111 (57.2%) 82 (42.8%) 1.000 
>5 99 (98%) 2 (2%) 
Mitotic index Grade 1 and 2 64 (98.5%) 1 (1.5%) 123 (63.4%) 70 (36.6%) 0.935 
Grade 3 57 (98.3%) 1 (1.7%) 
Nuclear 
pleomorphism 
Grade 1 and 2 58 (96.7%) 2 (3.3%) 123 (63.4%) 70 (36.6%) 0.150 
Grade 3 63 (100%) 0 
Tumor tubule 
formation 
Score 1 and 2 42 (100%) 0 123 (63.4%) 70 (36.6%) 0.154 
Score 3 79 (97.5%) 2 (2.5%) 
 





Table 4.11 Correlation of clinicopathological parameters of malignant IDC with CSGalNAcT-1 total percentage score (TPS) of diffuse stroma. 
No significant correlation was found. 
 
Clinicopathological parameters Total percentage score (TPS) P-value 
 ≤20 >20 Valid cases (%) Missing cases 
(%)  Number of cases 
(%) 
Number of cases 
(%) 
Age ≤50 41 (53.9%) 35 (46.1%) 192 (99%) 1 (1%) 0.464 
>50  56 (48.3%) 60 (51.7%) 
Race Chinese 60 (47.2%) 67 (52.8%) 153 (78.9%) 40 (21.1%) 0.464 
Malay 6 (54.5%) 5 (45.5%) 
Indian 3 (42.9%) 4 (57.1%) 
Others 6 (75%) 2 (25%) 
Tumor size ≤30mm 52 (50%) 52 (50%) 189 (97.4%) 4 (2.6%) 1.000 
>30mm 43 (50.6%) 42 (49.4%) 
Histological grade Grade 1 and 2 44 (49.4%) 45 (50.6%) 185 (95.4%) 8 (4.6%) 0.827 
Grade 3 49 (51%) 47 (49%) 
Staging Stage 1 and 2 41 (41%) 59 (59%) 111 (57.2%) 82 (42.8%) 0.763 
Stage 3 4 (36.4%) 7 (63.6%) 
DCIS nuclear grade None and low 38 (56.7%) 29 (43.3%) 174 (89.7%) 19 (10.3%) 0.197 
Intermediate and 
high 
50 (46.7%) 57 (53.3%) 
Lymph node 
involvement 
Negative 35 (42.7%) 47 (57.3%) 136 (70.1%) 57 (29.9%) 0.726 
Positive 25 (46.3%) 29 (53.7%) 
Lymph node stage 1-9 LN metastasis 68 (48.9%) 71 (51.1%) 180 (92.8%) 13 (7.2%) 0.987 
10 and above LN 20 (48.8%) 21 (51.2%) 






ER Negative 53 (54.1%) 45 (45.9%) 181 (93.3%) 12 (6.7%) 0.458 
Positive 40 (48.2%) 43 (51.8%) 
PR Negative 39 (49.4%) 40 (50.6%) 180 (92.8%) 13 (7.2%) 0.764 
Positive 53 (52.5%) 48 (47.5%) 
HER2 Negative 64 (50.8%) 62 (49.2%) 170 (87.6%) 23 (12.4%) 1.000 
Positive 22 (50%) 22 (50%) 
BloomRichardson ≤5 3 (30%) 7 (70%) 111 (57.2%) 82 (42.8%) 0.507 
>5 47 (46.5%) 54 (53.5%) 
Mitotic index Grade 1 and 2 31 (47.7%) 34 (52.3%) 123 (63.4%) 70 (36.6%) 0.523 
Grade 3 31 (53.4%) 27 (46.6%) 
Nuclear 
pleomorphism 
Grade 1 and 2 26 (43.3%) 34 (56.7%) 123 (63.4%) 70 (36.6%) 0.122 
Grade 3 36 (57.1%) 27 (42.9%) 
Tumor tubule 
formation 
Score 1 and 2 19 (45.2%) 23 (54.8%) 123 (63.4%) 70 (36.6%) 0.408 











Table 4.12 Correlation of clinicopathological parameters of malignant IDC with CSGalNAcT-1 weighted average intensity (WAI) of diffuse 
stroma. No significant correlation was found. 
 
Clinicopathological parameters Weighted average intensity (WAI) P-value 
 ≤1.0 >1.0 Valid cases (%) Missing cases 
(%)  Number of cases 
(%) 
Number of cases 
(%) 
Age ≤50 74 (97.4%) 2 (2.6%) 191 (98.5%) 2 (1.5%) 1.000 
>50  112 (97.4%) 3 (2.6%) 
Race Chinese 124 (98.4%) 2 (1.6%) 152 (78.4%) 41 (21.6%) 0.351 
Malay 10 (90.9%) 1 (9.1%) 
Indian 7 (100%) 0 (0%) 
Others 8 (100%) 0 
Tumor size ≤30mm 103 (99%) 1 (1%) 188 (96.9%) 5 (3.1%) 0.174 
>30mm 80 (95.2%) 4 (4.8%) 
Histological grade Grade 1 and 2 88 (100%) 0 184 (94.8%) 9 (5.2%) 0.078 
Grade 3 93 (96.9%) 3 (3.1%) 
Staging Stage 1 and 2 98 (98%) 2 (2%) 110 (57.2%) 83 (43.3%) 0.183 
Stage 3 10 (100%) 0 
DCIS nuclear grade None and low 66 (98.5%) 1 (1.5%) 173 (89.2%) 21 (10.8%) 0.843 
Intermediate and 
high 
104 (98.1%) 2 (1.9%) 
Lymph node 
involvement 
Negative 35 (42.7%) 47 (57.3%) 135 (69.6%) 58 (30.4%) 0.726 
Positive 25 (46.3%) 29 (53.7%) 
Lymph node stage 1-9 LN metastasis 79 (97.5%) 2 (2.5%) 179 (92.3%) 14 (7.7%) 0.516 
10 and above LN 54 (100%) 0 






ER Negative 98 (100%) 0 180 (92.8%) 13 (7.2%) 0.093 
Positive 79 (96.3%) 3 (3.7%) 
PR Negative 78 (98.7%) 1 (1.3%) 179 (92.3%) 14 (7.7%) 1.000 
Positive 98 (98%) 2 (2%) 
HER2 Negative 123 (97.6%) 3 (2.4%) 170 (87.6%) 23 (12.4%) 0.605 
Positive 42 (95.5%) 2 (4.5%) 
BloomRichardson ≤5 10 (100%) 0 110 (56.7%) 83 (43.3%) 1.000 
>5 98 (98%) 2 (2%) 
Mitotic index Grade 1 and 2 64 (98.5%) 1 (1.5%) 122 (62.9%) 71 (37.1%) 0.926 
Grade 3 56 (98.2%) 1 (1.8%) 
Nuclear 
pleomorphism 
Grade 1 and 2 57 (96.6%) 2 (3.4%) 122 (62.9%) 71 (37.1%) 0.150 
Grade 3 63 (100%) 0 
Tumor tubule 
formation 
Score 1 and 2 41 (100%) 0 122 (62.9%) 71 (37.1%) 0.154 










Immunoscores of CSGalNAcT-1 in epithelial cells, stromal cells and diffuse stroma were associated with clinicopathological parameters. 
Significant associations were only found in stromal cells between WAI and race, age cut off at 50, histological grade and mitotic index, as 
summarized in Table 4.9. Higher expression of CSGalNAcT-1 was found generally in older population; and in Chinese, Malay and Indian as 
compared to races of other kinds. On the other hand, stronger CSGalNAcT-1 expression was significantly associated to lower histological grade 
and mitotic index.  
 
4.6. Multivariate analysis in breast IDC 
By considering the presence and effect of other parameters simultaneously, multivariate test was performed to search for further meaningful and 
more in depth association in breast IDC cases. From Table 4.13, it shows that in the case of CSGalNAcT-1 staining in stromal cells, race of 
Chinese, Malay and Indian once again significantly correlated with CSGalNAcT-1 immunoscore WAI 0.90 after adjusting for age, histological 









Table 4.13 Multivariate analysis for association of multiple clinicopathological parameters and CSGalNAcT-1 staining in stromal cells. P-value 
with asterisk represents statistically significant results, after adjusting confounders (parameters). 
 
Dependent variable P-value Clinicopathological parameters Total number 
of cases 
Standardized coefficients  
(Beta) 
P-value for standardized 
coefficient (Beta) 
WAI 0.90 0.018* Race  
Chinese, Malay and Indian vs 
Others 
153 -0.196 0.028* 
Histological grade 
Grade 1 and 2 vs Grade 3 
185 -0.054 0.621 
Mitotic index 
Grade 1 and 2 vs Grade 3 
123 -0.125 0.252 
Age 
≤50 vs >50 











4.7. Survival and tumor recurrence data for survival analysis 
In this survival analysis, the data was available in 186 out of 193 cases and the 
patients‟ follow-up period ranged from 0.5 month to 134.47 months. The three 
timelines that were used to measure the mortality and recurrence of IDC 
patients are overall survival (OS), disease free survival (DFS), and survival 
after recurrence (SAR). Figure 4.4 illustrates the interpretation of these three 
parameters. Table 4.14 shows that death from breast cancer occurred in 25 
patients and 44 patients had tumor recurrence, of which six death from 
recurrence were reported. The remaining cases were censored cases, indicating 
no tumor recurrence and death was found at the end of follow-up period.  
 
 
Figure 4.4 The interpretation of overall survival (OS), disease free survival 
(DFS), and survival after recurrence (SAR) based on the date of diagnosis, 
date of tumor recurrence and date of death. 
 
Table 4.14 Descriptive statistics of OS, DFS and SAR in terms of mean, 
median and range of period in malignant IDC. The unit used is in month. 
 
 OS DFS SAR 
Number of cases 186 186 186 
Missing cases 7 7 7 
Number of events 25 44 6 
Mean (months) 39.9412 41.4177 17.43 
Median (months) 31.27 34.615 15.75 
Range (months) 4.90 to 104.53 4.90 to 111.90 1.16o 48.72 
 
 





4.8. Timeline analysis of mortality due to disease in patients with breast 
invasive ductal carcinoma 
Mortality due to breast IDC is investigated for any correlation with the 
immunoscores of CSGalNAcT-1 using Kaplan-Meier analysis. The timelines 
that were investigated were overall survival (OS) and survival after recurrence 
(SAR). In summary, Table 4.15 and 4.20 show that there was no significant 
correlation between CSGalNAcT-1 immunoscoring with the mortality of 
patients in terms of overall survival (OS) and survival after recurrence (SAR)  
in Kaplan-Meier analysis.  
 
4.8.1. Overall survival (OS) 
Table 4.15 Summary of the correlation between CSGalNAcT-1 




Parameters IRS 150 TP 90 WAI 1.70 
Log Rank (Mantel-Cox) 0.588 0.952 0.668 
 
Stromal cells 
Parameters IRS 50 TP 50 WAI 0.90 
Log Rank (Mantel-Cox) 0.986 0.986 0.440 
 
Diffuse stroma 
Parameters IRS 100 TP 20 WAI 1.0 
Log Rank (Mantel-Cox) 0.351 0.479 0.354 
 
To exclude the confounding effect from the other clinicopathological 
parameters, survival analysis was carried out for different patient sub-strata. 
This was done for every stained component, i.e. epithelial cells, stromal cells, 
and diffuse stroma, with timeline OS for the mortality data. The data was 
presented in Table 4.16 to Table 4.18 Significant correlation was found 





between IRS and WAI of CSGalNAcT-1 in diffuse stroma and patients who 
are ER positive, and have no lymph node involvement. The summary of the 
significant correlation is presented in Table 4.19 and results were presented in 
Kaplan-Meier graphs in Figure 4.5 to 4.8. 
 
4.8.1.1. Epithelial cells 
Table 4.16 Summary of the correlation between CSGalNAcT-1 epithelial cells 
immunohistochemical staining (IRS, TPS, WAI) and mortality in every 






IRS 150 TPS 90 WAI 1.70 
P-value 
Age ≤50 0.572 0.935 0.508 
>50 0.115 0.847 0.354 
Tumor size ≤30 mm 0.701 0.544 0.582 
>30mm 0.285 0.983 0.512 
Histological grade Grade 1 and 2 0.636 0.302 0.398 
Grade 3 0.191 0.569 0.088 
Staging Stage 1 and 2 0.484 0.846 0.881 
Stage 3 NA 0.400 0.074 
DCIS grade None and low 0.159 0.620 0.053 
Intermediate and 
high 
0.614 0.347 0.369 
Lymph node 
involvement 
Negative 0.560 0.938 0.305 
Positive 0.183 0.913 0.050 
Lymph node stage 1-9 LN metastasis 0.204 0.508 0.221 
10 and above LN 
metastasis 
0.570 0.399 0.409 
ER Negative 0.142 0.698 0.235 
Positive 0.549 0.511 0.380 
PR Negative  0.060 0.841 0.183 
Positive 0.401 0.799 0.784 
HER2 Negative 0.189 0.827 0.833 
Positive 0.713 0.521 0.713 
BloomRichardson 
score 
≤5 NA 0.063 NA 
>5 NA 0.455 0.753 
Mitotic index Grade 1 and 2 NA 0.431 0.563 
Grade 3 NA 0.470 0.090 
Nuclear 
pleomorphism 
Grade 1 and 2 NA 0.545 0.528 
Grade 3 NA 0.563 0.247 





Tubule formation Score 1 and 2 NA 0.895 0.500 
Score 3 NA 0.905 0.705 
 
4.8.1.2. Stromal cells 
Table 4.17 Summary of the correlation between CSGalNAcT-1 stromal cells 
immunohistochemical staining (IRS, TPS, WAI) and mortality in every 






IRS 50 TPS 50 WAI 0.90 
P-value 
Age ≤50 0.927 0.927 0.760 
>50 0.903 0.903 0.590 
Tumor size ≤30 mm 0.857 0.857 0.197 
>30mm 0.683 0.683 0.886 
Histological grade Grade 1 and 2 0.885 0.885 0.212 
Grade 3 0.902 0.902 0.579 
Staging Stage 1 and 2 0.955 0.955 0.609 
Stage 3 0.074 0.074 0.442 
DCIS grade None and low 0.751 0.751 0.379 
Intermediate and 
high 
0.901 0.901 0.729 
Lymph node 
involvement 
Negative 0.808 0.808 0.507 
Positive 0.637 0.637 0.859 
Lymph node stage 1-9 LN metastasis 0.548 0.548 0.110 
10 and above LN 
metastasis 
0.494 0.494 0.207 
ER Negative 0.390 0.390 0.548 
Positive 0.271 0.271 0.166 
PR Negative  0.145 0.145 0.477 
Positive 0.381 0.381 0.215 
HER2 Negative 0.670 0.670 0.347 
Positive 0.589 0.589 0.495 
BloomRichardson 
score 
≤5 NA NA 0.513 
>5 0.594 0.594 0.789 
Mitotic index Grade 1 and 2 0.447 0.447 0.272 
Grade 3 0.830 0.830 0.971 
Nuclear 
pleomorphism 
Grade 1 and 2 0.416 0.416 0.205 
Grade 3 0.921 0.921 0.547 
Tubule formation Score 1 and 2 0.669 0.669 0.951 
Score 3 0.334 0.334 0.712 
 
 





4.8.1.3. Diffuse stroma 
Table 4.18 Summary of the correlation between CSGalNAcT-1 diffuse stroma 
immunohistochemical staining (IRS, TPS, WAI) and mortality in every 
stratum of parameters in breast IDC. P-value with asterisk represents 






IRS 100 TPS 20 WAI 1.0 
P-value 
Age ≤50 0.738 0.052 0.738 
>50 0.192 0.505 0.197 
Tumor size ≤30 mm NA 0.444 NA 
>30mm 0.667 0.816 0.679 
Histological grade Grade 1 and 2 NA 0.598 NA 
Grade 3 0.513 0.845 0.513 
Staging Stage 1 and 2 0.064 0.751 0.064 
Stage 3 NA 0.279 NA 
DCIS grade None and low 0.680 0.669 0.680 
Intermediate and 
high 
0.723 0.779 0.721 
Lymph node 
involvement 
Negative 0.042* 0.455 0.044* 
Positive NA 0.923 NA 
Lymph node stage 1-9 LN metastasis 0.606 0.988 0.606 
10 and above LN 
metastasis 
0.065 0.248 0.066 
ER Negative NA 0.965 NA 
Positive 0.017* 0.133 0.018* 
PR Negative  NA 0.471 NA 
Positive 0.059 0.088 0.061 
HER2 Negative 0.080 0.895 0.066 
Positive 0.713 0.193 0.713 
BloomRichardson 
score 
≤5 NA 0.127 NA 
>5 0.558 0.395 0.556 
Mitotic index Grade 1 and 2 0.743 0.552 0.743 
Grade 3 0.587 0.771 0.583 
Nuclear 
pleomorphism 
Grade 1 and 2 0.573 0.361 0.570 
Grade 3 NA 0.973 NA 
Tubule formation Score 1 and 2 NA 0.052 NA 









Table 4.19 Summary of significant correlation between CSGalNAcT-1 
immunostaining IRS and WAI in diffuse stroma and mortality in breast IDCs 
for clinicopathological parameters stratum. 
 
 




IRS 100 Lymph 
node 
involvement 
No 0.042 (Patients 
with no lymph 
node involvement 
and low IRS have 
better survival) 
ER Positive 0.017 (Patients 
with ER positive 
and low IRS have 
better survival) 
WAI 1.0 Lymph 
node 
involvement 
No 0.044 (Patients 
with no lymph 
node involvement 
and low WAI have 
better survival) 
ER Positive 0.018 (Patients 
with ER positive 











Figure 4.5 This is the Kaplan-Meier curve where the X-axis shows the OS 
timeline follow-up in months. Y-axis shows the proportion of patients who are 
still alive. Blue line shows diffuse stroma IRS staining ≤100; while green line 
is IRS staining >100. The curve shows the significance of mortality in patients 
with no lymph node involvement and low diffuse stroma IRS score (≤100), i.e. 







Lymph node involvement= No 
Diffuse stroma IRS 
Overall Survival (OS) 






Figure 4.6 This is the Kaplan-Meier curve where the X-axis shows the OS 
timeline follow-up in months. Y-axis shows the proportion of patients who are 
still alive. Blue line shows diffuse stroma IRS staining ≤100; while green line 
is IRS staining >100. The curve shows the significance of mortality in patients 
with ER positive and low diffuse stroma IRS score (≤100), i.e. patients with 






Estrogen receptor= Positive 
Diffuse stroma IRS 
Overall Survival (OS) 






Figure 4.7 This is the Kaplan-Meier curve where the X-axis shows the OS 
timeline follow-up in months. Y-axis shows the proportion of patients who are 
still alive. Blue line shows diffuse stroma WAI staining ≤1.00; while green 
line is WAI staining >1.00. The curve shows the significance of mortality in 
patients with no lymph node involvement and low diffuse stroma WAI score 
(≤1.00), i.e. patients with no lymph node involvement and low WAI score 




Lymph node involvement= No 
Diffuse stroma WAI 
Overall Survival (OS) 







Figure 4.8 This is the Kaplan-Meier curve where the X-axis shows the OS 
timeline follow-up in months. Y-axis shows the proportion of patients who are 
still alive. Blue line shows diffuse stroma WAI staining ≤1.00; while green 
line is WAI staining >1.00. The curve shows the significance of mortality in 
patients with ER positive and low diffuse stroma WAI score (≤1.00), i.e. 




4.8.2. Survival after recurrence (SAR) 
Table 4.20 Summary of the correlation between CSGalNAcT-1 





Parameters IRS 150 TP 90 WAI 1.70 
Log Rank (Mantel-Cox) 0.334 0.914 0.641 
 
Stromal cells 
Parameters IRS 50 TP 50 WAI 0.90 
Log Rank (Mantel-Cox) 0.895 0.895 0.214 
 
Diffuse stroma 
Parameters IRS 100 TP 20 WAI 1.0 
Log Rank (Mantel-Cox) 0.190 0.408 0.192 
P-value= 0.018* 
Overall Survival (OS) 
Estrogen receptor= Positive 
Diffuse stroma WAI 





To exclude the confounding effect from the other clinicopathological 
parameters, survival analysis was carried out for different patient sub-strata. 
This was done for every stained component, i.e. epithelial cells, stromal cells, 
and diffuse stroma, with timeline SAR for the mortality data. The data was 
presented in Table 4.21 to Table 4.23. Significant relationship was found 
between immunoscoring of CSGalNAcT-1 in diffuse stroma (IRS) and IDC 
patients who are ER positive. The summary of the significant correlation is 
presented in Table 4.24 and the results were presented in Kaplan-Meier graphs 
in Figure 4.9. 
 
4.8.2.1. Epithelial cells 
Table 4.21 Summary of the correlation between CSGalNAcT-1 epithelial cells 
immunohistochemical staining (IRS, TPS, WAI) and mortality in every 






IRS 150 TPS 90 WAI 1.70 
P-value 
Age ≤50 0.704 0.742 0.639 
>50 0.117 0.774 0.601 
Tumor size ≤30 mm 0.742 0.626 0.638 
>30mm 0.159 0.919 0.524 
Histological grade Grade 1 and 2 0.670 0.319 0.449 
Grade 3 0.074 0.594 0.208 
Staging Stage 1 and 2 0.375 0.968 0.906 
Stage 3 NA 0.400 0.205 
DCIS grade None and low 0.071 0.349 0.234 
Intermediate and 
high 
0.675 0.450 0.459 
Lymph node 
involvement 
Negative 0.615 0.924 0.371 
Positive 0.121 0.818 0.558 
Lymph node stage 1-9 LN metastasis 0.091 0.184 0.387 
10 and above LN 
metastasis 
0.645 0.343 0.509 
ER Negative 0.136 0.811 0.356 
Positive 0.711 0.988 0.596 
PR Negative  0.062 0.788 0.157 





Positive 0.538 0.994 0.789 
HER2 Negative 0.144 0.932 0.529 
Positive 0.752 0.564 0.752 
BloomRichardson 
score 
≤5 NA 0.317 NA 
>5 NA 0.547 0.962 
Mitotic index Grade 1 and 2 NA 0.382 0.611 
Grade 3 NA 0.510 0.811 
Nuclear 
pleomorphism 
Grade 1 and 2 NA 0.297 0.667 
Grade 3 NA 0.609 0.515 
Tubule formation Score 1 and 2 NA 0.833 0.514 
Score 3 NA 0.658 0.774 
 
 
4.8.2.2. Stromal cells 
Table 4.22 Summary of the correlation between CSGalNAcT-1 stromal cells 
immunohistochemical staining (IRS, TPS, WAI) and mortality in every 






IRS 50 TPS 50 WAI 0.90 
P-value 
Age ≤50 0.571 0.571 0.542 
>50 0.930 0.930 0.325 
Tumor size ≤30 mm 0.953 0.953 0.173 
>30mm 0.663 0.663 0.559 
Histological grade Grade 1 and 2 0.893 0.893 0.143 
Grade 3 0.903 0.903 0.360 
Staging Stage 1 and 2 0.956 0.956 0.813 
Stage 3 0.205 0.205 0.442 
DCIS grade None and low 0.713 0.713 0.282 
Intermediate and 
high 
0.807 0.807 0.380 
Lymph node 
involvement 
Negative 0.906 0.906 0.329 
Positive 0.864 0.864 0.964 
Lymph node stage 1-9 LN metastasis 0.786 0.786 0.061 
10 and above LN 
metastasis 
0.808 0.808 0.607 
ER Negative 0.493 0.493 0.750 
Positive 0.441 0.441 0.062 
PR Negative  0.075 0.075 0.442 
Positive 0.402 0.402 0.056 
HER2 Negative 0.839 0.839 0.278 
Positive 0.647 0.647 0.705 
BloomRichardson ≤5 NA NA NA 





score >5 0.521 0.521 0.812 
Mitotic index Grade 1 and 2 0.443 0.443 0.152 
Grade 3 0.743 0.743 0.767 
Nuclear 
pleomorphism 
Grade 1 and 2 0.476 0.476 0.100 
Grade 3 0.946 0.946 0.776 
Tubule formation Score 1 and 2 0.445 0.445 0.935 
Score 3 0.468 0.468 0.364 
 
 
4.8.2.3. Diffuse stroma 
Table 4.23 Summary of the correlation between CSGalNAcT-1 diffuse stroma 
immunohistochemical staining (IRS, TPS, WAI) and mortality in every 
stratum of parameters in breast IDC. P-value with asterisk represents 






IRS 100 TPS 20 WAI 1.0 
P-value 
Age ≤50 0.789 0.051 0.789 
>50 0.117 0.698 0.120 
Tumor size ≤30 mm NA 0.415 NA 
>30mm 0.361 0.933 0.368 
Histological grade Grade 1 and 2 NA 0.582 NA 
Grade 3 0.619 0.532 0.619 
Staging Stage 1 and 2 0.081 0.390 0.081 
Stage 3 NA 0.343 NA 
DCIS grade None and low 0.728 0.551  0.728 
Intermediate and 
high 
0.768 0.802 0.767 
Lymph node 
involvement 
Negative 0.078 0.453 0.081 
Positive NA 0.486 NA 
Lymph node stage 1-9 LN metastasis 0.683 0.958 0.683 
10 and above LN 
metastasis 
0.080 0.165 0.088 
ER Negative NA 0.949 NA 
Positive 0.011* 0.100 0.77 
PR Negative  NA 0.561 NA 
Positive 0.076 0.099 0.079 
HER2 Negative 0.074 0.624 0.74 
Positive 0.752 0.143 0.752 
BloomRichardson 
score 
≤5 NA 0.317 NA 
>5 0.615 0.514 0.613 
Mitotic index Grade 1 and 2 0.773 0.521 0.773 
Grade 3 0.729 0.674 0.726 







Grade 1 and 2 0.667 0.669 0.664 
Grade 3 NA 0.977 NA 
Tubule formation Score 1 and 2 NA 0.082 NA 
Score 3 0.683 0.367 0.683 
 
 
Table 4.24 Summary of significant correlation between CSGalNAcT-1 
immunoscoring IRS in diffuse stroma and mortality in breast IDCs for 
clinicopathological parameters stratum. 
 
 




IRS 100 ER Positive 0.011 (Patients 
with ER positive 





Figure 4.9 This is the Kaplan-Meier curve where the X-axis shows the SAR 
timeline follow-up in months. Y-axis shows the proportion of patients who are 
still alive. Blue line shows diffuse stroma IRS staining ≤100; while green line 
is IRS staining >100. This curve shows the significance of mortality in 
patients with ER positive and low diffuse stroma IRS score (≤100), i.e. 
patients with ER positive and low IRS score have better survival. 
 
P-value= 0.011* 
Estrogen receptor= Positive 
Diffuse stroma IRS 
Survival After Recurrence (SAR) 





4.9. Timeline analysis of recurrence of disease in patients with breast invasive 
ductal carcinoma 
After correlating immunoscores with mortality of IDC, further statistical 
analyses using Kaplan-Meier analysis were done to investigate if the 
correlation exists in the aspect of tumor recurrence in patients, i.e. whether 
increase or decrease in immunoscores contributes to the chances of recurrence 
in IDC patients. The timeline disease free survival (DFS) was investigated. 
Table 4.25 shows that there was no significant correlation between 
CSGalNAcT-1 immunoscoring with the recurrence of breast invasive ductal 
carcinoma in patients.  
Table 4.25 Summary of the correlation between CSGalNAcT-1 
immunohistochemical staining and recurrence in breast IDCs. There is no 
significant correlation. 
Epithelial cells 
Parameters IRS 150 TP 90 WAI 1.70 
Log Rank (Mantel-Cox) 0.956 0.957 0.741 
 
Stromal cells 
Parameters IRS 50 TP 50 WAI 0.90 
Log Rank (Mantel-Cox) 0.801 0.801 0.609 
 
Diffuse stroma 
Parameters IRS 100 TP 20 WAI 1.0 
Log Rank (Mantel-Cox) 0.804 0.406 0.809 
 
To exclude the confounding effect from the other clinicopathological 
parameters, survival analysis was carried out for different patient sub-strata. 
This was done for every stained component, i.e. epithelial cells, stromal cells, 
and diffuse stroma, with DFS for the recurrence data. The data was presented 
in Table 4.26 to Table 4.28. Significant correlation was found between 
immunoscoring of CSGalNAcT-1 in diffuse stroma (TPS) and patients who 





are ER positive, and have lower scoring of tubule formation. The summary of 
the significant correlation is presented in Table 4.29 and results were 
presented in Kaplan-Meier graphs in Figure 4.10 and 4.11. 
 
4.9.1. Epithelial cells 
Table 4.26 Summary of the correlation between CSGalNAcT-1 epithelial cells 
immunohistochemical staining (IRS, TPS, WAI) and recurrence in every 





IRS 150 TPS 90 WAI 1.70 
P-value 
Age ≤50 0.461 0.675 0.362 
>50 0.336 0.837 0.796 
Tumor size ≤30 mm 0.487 0.732 0.353 
>30mm 0.565 0.993 0.922 
Histological grade Grade 1 and 2 0.512 0.562 0.241 
Grade 3 0.426 0.860 0.110 
Staging Stage 1 and 2 0.761 0.899 0.612 
Stage 3 NA 0.737 0.544 
DCIS grade None and low 0.413 0.876 0.103 
Intermediate and 
high 
0.434 0.889 0.196 
Lymph node 
involvement 
Negative 0.426 0.975 0.186 
Positive 0.442 0.883 0.143 
Lymph node stage 1-9 LN metastasis 0.720 0.839 0.851 
10 and above LN 
metastasis 
0.526 0.764 0.360 
ER Negative 0.345 0.383 0.556 
Positive 0.459 0.341 0.284 
PR Negative  0.070 0.982 0.535 
Positive 0.270 0.983 0.465 
HER2 Negative 0.362 0.924 0.889 
Positive 0.403 0.615 0.403 
BloomRichardson 
score 
≤5 NA 0.080 NA 
>5 NA 0.673 0.890 
Mitotic index Grade 1 and 2 NA 0.794 0.372 
Grade 3 NA 0.872 0.074 
Nuclear 
pleomorphism 
Grade 1 and 2 NA 0.706 0.426 
Grade 3 NA 0.859 0.492 
Tubule formation Score 1 and 2 NA 0.649 0.736 
Score 3 NA 0.665 0.572 
 





4.9.2. Stromal cells 
Table 4.27 Summary of the correlation between CSGalNAcT-1 stomal cells 
immunohistochemical staining (IRS, TPS, WAI) and recurrence in every 





IRS 50 TPS 50 WAI 0.90 
P-value 
Age ≤50 0.682 0.682 0.903 
>50 0.544 0.544 0.456 
Tumor size ≤30 mm 0.709 0.709 0.690 
>30mm 0.354 0.354 0.440 
Histological grade Grade 1 and 2 0.725 0.725 0.944 
Grade 3 0.684 0.684 0.979 
Staging Stage 1 and 2 0.591 0.591 0.768 
Stage 3 0.544 0.544 0.320 
DCIS grade None and low 0.317 0.317 0.968 
Intermediate and 
high 
0.766 0.766 0.408 
Lymph node 
involvement 
Negative 0.720 0.720 0.626 
Positive 0.872 0.872 0.642 
Lymph node stage 1-9 LN metastasis 0.545 0.545 0.888 
10 and above LN 
metastasis 
0.308 0.308 0.123 
ER Negative 0.671 0.671 0.596 
Positive 0.537 0.537 0.895 
PR Negative  0.578 0.578 0.787 
Positive 0.577 0.577 0.952 
HER2 Negative 0.817 0.817 0.469 
Positive 0.221 0.221 0.089 
BloomRichardson 
score 
≤5 NA NA 0.383 
>5 0.932 0.932 0.087 
Mitotic index Grade 1 and 2 0.895 0.895 0.445 
Grade 3 0.976 0.976 0.693 
Nuclear 
pleomorphism 
Grade 1 and 2 0.959 0.959 0.600 
Grade 3 0.949 0.949 0.482 
Tubule formation Score 1 and 2 0.132 0.132 0.188 











4.9.3. Diffuse stroma 
Table 4.28 Summary of the correlation between CSGalNAcT-1 diffuse stroma 
immunohistochemical staining (IRS, TPS, WAI) and recurrence in every 
stratum of parameters in breast IDC. P-value with asterisk represents 





IRS 100 TPS 20 WAI 1.0 
P-value 
Age ≤50 0.624 0.116 0.624 
>50 0.461 0.828 0.469 
Tumor size ≤30 mm NA 0.168 NA 
>30mm 0.921 0.621 0.906 
Histological grade Grade 1 and 2 NA 0.172 NA 
Grade 3 0.333 0.811 0.333 
Staging Stage 1 and 2 0.118 0.675 0.118 
Stage 3 NA 0.302 NA 
DCIS grade None and low 0.530 0.882 0.530 
Intermediate and 
high 
0.546 0.527 0.544 
Lymph node 
involvement 
Negative 0.195 0.465 0.201 
Positive NA 0.361 NA 
Lymph node stage 1-9 LN metastasis 0.414 0.587 0.414 
10 and above LN 
metastasis 
0.056 0.556 0.061 
ER Negative NA 0.665 NA 
Positive 0.158 0.255 0.164 
PR Negative  NA 0.412 NA 
Positive 0.289 0.047* 0.296 
HER2 Negative 0.089 0.901 0.069 
Positive 0.403 0.144 0.403 
BloomRichardson 
score 
≤5 NA 0.475 NA 
>5 0.404 0.204 0.401 
Mitotic index Grade 1 and 2 0.635 0.249 0.635 
Grade 3 0.467 0.723 0.462 
Nuclear 
pleomorphism 
Grade 1 and 2 0.460 0.329 0.455 
Grade 3 NA 0.538 NA 
Tubule formation Score 1 and 2 NA 0.013* NA 










Table 4.29 Summary of significant correlation between CSGalNAcT-1 
immunoscoring WAI in diffuse stroma and recurrence in breast IDCs for 
clinicopathological parameters stratum.  
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Figure 4.10 This is the Kaplan-Meier curve where the X-axis shows the DFS 
timeline follow-up in months. Y-axis shows the proportion of patients who 
have not had recurrence. Blue line shows diffuse stroma TPS staining ≤20; 
while green line is TPS staining >20. The curve shows the significance of 
recurrence in patients with positive PR and low diffuse stroma TPS score 








Progesterone receptor= Yes 
Diffuse stroma TPS 
Disease Free Survival (DFS) 






Figure 4.11 This is the Kaplan-Meier curve where the X-axis shows the DFS 
timeline follow-up in months. Y-axis shows the proportion of patients who 
have not had recurrence. Blue line shows diffuse stroma TPS staining ≤20; 
while green line is TPS staining >20. This curve shows the significance of 
recurrence in patients with low scoring of tubule formation (score 1 and 2) and 
low diffuse stroma TPS score (≤20), i.e. patients with lower scoring of tubule 
formation and low TPS score have longer recurrence free period. 
 
Tubule formation score 1 and 2 
P-value= 0.013* 
Diffuse stroma TPS 
Disease Free Survival (DFS) 
























5.  DISCUSSION 
5.1. Expression and functional analysis of CSGalNAcT-1 in breast cell lines 
5.1.1. Expression of CSGalNAcT-1 in breast cell lines 
This is the pilot study of CSGalNAcT-1 in breast cancer. There are extensive 
studies of galactosaminoglycans and its proteoglycans in breast cancer and 
other cancer types but no study was found to correlate the enzyme that 
determines the synthesis of galactosaminoglycans with cancer, let alone the 
signaling pathway that CSGalNAcT-1 is involved in. In current study, it is 
interesting to know that the mRNA copy of CSGalNAcT-1 was lower in all the 
breast cancer cell lines as compared with a normal breast cell line. This 
expression pattern gave a hint that CSGalNAcT-1 could play a role in breast 
cancer malignancy. Hence, to explore the role of CSGalNAcT-1, this gene was 
silenced in normal breast cell line, MCF-12A; while over-expressed in breast 
cancer cell line, MCF7 and MDA-MB-231. 
 
5.1.2. siRNA-mediated CSGalNAcT-1 silencing and CSGalNAcT-1 plasmid 
stable over-expression 
siRNA-mediated silencing of CSGalNAcT-1 was achieved optimally at 76% in 
MCF-12A (Figure 3.2). Dharmacon ON-TARGETplus SMARTpool siRNA 
comprises of four siRNA sequences in a single reagent was used in gene 
silencing. ON-TARGETplus SMARTpool siRNA is designed to reduce off-
targets effect using dual-strand (sense and antisense) modification so that the 
potency and specificity of target gene knockdown are guaranteed (Jackson et 
al., 2006). The innovation of dual-strand modifications is demonstrated by 
modifying sense strand to prevent interaction with RNA-induced silencing 





complex (RISC) and favor antisense strand uptake; and antisense strand seed 
region which most of the time contributes to off-target activity is also 
modified to impede off-target activity and enhance knockdown specificity 
(Jackson et al., 2006). The specificity of CSGalNAcT-1 knockdown was 
proven as isoform CSGalNAcT-2 did not exhibit significant change after 
CSGalNAcT-1 knockdown (Figure 3.3).  
 
On the contrary, CSGalNAcT-1 was over-expressed in MCF7 and MDA-MB-
231. Although GFP-tag was not cloned into the plasmid to serve as a report to 
the plasmid transfection efficiency, Neomycin G418 antibiotic serves as a 
specificity selection of cells that were successfully transfected with the 
plasmid.  
 
Gene knockdown and over-expression of CSGalNAcT-1 were validated at both 
gene transcript level via qRT-PCR and the protein level via western blotting 
and immunofluorescence technique (Figure 3.2, 3.4, 3.24 and 3.25).  
 
5.1.3. Functional significance and signaling pathway of CSGalNAcT-1 in 
breast cancer cell lines 
Knocking down CSGalNAcT-1 in normal breast cell line, MCF-12A, caused 
the cells to have increased migration, invasion, cell viability and apoptosis. On 
the contrary, over-expression of CSGalNAcT-1 in breast cancer cell lines, 
MCF7 and MDA-MB-231, hampered the cancer phenotypes, i.e. decreased 
migration and invasion, reduced cell viability and affected adhesion. 
Interestingly, microarray screening of CSGalNAcT-1 silenced MCF-12A 





detected a few novel genes that could be the downstream targets of 
CSGalNAcT-1. These genes, which include CXCL14, TRIM59, ONECUT2, 
APOL6 and CDKN1C, are plausible to be implicated in the phenotypic 
changes of CSGalNAcT-1 knockdown and over-expression cells. A 
hypothetical diagram on the mechanisms of CSGalNAcT-1 role in MCF-12A 
was illustrated in Figure 5.1. 
 
5.1.3.1. TRIM59 
TRIM59 was discovered as the plausible early signal transducer in both RAS 
and SV40Tag oncogenic pathway in a study (Valiyeva et al., 2011). The tumor 
phenotypes acquired in CSGalNAcT-1 knockdown MCF-12A could be 
attributed to the up-regulation of TRIM59 interacting with effector molecules 
from RAS and SV40Tag oncogenic pathways. 
 
TRIM59 is one of the members of the evolutionary conserved TRIM 
(TRIpartite Motif) family (Khatamianfar et al., 2012). The functions of most of 
the TRIM family members, including TRIM59, are poorly understood but 
studies showed that some of the gene members are implicated in critical 
cellular process including immunity (Ozato et al., 2008, James et al., 2007, 
Keeble et al., 2008), proliferation (Gack et al., 2007, Short and Cox, 2006), 
transcriptional regulation (Ozato et al., 2008, Lerner et al., 2007), neuro-
development (Balastik et al., 2008, Schwamborn et al., 2009), cell 
differentiation (Schwamborn et al., 2009) and cancer (Wang et al., 2009). In 
an immunohistochemical study, TRIM59 was shown to be a novel multiple 
cancer biomarker for detection of tumorigenesis (Khatamianfar et al., 2012). 





In the study itself, TRIM59 was demonstrated to be up-regulated in early 
tumorigenesis of prostate intraepithelial neoplasia and grade 1 of renal cell 
carcinoma. The specificity of TRIM59 expression in tumor was proven by 
significantly low or negative TRIM59 immunohistochemistry signal in control 
and normal area. The highest expression of TRIM59 was identified in lung, 
breast, liver, skin, tongue and mouth (squamous cell cancer) and endometrial 
cancers. 
 
Aberrant expression of TRIM59 in multiple cancer tissue revealed the 
implication of TRIM59 in tumorigenesis. Indeed, in a SV40 Tag oncogene-
directed transgenic mouse prostate cancer models, TRIM59 was shown to be 
upregulated in cDNA microarray analysis and was characterized to serve as a 
signaling pathway effector (Valiyeva et al., 2011). The function of TRIM59 
was elucidated by short hairpin RNA (shRNA)-mediated knockdown of the 
gene in human prostate cancer (CaP) cells. The CaP cells exhibited cell 
growth retardation and were arrested in S-phase. The proto-oncogenic function 
of TRIM59 was further evident by its ability to induce tumorigenesis in 
prostate cancer transgenic mouse model with up-regulated TRIM59 expression 
at prostate-specific site. GeneChip analysis on the transgenic mice revealed 
that genes related to Ras/Braf/MEK/ERK signaling pathway were upregulated 
by 2- to 10-fold. Besides, some genes which are involved in both 
Ras/Braf/MEK/ERK and SV40 Tag/pRB/p53 pathways were identified. It was 
hypothesized that TRIM59 was transducing a novel signaling route, which 
served as a link between Ras and SV40 Tag/pRB/p53 oncogene signal 
pathways. 





The RAS proteins are critical regulators in controlling signaling pathways of 
cellular growth in normal cellular function and during malignant 
transformation (Downward, 2003). Hence, a niche deregulation of the RAS 
genes or alterations in upstream or downstream signaling components could 
contribute to several aspects of the malignant phenotype. About 20% of all 
human tumors acquired activating point mutation in the RAS, most frequently 
in KRAS (Bos, 1989). Activated mutation of RAS prevented GTPase 
activating protein (GAP) from promoting hydrolysis of GTP to GDP thus 
locking RAS in the GTP-bound activated form (Downward, 2003). This 
mutation resulted in disordered tumor-cell growth, programmed cell death and 
invasion, as well as angiogenensis (Shields et al., 2000). Other mutations in 
RAS signaling pathways include GAP deletion (Weiss et al., 1999) and over-
expression of growth factor receptor, such as epidermal growth factor receptor 
(EGFR) and ERBB2 (also known as HER2/neu) (Mendelsohn and Baselga, 
2000). Over-expression of growth factor receptors are frequently found in 
many types of cancer, including breast, ovarian and stomach carcinomas. In 
addition, glioblastomas and some other tumor types harbor overacting 
truncated EGFR (Kuan et al., 2001). EGFR-family tyrosine kinases are 
commonly activated by autocrine production of EGF-like factors such as 
transforming growth factor-α (TGF-α) (Downward, 2003). BRAF, a 
serine/threonine kinase effector of RAS, which is responsible of activating 
downstream mitogen activated protein kinases (MAPK) is frequently activated 
by mutation in melanoma and colon carcinoma (Downward, 2003).  
 





Simian virus 40 (SV40) is a DNA tumor virus which express dominant acting 
oncoproteins large T antigen (T antigen) and small T antigen (t antigen) 
(Ahuja et al., 2005). Studies have firmly established that T antigen‟s inhibition 
of p53 and Rb-family of tumor suppressors are important for SV40-induced 
transformation (Ahuja et al., 2005). E2F transcription factor regulates 
transcription of genes encoding proteins required for DNA replication, 
nucleotide metabolism, DNA repair and cell cycle progression and  the 
activity of E2F is controlled by Rb-E2F interactions (Attwooll et al., 2004, 
Dimova and Dyson, 2005, Frolov and Dyson, 2004). By binding to Rb-
proteins, Large T antigen hampered repressive Rb-E2F complexes, promoting 
transcription of E2F-dependent genes and progression into S-phase (Sullivan 
et al., 2000, Zalvide et al., 1998). p53 is a tumor suppressor which functions as 
a transcriptional activator, regulating expression of a number of genes 
mediated in cell cycle arrest and apoptosis (Ahuja et al., 2005). Large T 
antigen blocks p53 growth-suppressive functions by interacting with the 
DNA-binding surface of p53 and interfering with its ability to bind promoters 
and regulate gene expression (Barfonetti et al., 1992, Tevethia et al., 1997, 
Rushton et al., 1997). 
 
5.1.3.2. ONECUT2 
Transcription factor one cut homeobox 2 (ONECUT2) is another proto-
oncogene which could possibly contribute to the increased migration and 
invasion of CSGalNAcT-1 silenced MCF-12A. ONECUT2 protein was 
substantially up-regulated in colorectal cancer tissues and the expression was 
negatively regulated by a tumor-suppressor miR-429 (Sun et al., 2014). In the 





study describing the functional role of ONECUT2 in colorectal cancer, 
ONECUT2 was targeted by miR-429 to inhibit the initiation of epithelial-
mesenchymal transition (EMT) and repress the expression of EMT-related 
markers found in TGF-β induced EMT pathway. TGF-β promotes EMT by 
regulating adherens junction either by interaction of TGF-β receptors and 
protein Par6 or by repressing E-cadherin transcription (Gregory et al., 2008). 
Besides, TGF-β also induced the expression of EMT inducing transcription 
factors such as ZEB1, ZEB2, SNAIL, and SLUG (Guarino, 2007, Thiery et al., 
2009, Said and Williams, 2011). Taken together, transcription factor 
ONECUT2 was involved in migration and invasion, which could explain the 
increased migration and invasion phenotypes obtained in MCF-12A after 
CSGalNAcT-1 knockdown. 
 
5.1.3.3. APOL6, CDKN1C, GAS1 and BAD coordinately induce apoptosis in 
CSGalNAcT-1 silenced MCF-12A 
Interestingly, while proto-oncogenes were up-regulated in CSGalNAcT-1 
silenced MCF-12A, pro-apoptotic genes were up-regulated at the same time; 
and one of these is Apoliproprotein L6 (APOL6). APOL6 was revealed as a 
novel pro-apoptotic Bcl-2 homology 3-only (BH3-only) protein (Liu et al., 
2005). In the study, over-expression of wild type APOL6 in p53-null 
colorectal cancer cells induced apoptosis via mitochondrial intrinsic pathway 
which was characterized by release of cytochrome c and Smac/DIABLO and 
activation of apoptosis initiator caspase caspase-8 and -9. The induction of 
apoptosis by APOL6 was accompanied with recruitment of and interaction 
with lipid/fatty acid components. BH3-only proteins belong to Bcl-2 family. 





They have been shown to promote apoptosis by binding to Bcl-2 family 
members to inhibit their activity (Cory and Adams, 2002, Letai et al., 2002b) 
and pro-apoptotic family members to ameliorate their activity (Kuwana et al., 
2002, Zong et al., 2001). To trigger a mitochondrial intrinsic apoptosis 
pathway, BH3-only proteins were shown to interact with voltage-dependent 
anion channel or the adenine nucleotide exchanger of the mitochondrial 
membrane proteins to induce mitochondrial dysfunction and cytochrome c 
release (Degli Esposti and Dive, 2003, Zamzami et al., 2000, Sugiyama et al., 
2002). Importantly, the recruitment of and interaction with lipid/fatty acids 
components during apoptosis induction by APOL6 further emphasize the role 
of lipid messengers in inducing matrix metalloproteinase and initiating 
apoptosis (Klolesnick and Kronke, 1998, Esposti, 2002, Garcia-Ruiz et al., 
2002). 
 
Another tumor suppressor gene being up-regulated in CSGalNAcT-1 silenced 
MCF-12A was cyclin-dependent kinase inhibitor 1C (CDKNIC or p57
KIP2
). 




are members of cyclin-
dependent kinase (CDK) inhibitors Cip/Kip family (Matsuokam et al., 1995). 
Studies have demonstrated the implications of CDKN1C in the regulation of 
many cellular events, including cell cycle control, differentiation, apoptosis, 
and metastasis (Joseph et al., 2009, Vlachos et al., 2007, Vlachos and Joseph, 
2009). The possible role of CDKN1C in the signaling pathway of 
CSGalNAcT-1 silenced MCF-12A could be attributed to its role in regulating 
cell death. CDKN1C enhanced drug-induced cell death in HeLa cells through 
caspase-dependent mitochondrial pathways. (Vlachos et al., 2007, Samuelsson 





et al., 2002). Another study showed that CDKN1C promoted anti-cancer drug 
induced apoptosis by inducing Bax, caspase-9 and -3 activities in 
mitochondrial intrinsic apoptosis pathway (Vlachos et al., 2007). 
 
In current study, increased caspase 3/7 activity in CSGalNAcT-1 silenced 
MCF-12A correlates with increased apoptosis (Section 3.2.6.1). Western blot 
examining the expression of a pro-apoptotic member of the Bcl-2 family, 
BAD, and its phosphorylated form (Downward, June 1999) in CSGalNacT-1 
silenced MCF-12A was conducted (Section 3.2.6.2). BAD is another BH3-
only protein which promotes apoptosis by binding to anti-apoptotic Bcl-2 and 
Bcl-XL so that the latter two are prevented from inhibiting Bax and related 
pro-apoptotic proteins to induce apoptosis (Yang et al., 1995). However, pro-
apoptotic activity of BAD was interrupted when serine residues 112 and 136 
of BAD were phosphorylated by protein kinase A (PKA) (Harada et al., 1999) 
and protein kinase B (PKB/Akt) (Datta et al., 1997, del Peso et al., 1997). 
Expression of total BAD was increased, though not significant, after 
CSGalNAcT-1 knockdown in MCF-12A. Pro-apoptotic activity of 
CSGalNAcT-1 silenced MCF-12A was reflected in the down-regulation of 
phosphorylated BAD (pBAD) and its relativity expression to total BAD 
(section 3.2.6.2). The de-phosphorylation of BAD is a consequent of the up-
regulation of growth arrest specific 1 (GAS1) from CSGalNAcT-1 knockdown 
in MCF-12A. GAS1 protein induced growth arrest and apoptosis by inhibiting 
GDNF-α-receptors and its co-receptor RET (Schueler-Furman et al., 2006), 
hence impeded the activation of AKT (Dominguez-Monzon et al., 2009, 
Lopez-Ramirez et al., 2008), which in turn reduced the phosphorylation of 





BAD. Hence BAD could translocate to the mitochondria to release 
cytochrome-c and trigger apoptosis (Zarco et al., 2012). The up-regulation of 
pro-apoptotic APOL6, CDKN1C, and GAS1 in mRNA level as well as down-
regulation of pBAD protein could have synergistically acted on mitochondrial 
intrinsic apoptosis pathway and resulted in the increased apoptosis in 
CSGalNAcT-1 silenced MCF-12A. 
 
5.1.4. F-actin staining reflects migration of CSGalNAcT-1 silenced and over-
expressed cells 
The migratory changes in CSGalNAcT-1 silenced MCF-12A were reflected in 
the F-actin immunofluorescence staining. In CSGalNAcT-1 silenced MCF-
12A, F-actin immunofluorescence intensity was increased compared to 
negative control (Figure 3.6); while reduced F-actin immunofluorescence 
staining intensity was observed in CSGalNAcT-1 over-expressed MCF7 and 
MDA-MB-231 compared to their empty vector clones, respectively (Figure 
3.29 and 3.30). Actin filaments assembly is crucial for cell migratory. During 
cell migration, actin filaments assembly drives the formation of lamellipodia 
and filopodia to extend the cells forward and form protrusions to adhere to 
extracellular matrix with actin cytoskeleton. Finally, forward movement is 
completed by retracting actomyosin and disassembly of adhesion from the rear 
(Le Clainche and Carlier, 2008). In a paper published much earlier using 
Chinese hamster ovary cell mutants deficient in glycosaminoglycans, F-actin 
formation and focal adhesion on fibronectin substrata were compromised, 
indicating that glycosaminoglycans could possibly mediate the dynamic of 
cellular cytoskeleton formation and its interaction with extracellular matrix 





components (LeBaron et al., 1988). However, the mechanism of how 
CSGalNAcT-1 regulates F-actin assembly and whether CSGalNAcT-1 
directly or indirectly regulates F-actin assembly remain to be elucidated.  
 
5.1.5. CSGalNAcT-1 mediates cell adhesion to fibronectin and collagen I 
Metastasis of tumor cells begins with alteration in cell-to-cell adhesion and 
cell adhesion to extracellular matrix. Successful metastasis required the loss of 
cell-to-cell adhesion, causing dissemination of tumor cells from the primary 
tumor site (Albelda, 1993). This is usually accompanied with down-regulation 
of E-cadherins (MK et al., 2011), replacement of E-cadherins by N-cadherins 
(AM et al., 2011), and participation of integrins in activating the activity of 
ECM-degrading enzymes metalloproteinases (DM and YM, 2011). Then, the 
tumor cells require efficient cell-to-ECM interaction to reside the tumor cells 
in secondary site (Albelda, 1993). Collagen I and fibronectin are one of 
numerous components in extracellular matrix (DM and YM, 2011). Silencing 
CSGalNAcT-1 in MCF-12A did not affect the adhesion of the cells to collagen 
I and fibronectin. Over-expression of CSGalNAcT-1 in MCF7 reduced in 
adhesion to collagen I and fibronectin. This results showed that over-
expression of CSGalNAcT-1 reduced the potentiality of MCF7 to adhere to 
ECM before it metastasizes. The same result was observed in the reduced 
adhesion of MDA-MB-231 to collagen I.  However, there was an increased of 
adhesion to fibronectin in CSGalNAcT-1 over-expressed MDA-MB-231. The 
contradictory result could be due to the insufficiency of CSGalNAcT-1 over-
expression level to hamper the adhesion of the cells to fibronectin. It is 
possible that MDA-MB-231, a poorly differentiated grade III breast cancer 





cell line requires higher expression level of CSGalNAcT-1 to modulate the 
adhesion to fibronectin than differentiated breast cancer cell lines, MCF7.  
 
5.1.6. CSGalNAcT-1 signals downstream to CXCL14 in cell behavioral 
changes 
Microarray results of CSGalNAcT-1 silenced MCF-12A picked up a number 
of genes which were up-regulated and down-regulated after the knockdown of 
CSGalNAcT-1 (Table 3.2). A few genes that are plausibly implicated in the 
phenotypic changes of CSGalNAcT-1 knockdown MCF-12A were discussed 
in previous section. One of the up-regulated genes was chemokine CXCL14. 
CXCL14 belongs to the chemokines superfamily of CXC group (Zlotnik and 
Yoshie, 2000). CXCL14 is also known as breast and kidney expressed 
chemokine (BRAK) because of its ubiquitous and high expression in the 
kidney and breast tissue (Gu et al., 2012).  CXCL14 expression is particularly 
more abundant in normal tissue than in malignant cell lines and cancerous 
tissues (Hromas et al., 1999, McKinnon et al., 2008); with the receptors yet to 
be identified (Kurth et al., 2001). The expression pattern of CXCL14 leads to 
the hypothesis of its role in regulating tumor progression (Frederick et al., 
2000).  
 
The microarray results showed that CXCL14 expression was up-regulated by 
2-fold in CSGalNAcT-1 knockdown MCF-12A (Figure 3.15), this is later 
validated by qRT-PCR with the up-regulation of 1.8-fold in the knockdown 
cells and the protein expression was verified to be up-regulated by 
immunofluorescence (Figure 3.16). Silencing of CSGalNAcT-1 changed the 





normal breast cell line MCF-12A to acquire tumor phenotypes, i.e. became 
more invasive and proliferative (Section 3.2.3 to 3.2.5). Hence, it was 
hypothesized that the up-regulation of CXCL14 was the downstream effect of 
CSGalNAcT-1 knockdown and the phenotypic changes observed in 
CSGalNAcT-1 knockdown MCF-12A could be attributed to the up-regulation 
of CXCL14. Hence to prove the hypothesis, double knockdown technique was 
employed. Double knockdown of CSGalNAcT-1 and CXCL14 was expected to 
restore the normal phenotypes of the MCF-12A. Above 90% silencing 
efficiency of CXCL14 was achieved by 5nM Ambion Silencer Select® siRNA, 
two siRNAs were used for validation and one of them was selected for double 
knockdown experiment (Figure 3.17). The expression of CSGalNAcT-1 in 
CXCL14 silenced MCF-12A was verified not affected (Figure 3.18). 
Phenotypic assays were not done to assess the CXCL14 silenced MCF-12A. 
This is because according to the hypothesis, CXCL14 was hypothesized to 
promote CSGalNAcT-1 silenced MCF-12A to acquire tumor phenotypes. 
Hence, knockdown of CXCL14 in normal breast cell line MCF-12A is 
redundant.   
 
Silencing efficiency of CSGalNAcT-1 and CXCL14 were above 90% in double 
knockdown experiment (Figure 3.19). Silencing efficiency of CSGalNAcT-1 in 
the double silencing model remarkably improved from 76% (Figure 3.2) to 93% 
(Figure 3.19). In the double knockdown model, each single-gene silencing 
group was added with the non-targeting siRNA together with the targeted gene 
siRNA. In CSGalNAcT-1 single silenced group, the same amount of Negative 
Control siRNA was added. Non-targeting siRNA serves as a negative control 





as it is presumably not to target any gene and cause any effect. However, there 
was publication describing the effect of non-targeting siRNA that was 
transfected into 293T cells (Wei et al., 2012). Cells were at stress and received 
non-targeting toxicity due to the persistent activation of siRNA-RISC complex. 
Hence, the changes in the CSGalNAcT-1 silencing efficiency in double 
knockdown model could be due to the interference of the non-targeting siRNA. 
 
In double knockdown experiments, CSGalNAcT-1 silenced MCF-12A had 
increased migration and invasion. This is in accordance to the results obtained 
from single silencing experiments although the magnitudes of changes were 
not as huge.  This could be due to the interference of non-targeting siRNA 
added in the CSGalNAcT-1 silenced group. CXCL14 silenced MCF-12A 
revealed decrease in migration and invasion and double knockdown of 
CSGalNAcT-1 and CXCL14 brought down the migration and invasion which 
was as good as reverting the cells back to normal (Figure 3.20 and 3.21). No 
significant changes in proliferation were observed in any group of double 
knockdown model. The non-targeting siRNA in CSGalNAcT-1 silenced group 
could have prevented the minimal changes in proliferation previously 
observed (Figure 3.8). In fibronectin adhesion assay, CXCL14 silenced MCF-
12A had increased adhesion but the change was not shown in double 
knockdown group. This could be due to the dampening effect brought by 
CSGalNAcT-1 silenced group that did not harbor significant changes thus 
dampened the increased fibronectin adhesiveness of MCF-12A in double 
knockdown group. While in collagen I adhesion assay, both CSGalNAcT-1 
and CXCL14 single silenced group had no significant changes; however, there 





was an increase in adhesion to collagen I in double silenced group. The 
CSGalNAcT-1 and CXCL14 downstream molecules may act synergistically to 
increase adhesion to collagen I. Hence, from the phenotypic results obtained 
here, we can preliminarily conclude that CXCL14 functions downstream of 
CSGalNAcT-1 and CXCL14 is pro-tumorigenic that contributes to the 
malignancy transformation of MCF-12A upon CSGalNAcT-1 knockdown.   
 
CXCL14, like other chemokines, has the immunological function to generate 
chemotaxis gradient and induce the migration in some immune cells, such as 
macrophages, natural killer cells and dendritic cells (Cao et al., 2000, Sleeman 
et al., 2000). In addition to the immunologic function of CXCL14, the 
biological roles of CXCL14 in tumorigenesis were extensively explored in 
recent years. In a study characterizing molecular and gene expression profile 
of the breast cancer tumor microenvironment, CXCL14 was found to be over-
expressed in myoepithelial cells and myofibroblasts and was able to promote 
the proliferation and invasiveness of breast cancer epithelial cells through 
paracrine effect (Allinen et al., 2004). In pancreatic cancer tissue, CXCL14 
expression was up-regulated compared to chronic pancreatitis and normal 
pancreas tissue; besides, CXCL14 stimulation increased invasiveness of 
pancreatic cancer cells in Matrigel assay (Wente et al., 2008). Cancer-
associated fibroblasts over-expressing CXCL14 were found in prostate cancer 
tissue. These fibroblasts promoted the growth of prostate cancer xenografts, 
and also increased tumor angiogenesis, macrophage infiltration; enhanced 
proliferation and migration of prostate cancer cells in vivo and in vitro, 
respectively (Augsten et al., 2009).  While in colorectal cancer, CXCL14 





expression levels were significantly associated with malignant 
clinicopathological parameters of the disease. High CXCL14 expression was 
associated to increased risk of recurrence in stage I/II patients and worse 
overall survival in advanced stage patients. In vitro knockdown of CXCL14 
impaired the tumorigenic behavior of colorectal carcinoma cells (Zeng et al., 
2013).  
 
The standard way of chemokines interacting with target cells is through 
binding to G-protein coupled receptors (Park et al., 2013). Chemokines can 
also regulate cellular activities through binding to polysaccharide-containing 
proteins, such as glycosaminoglycans, and lipids (Kuschert et al., 1999, Rybak 
et al., 1989). For example, CXCL10 was found to bind to heparin sulfate and 
heparin sulfate proteoglycan and interfere with cellular proliferation and 
migration (Jiang et al., 2010, Luster et al., 1995). CXCL14 was demonstrated 
to increase proliferation and migration of lung cancer cells by binding to cell 
surface heparin sulfate proteoglycans and sialic acids (Park et al., 2013). As 
CXCL14 could interact with heparin sulfate proteoglycans, there is high 
chance for CXCL14 to interact with chondroitin/ dermatan sulfate and/or 
respective proteoglycans and modulate cellular behaviors in normal biological 
process and/or in tumor progression. The likelihood of CXCL14 being pro-
tumorigenic is highly possible. As mentioned earlier, CXCL14 could attract 
macrophages, traffic activated natural killer (NK) cells to sites of 
inflammation or malignancy (Starnes et al., 2006) and induce dendritic cells 
(DC) infiltration and maturation (Shurin et al., 2005), causing inflammation to 
happen. Tumor promoting inflammation has become an enabling characteristic 





in the hallmark of cancer (Hanahan and Weinberg, 2011). Tumors were 
regarded by immune cells as wounds that never heal hence infiltrating 
inflammatory cells acts as a double-edged sword: tumor-antagonizing and 
tumor-promoting (Dvorak, 1986, Schafer and Werner, 2008). Tumor-
promoting inflammatory cells, such as macrophage subtypes, mast cells, 
neutrophils, T and B lymphocytes (Coffelt et al., 2010, DeNardo et al., 2010, 
Egeblad et al., 2010, Johansson et al., 2008, Murdoch et al., 2008), release 
growth factor, cytokines and chemokines, proangiogenic and/or proinvasive 
factors to amplify the inflammation by recruiting more immune cells and 
promoted tumor progression eventually (Murdoch et al., 2008, Qian and 
Pollard, 2010).  Moreover, inflammation may induce the production of 
reactive oxygen species and render surrounding normal cells and/or tumor 
cells to acquire genetic mutation (Grivennikov and Karin, 2010). Indeed in 
one breast cancer study, CXCL14 expression was up-regulated by ROS 
through novel signaling pathway and induced breast cancer cell invasiveness 
and proliferation (Pelicano et al., 2009).  
 
 






Figure 5.1 Hypothetical diagram on the signaling mechanisms of 
CSGalNAcT-1 in MCF-12A. Knockdown of CSGalNAcT-1 in MCF-12A 
induced an up-regulation of proto-oncogene CXCL14, TRIM59 and ONECUT2; 
and tumor-suppressor genes APOL6, CDKN1C and GAS1. Chemokine 
CXCL14 attracts and activates macrophages, natural killer (NK) cells and 
dendritic cells which results in more tumor promoting inflammation to take 
place. TRIM59 induces the expression of molecules in both 
RAS/BRAF/MEK/ERK and SV40 Tag/pRB/p53 pathways. TRIM59 is 
hypothesized to serve a link between these two tumor promoting pathways. 
Another proto-oncogene which was up-regulated was ONECUT2. ONECUT2 
induces the transcription of epithelial-mesenchymal transition biomarkers and 
results in increased migration and invasion of the cells. The increased 
apoptosis in CSGalNAcT-1 silenced MCF-12A was the results of the 
synergistic cooperation of APOL6, CDKN1C, GAS1 and BAD via 













5.2. CSGalNAcT-1 immunohistochemical analysis in invasive ductal 
carcinoma (IDC) 
Among different types of breast cancer, invasive ductal carcinoma is the most 
common type of breast malignancy, predominating 60% to 80% of all breast 
malignant lesions (Guinebretiere et al., 2005, Mallon et al., 2000). The 
expression of CSGalNAcT-1 was investigated in invasive ductal carcinoma 
tissue microarray in current study. The tissue microarray was constructed by 
Department of Pathology, Singapore General Hospital, comprising 297 cases 
from 1998 to 2004, among which 52 are normal tissue cases and 245 are IDC 
cases. All the tissues were from Singaporean female, aged 23 to 89 years old.  
 
In this study, CSGalNAcT-1 immunostaining was assessed based on three 
kinds of scoring measurements, i.e. immunoreactivity score (IRS), total 
percentage score (TPS) and weighted average intensity (WAI) of 
CSGalNAcT-1 immunopositive cells. CSGalNAcT-1 was found to express in 
cytoplasm of epithelial cells, stromal cells and diffuse stroma (Figure 4.1). 
Expression pattern of CSGalNAcT-1 was investigated by comparing between 
low histological grade (grade 1 and 2) and high histological grade (grade 3) 
IDC (Figure 4.3). Although only WAI of stromal cells showed significant 
difference, generally, all the three stained components had stronger expression 
of CSGalNAcT-1 in low grade IDC as compared with high grade IDC. On top 
of that, comparison of CSGalNAcT-1 expression between normal cases and 
IDC cases was performed (Figure 4.2). In epithelial cells and stromal cells of 
IDC cases, CSGalNAcT-1 had stronger staining compared to normal cases; 
however, expression of CSGalNAcT-1 was weaker in diffuse stroma of IDC 





cases compared to normal cases. These expression patterns showed that 
expression of CSGalNAcT-1 varied in different components of IDC and 
variably between normal and IDC cases and low grade and high grade IDC; 
this could mean that the implication and functional role of CSGalNAcT-1 in 
different components and IDC grade could vary in the pathogenesis of IDC. 
 
This is a pilot study examining expression of CSGalNAcT-1 in invasive ductal 
carcinoma thus far; hence the data collected is preliminary. However, there 
were extensive immunohistochemistry and expression analysis study 
correlating the expression of chondroin/dermatan sulfate with the clinical 
outcome of breast cancer patients. In a immunohistochemical study, 
expression of stroma decorin was shown to have the highest in normal breast 
tissue, lower in DCIS and the lowest in breast invasive components (Oda et al., 
2012). In another study which examined expression of lumican and decorin 
from node-negative invasive breast cancer by western blot analysis, low levels 
of both lumican and decorin correlated with aggressive clinicopathological 
parameters and associated with poor clinical outcome (Troup et al., 2003). 
These results supported the hypothesis that down-regulation of decorin and 
lumican facilitated the aggressiveness and progression of breast cancer.  
 
Elevated expression of chondroitin sulfate in malignant cells of primary breast 
cancer patients was associated with poor overall survival and shorter relapse-
free period (Svensson et al., 2011). In the case of versican, high relapse rate in 
patients is predicted by high versican level in peritumoral stroma of node-
negative primary breast cancer (Ricciardelli et al., 2002, Suwiwat et al., 2004). 





Hence, in contrast to decorin and lumican, chondroitin sulfate and versican 
exhibit pro-tumorigenic properties in breast tissue malignancies.  
 
5.2.1. Prognostic value of CSGalNAcT-1 in invasive ductal carcinoma (IDC) 
The significance of a molecule as a prognostic marker is its ability to predict 
the clinical outcome of disease in patients so that patients receive the most 
suitable and beneficial clinical management. Thus, it is useful to investigate 
the relevance of CSGalNAcT-1 expression with prognosis and survival of IDC 
patients.  
 
Among the three stained components in IDC, only immunoscore of stromal 
cells showed significant correlation with some of the clinicopathological 
parameters. Weighted average intensity (WAI) was significantly associated 
with ethnicity (Chinese, Malay and Indian) and age. Besides, higher weighted 
average intensity, meaning stronger expression of CSGalNAcT-1 was 
associated with lower histological grade and mitotic index (Table 4.9). In 
concordance to Singapore cancer registry report of 2009-2013 (Lee et al., 
2014), breast cancer was indeed the most common cancer among the three 
major ethnic groups in Singapore, i.e. Chinese, Malay and Indian. In the age 
per se, the incidence of cancer generally increases with age as gene mutations 
accumulate with the defect in repair mechanisms (Roses, 2005). The chance of 
a woman being diagnosed with breast cancer is 12.5% in her lifetime, and half 
of the risk happens after the age of 60 (Abeloff et al., 2004). Increasing age in 
IDC patients conferred to high expression of CSGalNAcT-1 in stromal cells. 
Histological grade has been used as a prognosis indicator to give an overview 





of the differentiation of tumor (Dabbs, 2012). Nottingham grading system 
combines nuclear pleomorphism, tubule formation and mitotic rate index, 
which were formerly from Scarff-Bloom-Richardson (SBR) (Black et al., 
1955); together with lymph node stage and tumor size to form a preferable and 
increasing popular grading system accepted by various international 
professional bodies (Tavassoli F, 2003, January 2005, Elston and Ellis, 1991). 
Mitotic rate index reflects the degree of proliferation of tumors and is 
examined from sections stained with hematoxylin and eosin (H&E) (Dabbs, 
2012). In present IDC immunohistochemical study, high CSGalNAcT-1 
expression in stromal cells correlated with low histological grade and low 
mitotic rate index. Hence, more CSGalNAcT-1 expression in stromal cells 
could possibly suggest a good prognosis in IDC patients. 
 
Breast cancer is a heterogeneous disease which a number of factors are taken 
into account for the pathogenesis and progression of the malignancy (Di 
Cosimo and Baselga, 2010). To perform a more meaningful and more in depth 
association in breast IDC cases, multivariate test was used to take into 
consideration of the effect of other parameters simultaneously. Ethnicity was 
found to affect weighted average intensity (WAI) of CSGalNAcT-1 in stromal 
cells after adjusting for histological grade, mitotic index and age. Hence, 
ethnicity of patients along with the presence of its respective confounders may 
affect the staining of CSGalNAcT-1 in breast IDC. 
 
In Kaplan-Meier survival analysis, low CSGalNAcT-1 immunopositivity (TPS) 
in diffuse stroma and lower scoring of tubule formation (score 1 and 2) was 





shown to predict longer recurrence-free survival (Figure 4.11). Tubule 
formation is yet another prognostic marker from Nottingham grading system 
and it is a feature to reflect degree of tumor differentiation (Dabbs, 2012). 
Highly malignant breast cancer that deviates largely from the histological 
appearance of normal glandular tissue of the breast will be given the highest 
score of three. Besides, lower expression of CSGalNAcT-1 in diffuse stroma 
and cases with positive estrogen and progesterone receptor were shown to 
have longer overall survival and recurrence-free survival (Figure 4.6, 4.8, 4.9, 
and 4.10). Estrogen receptor and progesterone receptor are very strong 
predictive factors to the response of patients to endocrine therapy (Dabbs, 
2012). Estrogen receptor is a nuclear transcription factor activated by estrogen 
hormone to regulate cell proliferation and differentiation of breast tissue 
(Clarke, 2003, Keen and Davidson, 2003, Fuqua SAW, 2004). Breast cancer 
cells are often over-proliferative via estrogen receptor signaling pathway and 
the consequence is detrimental to patients (Keen and Davidson, 2003, Fuqua 
SAW, 2004, Ellege RM, 2004). The expression of estrogen receptor serves as 
a powerful predictive factor for response to endocrine therapies, such as 
Tamoxifen and aromatase inhibitors (Ellege RM, 2004, Buzdar et al., 2004, 
Dowsett et al., 2005, Goss et al., 2007, Viale et al., 2007). The outcome of 
endocrine therapy in estrogen receptor positive patients is proven to be 
promising and effective (Ellege RM, 2004, Dahabreh et al., 2008, Fitzgibbons 
et al., 2000, Prat and Baselga, 2008). The expression of progesterone receptors 
is regulated by estrogen receptors; and as similar to estrogen receptors, 
progesterone receptors regulate cell proliferation when activated by 
progesterone hormone (Clarke, 2003, Ellege RM, 2004, Anderson, 2002, 





Jacobsen et al., 2003). The response of progesterone receptor-positive cells to 
endocrine therapy is very effective with even very minimal (≥1%) of cells 
expressing the receptors (Mohsin et al., 2004, Love et al., 2002).  Progesterone 
receptor-positive DCIS patients who received endocrine therapy after 
lumpectomy and radiation were proven to have reduced local recurrence 
(Allred et al., 2012). In sum, current IDC cases which had lower expression of 
CSGalNAcT-1 and positive hormone receptors resulted in a better outcome in 
patients. Lymph node involvement and lymph node metastases resulted breast 
cancer patients to acquire poor prognosis (Hortobagyi, 1998, Wilking et al., 
1992). Negative lymph node involvement and lower expression of 
CSGalNAcT-1 in diffuse stroma also warranted IDC patients with better 
overall survival (Figure 4.5 and 4.7). Hence, from the Kaplan Meier survival 
analysis, lower expression of CSGalNAcT-1 in diffuse stroma together with 
less aggressive phenotypes conferred better prognosis. 
 
In summary, the expression of CSGalNAcT-1 in stromal cells and diffuse 
stroma resulted in different implication to IDC malignancy. High expression 
of CSGalNAcT-1 in stromal cells correlated with less aggressive phenotypes 
in IDC patients, i.e. lower histological grade and mitotic index; but low 
expression of CSGalNAcT-1 in diffuse stroma conferred better prognosis in 
IDC patients. These results showed that the roles of CSGalNAcT-1 in IDC 
cancer depend on the compartment where the enzyme located as evident by 
the study of p27. The tumor suppressor p27 is a member of the CIP/KIP 
family of CKI. It is a tumor suppressor and an inhibitor of cell proliferation 
(Sherr and Robert, 2001). The anti-proliferative function of p27 was exerted in 





the nucleus by inhibiting the interactions with cyclin-CDK enzymes (Russo et 
al., 1996). However, studies showed that relocation of p27 from nucleus to 
cytoplasm have been correlated with high tumor grade, poor clinical outcome 
and increased metastasis in carcinomas of breast, cervix, oesophagus, uterus 
and in some lymphomas and leukemia (Anayama et al., 1998, Dellas et al., 
1998, Vrhovac et al., 1998, Kouvaraki et al., 2002, Watanabe et al., 2002). An 
explanation for these observations might be due to the role of p27 as a 
regulator of cytoskeletal structure and cell migration when located in the 
cytoplasm (McAllister et al., 2003). Hence, when p27 was located in 
cytoplasm, it inhibits apoptosis and stimulate cell migration by promoting the 
assembly and nuclear import of proliferation promoter cyclin D-CDK 
complexes (McAllister et al., 2003). Similar with p27, the roles of 
CSGalNAcT-1 in IDC is compartment-specific; however, the explanation for 
these observations needs further elucidation. 
 
 



















6. CONCLUSIONS AND FUTURE WORK 
Breast cancer is the leading cause of morbidity and mortality affecting female 
worldwide. Scientists put in a lot of effort to identify biomarkers and 
prognostic markers for the diagnosis of breast cancer and ultimately to seek 
the best therapeutic intervention for the patients. Since CSGalNAcT-1 is 
responsible in the biosynthesis of chondroitin sulfate and dermatan sulfate and 
the expression of this enzyme in normal breast cell line, MCF-12A, was found 
to be significantly higher than those of breast cancer cell lines, it is 
hypothesized that CSGalNAcT-1 could be functionally implicated in breast 
cancer phenotypic changes. In order to prove this hypothesis, reciprocal 
knockdown and over-expression of CSGalNAcT-1 were performed. 
CSGalNAcT-1 silenced MCF-12A cells showed increase in migration, 
invasion, proliferation and apoptosis. On the other hand, over-expression of 
CSGalNAcT-1 showed inhibition in migration, invasion, proliferation and 
mediate adhesion differently. In microarray analysis of CSGalNAcT-1 silenced 
MCF-12A, it is interesting to reveal that bringing down the level of 
CSGalNAcT-1 promoted the expression of both proto-oncogenes (TRIM59 and 
ONECUT2) and tumor suppressor genes (APOL6, CDKN1C and GAS1). This 
explains the reason MCF-12A cells exhibited increased migration, invasion 
and proliferation but had increased apoptosis. Among the deregulated genes 
from CSGalNAcT-1 silenced MCF-12A microarray analysis, CXCL14 was 
selected for further study. Knockdown of CSGalNAcT-1 in MCF-12A resulted 
in CXCL14 up-regulation in the cells. Hence, it is postulated that CXCL14 
contributed to the behavioral changes in MCF-12A after CSGalNAcT-1 was 
silenced. CXCL14 was verified to work downstream of CSGalNAcT-1 through 





double knockdown of both genes in MCF-12A. When CSGalNAcT-1 and 
CXCL14 were silenced together, tumor phenotypes of MCF-12A gained 
through CSGalNAcT-1 silencing were abolished.  
 
CSGalNAcT-1 expression was determined in invasive ductal carcinoma by 
immunohistochemical study and found to localize in the cytoplasm of 
epithelial cells, stromal cells and diffuse stroma. The association of 
CSGalNAcT-1 immunostaining with clinicopathological parameters in all the 
stained components did not give much significant correlation, except in 
stromal cells. Direct association of CSGalNAcT-1 immunostaining in stromal 
cells with ethnicity (Chinese, Malay and Indian), patients older than 50 years 
old, low histological grade and low mitotic rate index were established. 
However, interesting findings were obtained from the association of 
CSGalNAcT-1 with clinical outcome of IDC patients. In summary, low 
expression of CSGalNAcT-1 together with less aggressive phenotypes, i.e. 
hormonal receptors positive, lower score in tubule formation, and negative 
lymph node involvement promised longer disease free survival and better 
overall survival. Thus, CSGalNAcT-1 could be a potential prognostic marker 
in specific group of patients harboring the biological characteristics as 
mentioned above. The results from in vitro and immunohistochemical study 
are summarized in Figure 6.1.  






Figure 6.1 The result summary of functional role of CSGalNAcT-1 in 
mediating phenotypic changes of MCF-12A, MCF7 and MDA-MB-231 and 
the prognostic value of CSGalNAcT-1 in IDC in different compartments. 
 
As CSGalNAcT-1 catalyzes the biosynthesis of chondroitin sulfate and 
dermatan sulfate, it is unsure whether the results obtained was an indirect 
effect via chondroitin/dermatan sulfate chain or it was a direct implication 
from CSGalNAcT-1 itself. Hence, to resolve this query, chondroitinases could 
be used to enzymatically degrade the chondroitin/dermatan sulfate chains in 
CSGalNAcT-1 over-expressed MCF7 and MDA-MB-231. If the phenotypic 
changes in the over-expression clones still exist, we could conclude that 
CSGalNAcT-1 is the effector molecule that directly mediates the phenotypic 
changes in the cells. 
 
The molecular mechanism of which CSGalNAcT-1 interact with candidate 
downstream molecules, such as CXCL14, is still unknown.  
Immunoprecipitation could be employed to determine this interaction. The 





functional role of TRIM59, ONECUT2, APOL6, CDKN1C and GAS1 should 
be determined by experiments to confirm the roles of these genes with 
CSGalNAcT-1 in the signaling pathway. To enhance the understanding of the 
functions of CSGalNAcT-1 in breast cancer progression, stable CSGalNAcT-1 
over-expressed MCF7 and MDA-MB-231 cells could be delivered to animal 
model to investigate the function of CSGalNAcT-1. 
 
The results obtained from immunohistochemical study here is still preliminary. 
From the multivariate analysis, ethnicity affects the expression of 
CSGalNAcT-1 in IDC; hence, sample population from different ethnicity 
could be included in future study to determine the relationship between 
ethnicity and CSGalNAcT-1 in IDC. Besides, larger sample size could be 
collected in future for validation of the prognostic value of CSGalNAcT-1 in 
IDC. 
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